Updated on 2024/05/11

写真a

 
SAITO Akihiko
 
Organization
Graduate School of Medical and Dental Sciences Specially Appointed Professor
Title
Specially Appointed Professor
External link

Degree

  • 医学博士 ( 1989.3   新潟大学 )

Research Interests

  • diabetic kidney disease

  • chronic kidney disease

  • megalin

  • acute kidney injury

  • proximal tubule

Research Areas

  • Life Science / Nephrology

Research History (researchmap)

  • Niigata University   Graduate School of Medical and Dental Sciences   Specially Appointed Professor

    2006.5

      More details

  • Niigata University   Graduate School of Medical and Dental Sciences

    2003.4 - 2006.4

      More details

  • Niigata University   Graduate School of Medical and Dental Sciences   Research Assistant

    2001.4 - 2003.3

      More details

  • Niigata University   Faculty of Medicine   Research Assistant

    2000.4 - 2001.3

      More details

  • Niigata University   Faculty of Medicine   Research Assistant

    1997.1 - 2000.3

      More details

  • Niigata University   Faculty of Medicine

    1995.7 - 1996.12

      More details

  • 米国カリフォルニア大学サンディエゴ校   分子細胞医学部門 留学

    1992.7 - 1995.6

      More details

  • 信楽園病院   腎センター   医師

    1991.7 - 1992.6

      More details

  • Niigata University   Faculty of Medicine

    1990.4 - 1991.6

      More details

  • 新潟大学附属病院等   内科   研修医

    1983.4 - 1986.3

      More details

▶ display all

Research History

  • Niigata University   Graduate School of Medical and Dental Sciences   Specially Appointed Professor

    2006.4

  • Niigata University   Faculty of Medicine Institute of Nephrology   Research Assistant

    1997.1 - 1999.9

  • Niigata University   University Medical Hospital

    1995.7 - 1996.12

Education

  • Niigata University   医学研究科   内科学

    - 1990.3

      More details

    Country: Japan

    researchmap

  • Niigata University   Graduate School, Division of Medicine

    - 1989

      More details

  • Asahikawa Medical College   School of Medicine   Medical Course

    - 1983.3

      More details

    Country: Japan

    researchmap

  • Asahikawa Medical College   Faculty of Medicine

    - 1983

      More details

Professional Memberships

▶ display all

Studying abroad experiences

  • Columbia University in the U.S.A.   Postdoctoral fellow

    1988.4 - 1989.3

Qualification acquired

  • Doctor

 

Papers

  • Megalin is involved in angiotensinogen-induced, angiotensin II-mediated ERK1/2 signaling to activate Na+-H+ exchanger 3 in proximal tubules. Reviewed International journal

    Sawako Goto, Yutaka Yoshida, Michihiro Hosojima, Shoji Kuwahara, Hideyuki Kabasawa, Hiroyuki Aoki, Tomomichi Iida, Ryuhei Sawada, Daisuke Ugamura, Yuta Yoshizawa, Kazuya Takemoto, Koichi Komochi, Ryota Kobayashi, Ryohei Kaseda, Eishin Yaoita, Satoru Nagatoishi, Ichiei Narita, Kouhei Tsumoto, Akihiko Saito

    Journal of hypertension   2023.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Kidney angiotensin (Ang) II is produced mainly from liver-derived, glomerular-filtered angiotensinogen (AGT). Podocyte injury has been reported to increase the kidney Ang II content and induce Na+ retention depending on the function of megalin, a proximal tubular endocytosis receptor. However, how megalin regulates the renal content and action of Ang II remains elusive. METHODS: We used a mass spectrometry-based, parallel reaction-monitoring assay to quantitate Ang II in plasma, urine, and kidney homogenate of kidney-specific conditional megalin knockout (MegKO) and control (Ctl) mice. We also evaluated the pathophysiological changes in both mouse genotypes under the basal condition and under the condition of increased glomerular filtration of AGT induced by administration of recombinant mouse AGT (rec-mAGT). RESULTS: Under the basal condition, plasma and kidney Ang II levels were comparable in the two mouse groups. Ang II was detected abundantly in fresh spot urine in conditional MegKO mice. Megalin was also found to mediate the uptake of intravenously administered fluorescent Ang II by PTECs. Administration of rec-mAGT increased kidney Ang II, exerted renal extracellular signal-regulated kinase 1/2 (ERK1/2) signaling, activated proximal tubular Na+-H+ exchanger 3 (NHE3), and decreased urinary Na+ excretion in Ctl mice, whereas these changes were suppressed but urinary Ang II was increased in conditional MegKO mice. CONCLUSION: Increased glomerular filtration of AGT is likely to augment Ang II production in the proximal tubular lumen. Thus, megalin-dependent Ang II uptake should be involved in the ERK1/2 signaling that activates proximal tubular NHE3 in vivo, thereby causing Na+ retention.

    DOI: 10.1097/HJH.0000000000003555

    PubMed

    researchmap

  • A case of idiopathic nodular glomerulosclerosis successfully treated by intensive blockade of the renin-angiotensin-aldosterone system.

    Hiroki Yamaguchi, Michihiro Hosojima, Hideyuki Kabasawa, Yumi Ito, Yoshiki Suzuki, Akihiko Saito, Masaaki Arakawa, Ichiei Narita

    CEN case reports   2022.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Idiopathic nodular glomerulosclerosis has a poor renal prognosis and is characterized by diffuse nodular glomerulosclerotic lesions in the absence of diabetic mellitus. Here, we report the case of a 69-year-old woman with no smoking history who developed renal dysfunction and proteinuria in the absence of overt diabetes or obesity. A biopsy specimen showed nodular mesangial sclerosis with arteriolar hyalinosis and severe large-vessel arteriosclerosis, leading to a diagnosis of idiopathic nodular glomerulosclerosis. Addition of esaxerenone to her existing renin-angiotensin-aldosterone inhibitor therapy led to a rapid decrease in the proteinuria levels and the maintenance of renal function without any complications for more than a year. The results suggest that intensive renin-angiotensin-aldosterone blockade might be an effective treatment for idiopathic nodular glomerulosclerosis.

    DOI: 10.1007/s13730-022-00766-3

    PubMed

    researchmap

  • Efficacy of Low-Protein Rice for Dietary Protein Restriction in CKD Patients: A Multicenter, Randomized, Controlled Study. International journal

    Michihiro Hosojima, Hideyuki Kabasawa, Ryohei Kaseda, Tomomi Ishikawa-Tanaka, Yoshitsugu Obi, Toshiko Murayama, Shoji Kuwahara, Yoshiki Suzuki, Ichiei Narita, Akihiko Saito

    Kidney360   3 ( 11 )   1861 - 1870   2022.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The benefits of dietary protein restriction in CKD remain unclear, largely due to inadequate adherence in most clinical trials. We examined whether low-protein rice (LPR) previously developed to reduce the protein content of rice, a major staple food, would help improve adherence to dietary protein restriction. METHODS: This open-label, multicenter, randomized, controlled trial evaluated the efficacy of LPR use for reducing dietary protein intake (DPI) in patients with CKD stages G3aA2-G4. Participants were randomly assigned in a 1:1 ratio to an LPR or control group and were followed up for 24 weeks. Both groups received regular counseling by dietitians to help achieve a target DPI of 0.7 g/kg ideal body weight (IBW) per day. The amount of protein in LPR is about 4% of that in ordinary rice, and the participants in the LPR group were instructed to consume LPR with at least two meals per day. The primary outcome was estimated dietary protein intake (eDPI) determined using the Maroni formula. The secondary outcomes included creatinine clearance (CCr) and urinary protein on the basis of 24-hour urine collection. RESULTS: In total, 51 patients were randomized to either the LPR group or the control group. At baseline, mean age was 62.5 years, 70% were men, mean CCr was 52.0 ml/min, and mean eDPI was 0.99 g/kg IBW per day. At 24 weeks, mean eDPI decreased to 0.80 g/kg IBW per day in the LPR group and to 0.91 g/kg IBW per day in the control group, giving a between-group difference of 0.11 g/kg IBW per day (95% confidence interval, 0.03 to 0.19 g/kg IBW per day; P=0.006). There was no significant between-group difference in CCr, but urinary protein was lower at 24 weeks in the LPR group than in the control group. CONCLUSIONS: LPR is a feasible tool for efficiently reducing DPI in patients with CKD. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Randomized, Multicenter, Controlled Study for the Efficacy of Low-Protein Rice Diet in Patients with Chronic Kidney Disease, UMIN000015630.

    DOI: 10.34067/KID.0002982022

    PubMed

    researchmap

  • Urinary A- and C-megalin predict progression of diabetic kidney disease: an exploratory retrospective cohort study. International journal

    Tomomichi Iida, Michihiro Hosojima, Hideyuki Kabasawa, Keiko Yamamoto-Kabasawa, Sawako Goto, Takahiro Tanaka, Nobutaka Kitamura, Mitsutaka Nakada, Shino Itoh, Shinya Ogasawara, Ryohei Kaseda, Yoshiki Suzuki, Ichiei Narita, Akihiko Saito

    Journal of diabetes and its complications   36 ( 11 )   108312 - 108312   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    AIMS: Megalin, a proximal tubular endocytosis receptor, is excreted in urine in two forms: ectodomain (A-megalin) and full-length (C-megalin). We explored whether urinary megalin levels can be used as independent prognostic biomarkers in the progression of diabetic kidney disease (DKD). METHODS: The associations between baseline urinary A-megalin/creatinine (Cr) and/or C-megalin/Cr levels and the subsequent estimated glomerular filtration rate (eGFR) slope were analyzed using a generalized estimating equation. Patients were categorized into higher or lower groups based on the optimal cutoff values, obtained from a receiver operating characteristic curve, of the two forms of urinary megalin. RESULTS: We retrospectively analyzed 188 patients with type 2 diabetes. The eGFR slopes of the higher A-megalin/Cr and higher C-megalin/Cr groups were - 0.904 and -0.749 ml/min/1.73 m2/year steeper than those of the lower groups, respectively. Moreover, the eGFR slope was -1.888 ml/min/1.73 m2/year steeper in the group with both higher A- and higher C-megalin/Cr than in the other group. These results remained significant when adjusted for known urinary biomarkers (albumin, α1-microglobulin, β2-microglobulin, and N-acetyl-β-d-glucosaminidase). CONCLUSIONS: Urinary A- and C-megalin/Cr levels are likely to be prognostic biomarkers in the progression of DKD independent of other urinary biomarkers.

    DOI: 10.1016/j.jdiacomp.2022.108312

    PubMed

    researchmap

  • Intradialytic parenteral nutrition using a standard amino acid solution not for renal failure in maintenance hemodialysis patients with malnutrition: a multicenter pilot study

    Ryota Yasukawa, Michihiro Hosojima, Hideyuki Kabasawa, Aya Takeyama, Daisuke Ugamura, Yoshiki Suzuki, Akihiko Saito, Ichiei Narita

    RENAL REPLACEMENT THERAPY   8 ( 1 )   2022.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BMC  

    Background Standard amino acid solutions have recently been removed from the contraindications for use in dialysis patients in Japan. However, the details of their safety and efficacy in these patients are still not known. In this study, we investigated the safety and efficacy of intradialytic parenteral nutrition (IDPN) using ENEFLUID (R) injection containing standard amino acids, glucose, electrolytes, fats, and water-soluble vitamins in maintenance hemodialysis patients with malnutrition. Methods This clinical trial was designed as a multicenter, prospective, non-randomized, open-label, single-arm, observational pilot study. The participants were patients on maintenance hemodialysis who were in the nutritional high-risk group according to the Nutritional Risk Index for Japanese Hemodialysis Patients. One bag of ENEFLUID (R) injection was administered during every hemodialysis session for 12 weeks. The primary endpoint was change in serum transthyretin levels between before and after the 12-week period. As safety endpoints, we evaluated changes in body fluid volume and blood biochemical tests, including blood urea nitrogen and electrolytes, as well as blood glucose variability using flash glucose monitoring (FGM). Results The mean age and body mass index of the 13 participants were 79.0 +/- 10.7 years and 18.0 +/- 1.7 kg/m(2), respectively. No significant changes were observed in nutritional parameters, including serum transthyretin, between before and after the start of the study. After IDPN initiation, there was no obvious fluid overload or significant changes in blood biochemical tests, including electrolytes, and the treatment could be safely continued for 12 weeks. In the FGM analysis, asymptomatic hypoglycemia during hemodialysis was observed at the beginning of the study, but there was a trend toward improvement after 12 weeks (area over the curve < 70 mg/dl per dialysis session: 747.5 +/- 1333.9 to 21.6 +/- 54.3, P = 0.09). Conclusions IDPN using ENEFLUID (R) injection can be safely continued, although it does not significantly improve markers of nutritional status. It also showed the potential to ameliorate asymptomatic hypoglycemia during hemodialysis sessions. More detailed studies of the improvement in nutritional indicators are needed. Trial registration: This study was registered with the University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR) on May 9, 2021 (registration ID, UMIN000044051).

    DOI: 10.1186/s41100-022-00432-5

    Web of Science

    researchmap

  • An exploratory clinical trial on the efficacy and safety of glucagon-like peptide-1 receptor agonist dulaglutide in patients with type 2 diabetes on maintenance hemodialysis

    Daisuke Ugamura, Michihiro Hosojima, Hideyuki Kabasawa, Naohito Tanabe, Yuta Yoshizawa, Yoshiki Suzuki, Akihiko Saito, Ichiei Narita

    RENAL REPLACEMENT THERAPY   8 ( 1 )   2022.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BMC  

    Background Dulaglutide is a once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist approved for the treatment of type 2 diabetes mellitus (T2DM). However, the efficacy and safety of dulaglutide remain unclear in insulin-treated patients with T2DM on maintenance hemodialysis (HD). Methods Dulaglutide treatment was initiated, and the insulin dose was adjusted according to the needs of individual participants. Primary outcomes were changes in the mean and standard deviation (SD) of blood glucose (BG) levels and mean amplitude of glycemic excursions (MAGE) evaluated by continuous glucose monitoring (CGM) for six days, glycated albumin (GA), glycated hemoglobin (HbA1c), pre-dialysis blood glucose levels, and daily total insulin dose from the baseline over 24 weeks. Secondary outcomes were changes in treatment satisfaction and QOL levels from the baseline, measured by using the Diabetes Treatment Satisfaction Questionnaire (DTSQ) and the Diabetes Therapy-Related Quality of Life questionnaire (DTR-QOL) scores. Results The analysis was performed on the 12 participants who completed the study. The GA level (median - 1.8 [interquartile range - 6.6, - 0.3] %; p = 0.026) and daily total insulin dose (- 15.0 [- 24.5, - 9.4] U/day; p = 0.002) significantly decreased without increasing hypoglycemia (area over the glucose curve < 70 mg/dL: 0.0 [- 0.2, 0.0] mg center dot 24 h/dl; p = 0.917). Four patients successfully withdrew from insulin therapy. The levels of HbA1c, SD of BG, and MAGE showed a decreasing tendency, but no significant improvement. Regarding treatment satisfaction and QOL, the total scores of DTSQ (8.0 [0.3, 12.5]; p = 0.041) and DTR-QOL (15.5 [- 1.8, 42.0]; p = 0.023) significantly improved. Conclusion Dulaglutide may help improve glycemic control, treatment satisfaction, and QOL without increasing hypoglycemia in insulin-treated patients with T2DM on maintenance HD. Trial registration This study was registered with the University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR) on October 11, 2016 (registration ID, UMIN000024283).

    DOI: 10.1186/s41100-022-00409-4

    Web of Science

    researchmap

  • Association of metabolic syndrome traits with urinary biomarkers in Japanese adults. International journal

    Keiko Kabasawa, Michihiro Hosojima, Yumi Ito, Kazuo Matsushima, Junta Tanaka, Masanori Hara, Kazutoshi Nakamura, Ichiei Narita, Akihiko Saito

    Diabetology & metabolic syndrome   14 ( 1 )   9 - 9   2022.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Although metabolic syndrome traits are risk factors for chronic kidney disease, few studies have examined their association with urinary biomarkers. METHODS: Urinary biomarkers, including A-megalin, C-megalin, podocalyxin, albumin, α1-microglobulin, β2-microglobulin, and N-acetyl-β-D-glucosaminidase, were cross-sectionally assessed in 347 individuals (52.7% men) with a urine albumin-to-creatinine ratio (ACR)  < 300 mg/g in a health checkup. Metabolic syndrome traits were adopted from the National Cholesterol Education Program (third revision) of the Adult Treatment Panel criteria modified for Asians. RESULTS: Participants had a mean body mass index, estimated glomerular filtration rate (eGFR), and median ACR of 23.0 kg/m2, 74.8 mL/min/1.73 m2, and 7.5 mg/g, respectively. In age- and sex-adjusted logistic regression analysis, A-megalin and albumin were significantly associated with the clustering number of metabolic syndrome traits (3 or more). After further adjustment with eGFR, higher quartiles of A-megalin and albumin were each independently associated with the clustering number of metabolic syndrome traits (adjusted odds ratio for A-megalin: 1.30 per quartile, 95% CI 1.03-1.64; albumin: 1.42 per quartile, 95% CI 1.12-1.79). CONCLUSIONS: Both urinary A-megalin and albumin are associated with the clustering number of metabolic syndrome traits. Further research on urinary A-megalin is warranted to examine its role as a potential marker of kidney damage from metabolic risk factors.

    DOI: 10.1186/s13098-021-00779-5

    PubMed

    researchmap

  • Urinary FABP1 is a biomarker for impaired proximal tubular protein reabsorption and is synergistically enhanced by concurrent liver injury. International journal

    Ryo Kawakami, Miki Matsui, Ayumu Konno, Ryosuke Kaneko, Shreya Shrestha, Suman Shrestha, Hiroaki Sunaga, Hirofumi Hanaoka, Sawako Goto, Michihiro Hosojima, Hideyuki Kabasawa, Masaru Obokata, Norimichi Koitabashi, Hiroki Matsui, Tsutomu Sasaki, Akihiko Saito, Motoko Yanagita, Hirokazu Hirai, Masahiko Kurabayashi, Tatsuya Iso

    The Journal of pathology   255 ( 4 )   362 - 373   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Urinary fatty acid binding protein 1 (FABP1, also known as liver-type FABP) has been implicated as a biomarker of acute kidney injury (AKI) in humans. However, the precise biological mechanisms underlying its elevation remain elusive. Here, we show that urinary FABP1 primarily reflects impaired protein reabsorption in proximal tubule epithelial cells (PTECs). Bilateral nephrectomy resulted in a marked increase in serum FABP1 levels, suggesting that the kidney is an essential organ for removing serum FABP1. Injected recombinant FABP1 was filtered through the glomeruli and robustly reabsorbed via the apical membrane of PTECs. Urinary FABP1 was significantly elevated in mice devoid of megalin, a giant endocytic receptor for protein reabsorption. Elevation of urinary FABP1 was also observed in patients with Dent disease, a rare genetic disease characterized by defective megalin function in PTECs. Urinary FABP1 levels were exponentially increased following acetaminophen overdose, with both nephrotoxicity and hepatotoxicity observed. FABP1-deficient mice with liver-specific overexpression of FABP1 showed a massive increase in urinary FABP1 levels upon acetaminophen injection, indicating that urinary FABP1 is liver-derived. Lastly, we employed transgenic mice expressing diphtheria toxin receptor (DT-R) either in a hepatocyte- or in a PTEC-specific manner, or both. Upon administration of diphtheria toxin (DT), massive excretion of urinary FABP1 was induced in mice with both kidney and liver injury, while mice with either injury type showed marginal excretion. Collectively, our data demonstrated that intact PTECs have a considerable capacity to reabsorb liver-derived FABP1 through a megalin-mediated mechanism. Thus, urinary FABP1, which is synergistically enhanced by concurrent liver injury, is a biomarker for impaired protein reabsorption in AKI. These findings address the use of urinary FABP1 as a biomarker of histologically injured PTECs that secrete FABP1 into primary urine, and suggest the use of this biomarker to simultaneously monitor impaired tubular reabsorption and liver function. © 2021 The Authors. The Journal of Pathology published by John Wiley & Sons, Ltd. on behalf of The Pathological Society of Great Britain and Ireland.

    DOI: 10.1002/path.5775

    PubMed

    researchmap

  • Rice Endosperm Protein Improves the Anti-Inflammatory Effects of High-Density Lipoprotein and Produces Lower Atherosclerotic Lesion Accelerated by the Renal Mass Reduction than Casein in a Mouse Model. International journal

    Ryohei Kaseda, Michihiro Hosojima, Shoji Kuwahara, Hideyuki Kabasawa, Hiroyuki Aoki, Yuki Higuchi, Valentina Kon, Ichiei Narita, Akihiko Saito

    Journal of the American College of Nutrition   41 ( 7 )   1 - 11   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Chronic kidney disease (CKD) impairs the anti-inflammatory effects of high-density lipoprotein (HDL) and increases cardiovascular mortality. Though the potential role of dietary interventions to manage HDL is well studied, the clinical trials aimed to increase HDL levels have failed to reduce cardiovascular risk, rendering HDL function to be explored as a more relevant clinical parameter. This study investigates the effects of rice endosperm protein (REP), a plant-based protein, on the anti-inflammatory properties of HDL and renal injury-driven atherosclerosis in comparison with casein, an animal protein. Ten-week-old apolipoprotein E-deficient hyperlipidemic mice underwent uninephrectomy. The mice (n = 6 each) were pair-fed a normal casein-based diet or a REP-based diet (both with 20.0% protein content) for seven weeks. Atherosclerotic lesions were detected by en face Sudan IV staining of the aorta. The number and sizes of the atherosclerotic lesions were significantly lower in the REP-based diet-fed group than the casein-based diet-fed group (p = 0.038). However, the REP-based diet neither elicited an ameliorative effect on kidney function or histology nor impacted the cholesterol profiles. Furthermore, HDL from the REP-based diet-fed mice significantly suppressed the inflammatory cytokine response of human umbilical vein endothelial cells than that from the casein-based diet-fed mice (MCP-1, p = 0.010; IL-6, p = 0.011; IL-1β, p = 0.028). The REP-based diet has a higher potential to lessen the atherosclerotic lesions accelerated by renal mass reduction than a casein-based diet, which could be associated with the anti-inflammatory effects of HDL.

    DOI: 10.1080/07315724.2021.1950584

    PubMed

    researchmap

  • Measurement of Plasma Glucagon Levels Using Mass Spectrometry in Patients with Type 2 Diabetes on Maintenance Hemodialysis. International journal

    Yuta Yoshizawa, Michihiro Hosojima, Hideyuki Kabasawa, Naohito Tanabe, Atsushi Miyachi, Hitoshi Hamajima, Eri Mieno, Masaki Kobayashi, Tadahiro Kitamura, Ichiei Narita, Akihiko Saito

    Kidney & blood pressure research   46 ( 5 )   1 - 5   2021.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Recently, attention has been focused on the effect of glucagon on blood glucose variability. The dynamics of glucagon have attracted attention as a new target in the treatment of diabetes patients. However, the dynamics of glucagon in hemodialysis (HD) patients with type 2 diabetes mellitus (T2DM) remain unclear. OBJECTIVES: The aim of this study was to assess the dynamics of glucagon in HD patients with T2DM. MATERIALS AND METHODS: We measured plasma glucagon in HD patients with T2DM by liquid chromatography-high-resolution mass spectrometry (LC-HRMS), sandwich enzyme-linked immunosorbent assay (ELISA), and radioimmunoassay (RIA). The glucagon levels measured by each method were compared. We used the glucagon levels determined by our developed LC-HRMS method as the standard in this study. RESULTS: Plasma glucagon levels measured by LC-HRMS before HD were significantly higher than those measured after HD. Plasma glucagon levels measured using sandwich ELISA had a significantly higher correlation with those measured using LC-HRMS compared with RIA. CONCLUSIONS: This was the first study to assess glucagon levels in HD patients with T2DM using LC-HRMS, which is considered a highly accurate method. Sandwich ELISA was shown to measure glucagon levels accurately as well.

    DOI: 10.1159/000518027

    PubMed

    researchmap

  • 糸球体結節性病変と係蹄壁へのIgG線状沈着を呈した境界型糖尿病の1例

    山口 浩毅, 細島 康宏, 蒲澤 秀門, 後藤 佐和子, 後藤 慧, 伊藤 由美, 今井 直史, 金子 佳賢, 鈴木 芳樹, 齋藤 亮彦, 成田 一衛

    糖尿病   64 ( 7 )   411 - 411   2021.7

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • 進行期CKD患者における栄養指導の実際(横断研究) REACH-J-CKDコホート研究より

    細島 康宏, 蒲澤 秀門, 村山 稔子, 若杉 三奈子, 鈴木 芳樹, 斎藤 亮彦, 岡田 浩一, 和田 隆志, 山縣 邦弘, 柏原 直樹, 成田 一衛

    日本腎臓学会誌   63 ( 4 )   461 - 461   2021.6

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • 透析患者における経腸栄養と静脈栄養 up to date 維持血液透析患者における透析時静脈栄養(IDPN)の実際

    細島 康宏, 蒲澤 秀門, 鈴木 芳樹, 斎藤 亮彦, 成田 一衛

    日本透析医学会雑誌   54 ( Suppl.1 )   217 - 217   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本透析医学会  

    researchmap

  • 小児尿中メガリン基準値の設定

    金子 昌弘, 山田 剛史, 後藤 佐和子, 蒲澤 秀門, 細島 康宏, 斎藤 亮彦

    日本小児腎臓病学会雑誌   34 ( 1Suppl. )   136 - 136   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本小児腎臓病学会  

    researchmap

  • 2型糖尿病患者におけるCOVID-19の流行が食事習慣に及ぼす影響に関する自記式食事歴法質問票(DHQ)を用いた検討

    蒲澤 秀門, 細島 康宏, 村山 稔子, 桑原 頌治, 鈴木 芳樹, 成田 一衛, 斎藤 亮彦

    糖尿病   64 ( Suppl.1 )   I - 5   2021.5

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • 腎臓における脂肪酸処理の正しく評価されていないメカニズム 脂肪酸再吸収のための優れた機能(Unappreciated mechanisms of fatty acids handling in the kidney: Remarkable capability for fatty acid reabsorption)

    川上 亮, 大日方 英, 花岡 宏史, 金井 彩香, 中野 大介, 齋藤 亮彦, 西山 成, 柳田 素子, 倉林 正彦, 磯 達也

    日本内分泌学会雑誌   96 ( 4 )   1116 - 1116   2021.4

     More details

    Language:English   Publisher:(一社)日本内分泌学会  

    researchmap

  • Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study

    Yuta Yoshizawa, Michihiro Hosojima, Hideyuki Kabasawa, Naohito Tanabe, Daisuke Ugamura, Yutaka Koda, Hisaki Shimada, Tetsuya Takasawa, Takahito Ito, Tadahiro Kitamura, Masaki Kobayashi, Yoshiki Suzuki, Ichiei Narita, Akihiko Saito

    DIABETES THERAPY   12 ( 3 )   655 - 667   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER HEIDELBERG  

    Introduction: Dipeptidyl peptidase 4 (DPP4) inhibitors are widely used in patients with type 2 diabetes mellitus (T2DM) on maintenance hemodialysis (HD), but the efficacy of the once-weekly DPP4 inhibitor omarigliptin is not known.Methods: This prospective, randomized, open-label, parallel-group, non-inferiority/superiority, once-daily DPP4 inhibitor linagliptin-controlled, multicenter study examined glycemic control and safety of omarigliptin (UMIN000024284). Sample size was calculated to confirm non-inferiority in terms of changes in glycated hemoglobin (HbA1c). We enrolled 33 patients with T2DM on maintenance HD who had been treated with linagliptin for at least 3 months. The patients were randomized to receive omarigliptin (12.5 mg/week; n = 16) or linagliptin (5 mg/day; n = 17). Primary endpoints were changes in HbA1c and glycoalbumin (GA) over 24 weeks.Results: Differences in the mean change in primary endpoint values between the omarigliptin and linagliptin groups were - 0.61% [- 1.14, - 0.09] for HbA1c, with a two-tailed upper 95% limit (i.e., one-tailed 97.5% upper limit) of 0.25%, below the non-inferiority limit, and - 1.67% [- 4.23, + 0.88] for GA, with a two-tailed upper 95% limit of 0.75%, above the non-inferiority limit. At 24 weeks, the omarigliptin group showed significantly greater reduction in HbA1c than the linagliptin group (- 0.2% +/- 0.6% vs. 0.4% +/- 0.8%, two-tailed p = 0.024) and significantly greater reduction in blood glucose after a single HD session (- 18.4 +/- 31.4 mg/dL vs. 25.2 +/- 59.5 mg/dL, respectively, two-tailed p = 0.019). No subjects in the omarigliptin group developed hypoglycemia.Conclusions: Our data showed that omarigliptin was non-inferior to linagliptin in glycemic control. Omarigliptin is feasible for glycemic control in patients with T2DM on maintenance HD.

    DOI: 10.1007/s13300-020-00991-y

    Web of Science

    researchmap

  • Effects of the Once-Weekly DPP4 Inhibitor Omarigliptin on Glycemic Control in Patients with Type 2 Diabetes Mellitus on Maintenance Hemodialysis: A 24-Week Open-Label, Multicenter Randomized Controlled Study. International journal

    Yuta Yoshizawa, Michihiro Hosojima, Hideyuki Kabasawa, Naohito Tanabe, Daisuke Ugamura, Yutaka Koda, Hisaki Shimada, Tetsuya Takasawa, Takahito Ito, Tadahiro Kitamura, Masaki Kobayashi, Yoshiki Suzuki, Ichiei Narita, Akihiko Saito

    Diabetes therapy : research, treatment and education of diabetes and related disorders   12 ( 3 )   655 - 667   2021.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: Dipeptidyl peptidase 4 (DPP4) inhibitors are widely used in patients with type 2 diabetes mellitus (T2DM) on maintenance hemodialysis (HD), but the efficacy of the once-weekly DPP4 inhibitor omarigliptin is not known. METHODS: This prospective, randomized, open-label, parallel-group, non-inferiority/superiority, once-daily DPP4 inhibitor linagliptin-controlled, multicenter study examined glycemic control and safety of omarigliptin (UMIN000024284). Sample size was calculated to confirm non-inferiority in terms of changes in glycated hemoglobin (HbA1c). We enrolled 33 patients with T2DM on maintenance HD who had been treated with linagliptin for at least 3 months. The patients were randomized to receive omarigliptin (12.5 mg/week; n = 16) or linagliptin (5 mg/day; n = 17). Primary endpoints were changes in HbA1c and glycoalbumin (GA) over 24 weeks. RESULTS: Differences in the mean change in primary endpoint values between the omarigliptin and linagliptin groups were - 0.61% [- 1.14, - 0.09] for HbA1c, with a two-tailed upper 95% limit (i.e., one-tailed 97.5% upper limit) of 0.25%, below the non-inferiority limit, and - 1.67% [- 4.23, + 0.88] for GA, with a two-tailed upper 95% limit of 0.75%, above the non-inferiority limit. At 24 weeks, the omarigliptin group showed significantly greater reduction in HbA1c than the linagliptin group (- 0.2% ± 0.6% vs. 0.4% ± 0.8%, two-tailed p = 0.024) and significantly greater reduction in blood glucose after a single HD session (- 18.4 ± 31.4 mg/dL vs. 25.2 ± 59.5 mg/dL, respectively, two-tailed p = 0.019). No subjects in the omarigliptin group developed hypoglycemia. CONCLUSIONS: Our data showed that omarigliptin was non-inferior to linagliptin in glycemic control. Omarigliptin is feasible for glycemic control in patients with T2DM on maintenance HD. CLINICAL TRIALS REGISTRATION: UMIN000024284.

    DOI: 10.1007/s13300-020-00991-y

    PubMed

    researchmap

  • Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity. International journal

    Masashi Arita, Satoshi Watanabe, Nobumasa Aoki, Shoji Kuwahara, Ryo Suzuki, Sawako Goto, Yuko Abe, Miho Takahashi, Miyuki Sato, Satoshi Hokari, Aya Ohtsubo, Satoshi Shoji, Koichiro Nozaki, Kosuke Ichikawa, Rie Kondo, Masachika Hayashi, Yasuyoshi Ohshima, Hideyuki Kabasawa, Michihiro Hosojima, Toshiyuki Koya, Akihiko Saito, Toshiaki Kikuchi

    Scientific reports   11 ( 1 )   750 - 750   2021.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cisplatin, one of the most active anticancer agents, is widely used in standard chemotherapy for various cancers. Cisplatin is more poorly tolerated than other chemotherapeutic drugs, and the main dose-limiting toxicity of cisplatin is its nephrotoxicity, which is dose-dependent. Although less toxic methods of cisplatin administration have been established, cisplatin-induced nephrotoxicity remains an unsolved problem. Megalin is an endocytic receptor expressed at the apical membrane of proximal tubules. We previously demonstrated that nephrotoxic drugs, including cisplatin, are reabsorbed through megalin and cause proximal tubular cell injury. We further found that cilastatin blocked the binding of cisplatin to megalin in vitro. In this study, we investigated whether cilastatin could reduce cisplatin-induced nephrotoxicity without influencing the antitumor effects of cisplatin. Nephrotoxicity was decreased or absent in mice treated with cisplatin and cilastatin, as determined by kidney injury molecule-1 staining and the blood urea nitrogen content. Combined with cilastatin, a twofold dose of cisplatin was used to successfully treat the mice, which enhanced the antitumor effects of cisplatin but reduced its nephrotoxicity. These findings suggest that we can increase the dose of cisplatin when combined with cilastatin and improve the outcome of cancer patients.

    DOI: 10.1038/s41598-020-80853-6

    PubMed

    researchmap

  • Effects of DPP-4 Inhibitors on Blood Glucose Variability in Japanese Patients with Type 2 Diabetes on Maintenance Hemodialysis: A Prospective Observational Exploratory Study. International journal

    Tomomi Ishikawa-Tanaka, Michihiro Hosojima, Hideyuki Kabasawa, Ryohei Kaseda, Ryota Yasukawa, Yusuke Yata, Shoji Kuwahara, Emiko Kono, Takuma Takata, Noriaki Iino, Takahiro Tanaka, Nobutaka Kitamura, Yoshiki Suzuki, Akihiko Saito, Ichiei Narita

    Diabetes therapy : research, treatment and education of diabetes and related disorders   11 ( 12 )   2845 - 2861   2020.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    INTRODUCTION: The precise blood glucose (BG) profile of hemodialysis patients is unclear, as is the effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors in hemodialysis patients with type 2 diabetes. Here, we used continuous glucose monitoring (CGM) to evaluate BG variability in these patients and to assess the efficacy of DPP-4 inhibitors, particularly during hemodialysis sessions and at nighttime (UMIN000012638). METHODS: We examined BG profiles using CGM in 31 maintenance hemodialysis patients with type 2 diabetes. Differences between patients with and without DPP-4 inhibitors (n = 15 and 16, respectively) were analyzed using a linear mixed-effects model to assess changes in glucose levels in 5-min intervals. RESULTS: The model revealed that DPP-4 inhibitor use was significantly associated with suppression of a rapid drop in glucose levels, both with and without adjustment for BG levels at the start of hemodialysis. Moreover, the model revealed that the two groups differed significantly in the pattern of changes in BG levels from 0:00 to 6:55 am. DPP-4 inhibitors suppressed the tendency for subsequent nocturnal hypoglycemia. CONCLUSIONS: This prospective observational exploratory study showed that DPP-4 inhibitors could suppress BG variability during hemodialysis sessions as well as subsequent nocturnal changes in patients with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov identifier, UMIN000012638.

    DOI: 10.1007/s13300-020-00928-5

    PubMed

    researchmap

  • インスリン使用中の維持血液透析患者におけるデュラグルチド併用による血糖管理の有効性およびQOL改善に関する探索的臨床試験

    宇賀村 大亮, 細島 康宏, 蒲澤 秀門, 田邊 直仁, 吉澤 優太, 忰田 亮平, 鈴木 芳樹, 成田 一衛, 斎藤 亮彦

    糖尿病   63 ( Suppl.1 )   S - 300   2020.8

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • Rice bran protein ameliorates diabetes, reduces fatty liver, and has renoprotective effects in Zucker Diabetic Fatty rats

    Masatoshi Kubota, Reiko Watanabe, Michihiro Hosojima, Akihiko Saito, Ai Sasou, Takehiro Masumura, Yukikazu Harada, Hiroyuki Hashimoto, Shinobu Fujimura, Motoni Kadowaki

    Journal of Functional Foods   70   103981 - 103981   2020.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Elsevier BV  

    DOI: 10.1016/j.jff.2020.103981

    researchmap

  • DKDと食事 Up to date CKD、DKD患者への食事療法 腎臓専門医の立場から(たんぱく質制限の効果も含め)

    細島 康宏, 蒲澤 秀門, 成田 一衛, 鈴木 芳樹, 斎藤 亮彦

    日本腎臓学会誌   62 ( 4 )   228 - 228   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • メガリンを介する腎内レニン-アンジオテンシン(Ang)系(RAS)の動的均衡化制御機構

    後藤 佐和子, 吉田 豊, 細島 康宏, 蒲澤 秀門, 忰田 亮平, 成田 一衛, 斎藤 亮彦

    日本腎臓学会誌   62 ( 4 )   370 - 370   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • マウス尿中メガリン測定用サンドイッチELISAの開発とその応用

    早福 莉那, 後藤 佐和子, 細島 康宏, 蒲澤 秀門, 忰田 亮平, 成田 一衛, 斎藤 亮彦

    日本腎臓学会誌   62 ( 4 )   339 - 339   2020.7

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • The cellular model of albumin endocytosis uncovers link between membrane and nuclear proteins. Reviewed International journal

    Seiya Urae, Yutaka Harita, Tomohiro Udagawa, Koji L Ode, Masami Nagahama, Yuko Kajiho, Shoichiro Kanda, Akihiko Saito, Hiroki R Ueda, Masaomi Nangaku, Akira Oka

    Journal of cell science   133 ( 13 )   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Cubilin (CUBN) and amnionless (AMN), expressed in kidney and intestine, form a multiligand receptor complex called CUBAM that plays a crucial role in albumin absorption. To date, the mechanism of albumin endocytosis mediated by CUBAM remains to be elucidated. Here, we established an assay to quantitatively evaluate the albumin uptake by CUBAM using cells expressing full-length CUBN, which elucidated the crucial role of C-terminal part of CUBN and endocytosis signal motifs of AMN in albumin endocytosis. We also demonstrated that nuclear valosin-containing protein-like 2 (NVL2), an interacting protein of AMN, is involved in this process. While NVL2 was mainly localized in the nucleolus in cells without AMN expression, it was translocated to the extranuclear compartment when co-expressed with AMN. NVL2 knockdown significantly impaired the internalization of the CUBN-albumin complex in cultured cells, demonstrating an involvement of NVL2 in endocytic regulation. These findings uncover a link between membrane and nucleolar proteins which is involved in endocytic processes.

    DOI: 10.1242/jcs.242859

    PubMed

    researchmap

  • Low bone mineral density due to secondary hyperparathyroidism in the GlatmTg(CAG-A4GALT) mouse model of Fabry disease. International journal

    Hiroki Maruyama, Atsumi Taguchi, Mariko Mikame, Hongmei Lu, Norihiro Tada, Muneaki Ishijima, Haruka Kaneko, Mariko Kawai, Sawako Goto, Akihiko Saito, Riuko Ohashi, Yuji Nishikawa, Satoshi Ishii

    FASEB bioAdvances   2 ( 6 )   365 - 381   2020.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Low bone mineral density (BMD)-diagnosed as osteoporosis or osteopenia-has been reported as a new characteristic feature of Fabry disease; however, the mechanism underlying the development of low BMD is unknown. We previously revealed that a mouse model of Fabry disease [GlatmTg(CAG-A4GALT)] exhibits impaired functioning of medullary thick ascending limb (mTAL), leading to insufficient Ca2+ reabsorption and hypercalciuria. Here, we investigated bone metabolism in GlatmTg(CAG-A4GALT) mice without marked glomerular or proximal tubular damage. Low BMD was detected by 20 weeks of age via micro-X-ray-computed tomography. Bone histomorphometry revealed that low BMD results by accelerated bone resorption and osteomalacia. Plasma parathyroid hormone levels increased in response to low blood Ca2+-not plasma fibroblast growth factor 23 (FGF-23) elevation-by 5 weeks of age and showed progressively increased phosphaturic action. Secondary hyperparathyroidism developed by 20 weeks of age and caused hyperphosphatemia, which increased plasma FGF-23 levels with phosphaturic action. The expression of 1α-hydroxylase [synthesis of 1α,25(OH)2D3] in the kidney did not decrease, but that of 24-hydroxylase [degradation of 1α,25(OH)2D3] decreased. Vitamin D deficiency was ruled out as the cause of osteomalacia, as plasma 1α,25(OH)2D3 and 25(OH)D3 levels were maintained. Results demonstrate that secondary hyperparathyroidism due to mTAL impairment causes accelerated bone resorption and osteomalacia due to hyperphosphaturia and hypercalciuria, leading to low BMD in Fabry model mice.

    DOI: 10.1096/fba.2019-00080

    PubMed

    researchmap

  • SGLT2阻害薬による腎保護作用機序と尿中コンパニオン診断法の検討

    忰田 亮平, 飯田 倫理, 細島 康宏, 蒲澤 秀門, 後藤 佐和子, 桑原 頌治, 宇賀村 大亮, 吉澤 優太, 田中 崇裕, 成田 一衛, 斎藤 亮彦

    臨床薬理の進歩   ( 41 )   148 - 153   2020.6

     More details

    Language:Japanese   Publisher:(公財)臨床薬理研究振興財団  

    軽度〜中等度腎機能障害を有する成人2型糖尿病患者(残存機能ネフロンに過剰代謝負荷がかかっていることが推測される)を対象に、エンパグリフロジンによる腎機能保護作用を検証するとともに尿中メガリン(およびメガリンリガンド分子)の動態を調べ、腎機能保護作用がメガリン機能に関連したものであるか検討した。さらに、尿中メガリンなどの検査がコンパニオン診断として有用であるか、探索的な検討を行った。また、SGLT2阻害薬がメガリンの発現・機能に及ぼす影響についても検討を継続した。臨床試験の被験者51名で、平均年齢は62歳であり、男性が32名であった。2名が有害反応のため脱落したが、6ヵ月後、HbA1cとBMIが減少した。現在、メガリンを含む尿中バイオマーカーの推移について解析を行っている。ダパグリフロジン、エンパグリフロジンを投与されたマウスでは尿中の糖排泄増加を認めたが血糖値に差は認められなかった。免疫組織化学染色では近位尿細管におけるメガリンの染色性が低下していることが確認された。またウエスタンブロット法において、メガリンの蛋白がvehicle群と比較して低下していることが認められた。リアルタイムRT-PCRにおいてもメガリンmRNAがvehicle群と比較して低下していることが確認された。ダパグリフロジンを添加されたIRPTCではメガリン蛋白の低下が認められ、mRNAの低下も認められた。

    researchmap

  • Rice Endosperm Protein Administration to Juvenile Mice Regulates Gut Microbiota and Suppresses the Development of High-Fat Diet-Induced Obesity and Related Disorders in Adulthood. Reviewed International journal

    Yuki Higuchi, Michihiro Hosojima, Hideyuki Kabasawa, Shoji Kuwahara, Sawako Goto, Koji Toba, Ryohei Kaseda, Takahiro Tanaka, Nobutaka Kitamura, Hayato Takihara, Shujiro Okuda, Masayuki Taniguchi, Hitoshi Arao, Ichiei Narita, Akihiko Saito

    Nutrients   11 ( 12 )   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Obesity and related disorders, which are increasing in adults worldwide, are closely linked to childhood diet and are associated with chronic inflammation. Rice endosperm protein (REP) intake during adulthood has been reported to improve lipid metabolism and suppress the progression of diabetic kidney disease in animal models. However, the effects of REP intake during childhood on adulthood health are unclear. Therefore, we used a mouse model to experimentally investigate the preconditioning effects of REP intake during childhood on the development of obesity and related disorders in adulthood. Male C57BL/6J mice were pair-fed a normal-fat diet containing casein or REP during the juvenile period and then a high-fat diet (HFD) containing casein or REP during adulthood. Mice fed REP during the juvenile period showed better body weight, blood pressure, serum lipid profiles, lipopolysaccharide (LPS)-binding protein levels, and glucose tolerance in adulthood than those fed casein during the juvenile period. HFD-induced renal tubulo-glomerular alterations and hepatic microvesicular steatosis were less evident in REP-fed mice than in casein-fed ones. REP intake during the juvenile period improved HFD-induced dysbiosis (i.e., Escherichia genus proliferation and reduced gut microbiota diversity), thereby suppressing endotoxin-related chronic inflammation. Indeed, REP-derived peptides showed antibacterial activity against Escherichia coli, a major producer of LPS. In conclusion, REP supplementation during the juvenile period may regulate the gut microbiota and thus suppress the development of obesity and related disorders in adulthood in mice.

    DOI: 10.3390/nu11122919

    PubMed

    researchmap

  • Correlation of prechemotherapy urinary megalin ectodomain (A-megalin) levels with the development of cisplatin-induced nephrotoxicity: a prospective observational study. Reviewed International journal

    Satoshi Shoji, Michihiro Hosojima, Hideyuki Kabasawa, Rie Kondo, Satoru Miura, Satoshi Watanabe, Nobumasa Aoki, Ryohei Kaseda, Shoji Kuwahara, Naohito Tanabe, Yoshiaki Hirayama, Ichiei Narita, Toshiaki Kikuchi, Hiroshi Kagamu, Akihiko Saito

    BMC cancer   19 ( 1 )   1170 - 1170   2019.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Cisplatin is a potent chemotherapeutic agent used to treat a variety of solid tumors. One of the major side effects of cisplatin is dose-limiting nephrotoxicity. We recently demonstrated that the renal uptake of cisplatin and resultant cisplatin-induced nephrotoxicity are mediated in part by megalin, an endocytic receptor in proximal tubule epithelial cells (PTECs). We also developed sandwich enzyme-linked immunosorbent assays to measure the megalin ectodomain (A-megalin) and full-length megalin (C-megalin) in urine using monoclonal antibodies against the amino- and carboxyl-termini of megalin, respectively. The present study examined the correlation of urinary megalin level with cisplatin-induced nephrotoxicity and its utility as a biomarker in patients with thoracic cancer. METHODS: This prospective observational study involved 45 chemotherapy-naïve patients scheduled to receive chemotherapy with ≥60 mg/m2 cisplatin for histologically diagnosed small cell lung cancer, non-small cell lung cancer, or malignant pleural mesothelioma. Before and after the first course of chemotherapy, we measured urinary A- and C-megalin and other markers of PTEC injury, such as N-acetyl-β-D-glucosaminidase, α1-microglobulin, β2-microglobulin, neutrophil gelatinase-associated lipocalin, and liver-type fatty acid-binding protein, and compared the values with the change in the estimated glomerular filtration rate (eGFR) and clinical risk factors for renal impairment. RESULTS: A negative correlation was found between baseline urinary A-megalin levels and change in eGFR (r = - 0.458, P = 0.002). According to Kaplan-Meier survival curves, eGFR decline was associated with the baseline urinary A-megalin quartile (P = 0.038). In addition, according to the hazard ratios (HRs) for eGFR decline > 10 mL/min/1.73 m2 calculated using a Cox proportional hazard model, the highest quartile had a significantly higher risk of eGFR decline compared with the lowest quartile (HR 7.243; 95% confidence interval 1.545-33.962). Other baseline urinary markers showed no correlation with eGFR decline. CONCLUSIONS: This is the first report demonstrating that prechemotherapy urinary A-megalin levels are correlated with the development of cisplatin-induced nephrotoxicity. This finding has clinical implications for the identification of patients at risk for cisplatin-induced nephrotoxicity and the development of possible prophylactic therapies.

    DOI: 10.1186/s12885-019-6398-2

    PubMed

    researchmap

  • Higher estimated net endogenous acid production with lower intake of fruits and vegetables based on a dietary survey is associated with the progression of chronic kidney disease. Reviewed International journal

    Koji Toba, Michihiro Hosojima, Hideyuki Kabasawa, Shoji Kuwahara, Toshiko Murayama, Keiko Yamamoto-Kabasawa, Ryohei Kaseda, Eri Wada, Reiko Watanabe, Naohito Tanabe, Yoshiki Suzuki, Ichiei Narita, Akihiko Saito

    BMC nephrology   20 ( 1 )   421 - 421   2019.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Dietary acid load has been suggested to mediate the progression of chronic kidney disease (CKD). However, it is unclear what kinds of foods are actually associated with dietary acid load in patients with CKD. The self-administered diet history questionnaire (DHQ), which semi-quantitatively assesses the dietary habits of Japanese individuals through 150 question items, can estimate average daily intake of various foods and nutrients during the previous month. Using the DHQ, we investigated the association of dietary acid load with CKD progression. We also analyzed the kinds of food that significantly affect dietary acid load. METHODS: Subjects were 96 outpatients with CKD (average estimated glomerular filtration rate [eGFR], 53.0 ± 18.1 ml/min/1.73 m2) at Niigata University Hospital, who had completed the DHQ in 2011. We calculated net endogenous acid production (NEAP) from potassium and protein intake evaluated by the DHQ in order to assess dietary acid load. CKD progression was assessed by comparing eGFR between 2008 and 2014. RESULTS: NEAP was not correlated with protein intake (r = 0.088, p = 0.398), but was negatively correlated with potassium intake (r = - 0.748, p < 0.001). Reduction in eGFR from 2008 to 2014 was estimated to be significantly greater in patients with higher NEAP (NEAP > 50.1 mEq/day, n = 45) than in those with lower NEAP (NEAP ≤50.1 mEq/day, n = 50) by 5.9 (95% confidence interval [95%CI], 0.1 to 11.6) ml/min/1.73 m2. According to multiple logistic regression analysis, higher NEAP was significantly associated with lower intake of fruits (odds ratio [OR], 6.454; 95%CI, 2.19 to 19.00), green and yellow vegetables (OR, 5.18; 95%CI, 1.83 to14.66), and other vegetables (OR, 3.87; 95%CI, 1.29 to 11.62). CONCLUSIONS: Elevated NEAP could be a risk factor for CKD progression. Low intake of fruits and vegetables would increase dietary acid load and might affect the progression of renal dysfunction in Japanese CKD patients.

    DOI: 10.1186/s12882-019-1591-8

    PubMed

    researchmap

  • Podocyte Injury Augments Intrarenal Angiotensin II Generation and Sodium Retention in a Megalin-Dependent Manner. Reviewed International journal

    Masahiro Koizumi, Kohei Ueda, Fumio Niimura, Akira Nishiyama, Motoko Yanagita, Akihiko Saito, Ira Pastan, Toshiro Fujita, Masafumi Fukagawa, Taiji Matsusaka

    Hypertension (Dallas, Tex. : 1979)   74 ( 3 )   509 - 517   2019.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We have previously shown that podocyte injury increases the glomerular filtration of liver-derived Agt (angiotensinogen) and the generation of intrarenal Ang II (angiotensin II) and that the filtered Agt is reabsorbed by proximal tubules in a manner dependent on megalin. In the present study, we aimed to study the role of megalin in the generation of renal Ang II and sodium handling during nephrotic syndrome. We generated proximal tubule-specific megalin KO (knockout) mice and crossed these animals with NEP25 mice, in which podocyte-specific injury can be induced by injection of the immunotoxin LMB2. Without podocyte injury, renal Agt staining was markedly diminished and urinary Agt increased in KO mice. However, renal Ang II was similar between KO and control mice on average: 117 (95% CI, 101-134) versus 101 (95% CI, 68-133) fmol/g tissue. We next tested the effect of megalin KO on intrarenal Ang II generation with podocyte injury. Control NEP25 mice showed markedly increased renal Agt staining and renal Ang II levels: 450 (336-565) fmol/g tissue. Megalin KO/NEP25 mice showed markedly diminished Agt reabsorption and attenuated renal Ang II: 199 (156-242) fmol/g tissue (P<0.001). Compared with control NEP25 mice, megalin KO/NEP25 mice excreted 5-fold more sodium in the urine. Western blot analysis showed that megalin KO decreased NHE3 and the cleaved α and γ forms of Epithelial Na Channel. These data indicate that Agt reabsorbed by proximal tubules via megalin in nephrotic syndrome is converted to Ang II, which may contribute to sodium retention and edema formation by activating NHE3 and Epithelial Na Channel.

    DOI: 10.1161/HYPERTENSIONAHA.118.12352

    PubMed

    researchmap

  • シラスタチンによりシスプラチン腎症を抑制することでシスプラチン投与を増量できる(Cilastatin suppresses cisplatin-induced nephrotoxicity and enables to increase the dose of cisplatin for cancer therapy)

    有田 将史, 渡部 聡, 青木 信将, 高橋 美帆, 庄子 聡, 野嵜 幸一郎, 市川 紘将, 近藤 利恵, 桑原 頌治, 田中 純太, 小屋 俊之, 斎藤 亮彦, 菊地 利明

    日本癌学会総会記事   78回   P - 1398   2019.9

     More details

    Language:English   Publisher:日本癌学会  

    researchmap

  • 2型糖尿病を合併した維持血液透析患者におけるオマリグリプチンの有用性の検討

    吉澤 優太, 細島 康宏, 蒲澤 秀門, 田邊 直仁, 甲田 豊, 島田 久基, 高澤 哲也, 伊藤 孝仁, 鈴木 芳樹, 成田 一衛, 斎藤 亮彦

    糖尿病   62 ( 7 )   419 - 419   2019.7

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • Association of estimated dietary acid load with albuminuria in Japanese adults: a cross-sectional study. Reviewed

    Kabasawa K, Hosojima M, Takachi R, Nakamura K, Ito Y, Saito A, Sawada N, Tsugane S, Tanaka J, Narita I

    BMC nephrology   20 ( 1 )   194   2019.5

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1186/s12882-019-1352-8

    PubMed

    researchmap

    Other Link: http://link.springer.com/article/10.1186/s12882-019-1352-8/fulltext.html

  • 自記式食事歴質問票(DHQ)を用いたSGLT2阻害薬の効果と食事摂取状況の検討

    村山 稔子, 細島 康宏, 蒲澤 秀門, 桑原 頌治, 田中 崇裕, 鈴木 芳樹, 成田 一衛, 斎藤 亮彦

    糖尿病   62 ( Suppl.1 )   S - 263   2019.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • Significance of urinary C-megalin excretion in vitamin D metabolism in pre-dialysis CKD patients. Reviewed International journal

    Toi N, Inaba M, Ishimura E, Tsugawa N, Imanishi Y, Emoto M, Hirayama Y, Nakatani S, Saito A, Yamada S

    Scientific reports   9 ( 1 )   2207 - 2207   2019.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Serum 1,25(OH)2D and 24,25(OH)2D are decreased in CKD. Megalin in proximal tubular epithelial cells reabsorbs glomerular-filtered 25(OH)D-DBP complex to convert 25(OH)D to 1,25(OH)2D and 24,25(OH)2D. Urinary C-megalin excretion is increased via exocytosis from injured nephrons overloaded with megalin-mediated protein metabolism. This study investigated the significance of urinary C-megalin excretion in vitamin D metabolism in 153 pre-dialysis CKD patients. Urinary C-megalin was positively associated with urinary protein, β2MG and α1MG, and exhibited negative correlations with serum 25(OH)D, 1,25(OH)2D and 24,25(OH)2D. Multiple regression analysis showed that urinary C-megalin had a significantly negative association with 25(OH)D. Serum 1,25(OH)2D and 24,25(OH)2D, as well as 1,25(OH)2D/25(OH)D and 24,25(OH)2D/25(OH)D ratios, showed positive correlations with eGFR. Additionally, wholePTH was positively associated with 1,25(OH)2D/25(OH)D and 1,25(OH)2D/24,25(OH)2D, while FGF23 was positively associated with 24,25(OH)2D/25(OH)D and negatively with 1,25(OH)2D/24,25(OH)2D. Urinary C-megalin emerged as an independent factor positively associated with 1,25(OH)2D/25(OH)D and 1,25(OH)2D/24,25(OH)2D. Although 1,25(OH)2D and 24,25(OH)2D are decreased in CKD patient serum, our findings suggest that PTH and FGF23 retain their effects to regulate vitamin D metabolism even in the kidneys of these patients, while production of 1,25(OH)2D and 24,25(OH)2D from 25(OH)D is restricted due to either impairment of megalin-mediated reabsorption of the 25(OH)D-DBP complex or reduced renal mass.

    DOI: 10.1038/s41598-019-38613-8

    PubMed

    researchmap

  • β2-Microglobulin and Neutrophil Gelatinase-Associated Lipocalin, Potential Novel Urine Biomarkers in Periodontitis: A Cross-Sectional Study in Japanese. Reviewed International journal

    Mayuka Nakajima, Michihiro Hosojima, Koichi Tabeta, Sayuri Miyauchi, Miki Yamada-Hara, Naoki Takahashi, Haruna Miyazawa, Yumi Matsuda-Matsukawa, Keisuke Sato, Noriko Sugita, Yasutaka Komatsu, Tomomi Ishikawa, Kazuhiro Akiishi, Kazuhisa Yamazaki, Kiminori Kato, Akihiko Saito, Hiromasa Yoshie

    International journal of dentistry   2019   1394678 - 1394678   2019

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Objectives: Several serum biomarkers have been reported to increase in periodontitis patients as possible mediators linking periodontal inflammation to systemic diseases. However, the relationship between periodontitis and urine biomarkers is still unclear. The aim of this cross-sectional study was to investigate potential urine biomarkers of periodontitis in a Japanese population. Materials and Methods: This study included 108 male subjects, and microbiological and clinical parameters were evaluated as a periodontitis marker. The correlation between nine urine biomarkers (typically used to diagnose kidney disease) and periodontal parameters was analyzed. Based on the findings, β2-microglobulin (β2-MG) and neutrophil gelatinase-associated lipocalin (NGAL) were selected for comparison and multivariate regression analysis, and the Kruskal-Wallis test followed by Bonferroni correction was used to identify differences in their concentrations between the three periodontitis groups (severe, moderate, and no/mild periodontitis). Results: β2-MG and NGAL exhibited a significant correlation with clinical parameters of periodontitis. The prevalence of clinical parameters such as bleeding on probing and number of sites with probing depth (PD) ≥ 6 mm were greater in the β2-MG high group (≥300 μg/g creatinine) than in the normal group (P=0.017 and 0.019, respectively). Multivariate regression analysis indicated that the number of sites with PD ≥ 6 mm was independently associated with urine β2-MG. Moreover, the number of sites with the clinical attachment level (CAL) ≥ 6 mm was greater in the NGAL high group (highest quartile) (P=0.041). Multivariate regression analysis showed that the number of sites with CAL ≥ 6 mm was associated independently with urine NGAL. Finally, β2-MG was significantly higher in the severe periodontitis subjects compared to the no/mild periodontitis subjects. Conclusion: The significant association between urine β2-MG or NGAL and periodontitis was revealed. These biomarkers can potentially be used to screen for or diagnose periodontitis. This trial is registered with the UMIN Clinical Trials Registry UMIN000013485.

    DOI: 10.1155/2019/1394678

    PubMed

    researchmap

  • Circulating FABP4 is eliminated by the kidney via glomerular filtration followed by megalin-mediated reabsorption Reviewed International journal

    Shrestha S, Sunada S, Hanaoka H, Yamaguchi A, Kuwahara S, Umbarawan Y, Nakajima K, Machida T, Murakami M, Saito A, Tsushima Y, Kurabayashi M, Iso T

    Scientific Reports (2018)   8 ( 16451 )   16451 - 16451   2018.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Circulating fatty acid binding protein 4 (FABP4), secreted from adipocytes, is a potential biomarker for metabolic and cardiovascular diseases. Circulating FABP4 levels are positively associated with adiposity and adrenergic stimulation, but negatively with renal function. In this study, we addressed the issue of how the kidney regulates clearance of circulating FABP4. Tracing study revealed remarkable accumulation of 125I-labeled FABP4 in the kidney. Exogenous FABP4 was exclusively detected in the apical membrane of proximal tubule epithelial cells (PTECs). Bilateral nephrectomy resulted in marked elevation of circulating FABP4 levels. Accelerated lipolysis by β-3 adrenergic stimulation led to a marked elevation in circulating FABP4 in mice with severe renal dysfunction. Megalin, an endocytic receptor expressed in PTECs, plays a major role in reabsorption of proteins filtered through glomeruli. Quartz-crystal microbalance study revealed that FABP4 binds to megalin. In kidney-specific megalin knockout mice, a large amount of FABP4 was excreted in urine while circulating FABP4 levels were significantly reduced. Our data suggest that circulating FABP4 is processed by the kidney via the glomerular filtration followed by megalin-mediated reabsorption. Thus, it is likely that circulating FABP4 levels are determined mainly by balance between secretion rate of FABP4 from adipocytes and clearance rate of the kidney.

    DOI: 10.1038/s41598-018-34902-w

    PubMed

    researchmap

  • 週1回のGLP-1受容体作動薬エキセナチド使用中に腸管気腫症の増悪を来した1例

    石川 友美, 細島 康宏, 佐藤 健, 塩谷 基, 蒲澤 秀門, 忰田 亮平, 中枝 武司, 和田 庸子, 鈴木 芳樹, 斎藤 亮彦, 成田 一衛

    糖尿病   61 ( 9 )   624 - 624   2018.9

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • Increased serum PCSK9, a potential biomarker to screen for periodontitis, and decreased total bilirubin associated with probing depth in a Japanese community survey Reviewed

    K. Tabeta, M. Hosojima, M. Nakajima, S. Miyauchi, H. Miyazawa, N. Takahashi, Y. Matsuda, N. Sugita, Y. Komatsu, K. Sato, T. Ishikawa, K. Akiishi, K. Yamazaki, K. Kato, A. Saito, H. Yoshie

    Journal of Periodontal Research   53 ( 3 )   446 - 456   2018.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Blackwell Munksgaard  

    Background and Objectives: Previous reports suggest that several serum biomarkers play roles in the pathogenesis, inflammatory response, and oxidative stress in periodontitis caused by bacterial infections, linking chronic periodontitis to atherosclerotic vascular disease (ASVD). The aim of this preliminary study was to investigate, in a Japanese cross-sectional community survey, potential serum biomarkers of periodontitis that are associated with ASVD and chronic periodontitis. Material and Methods: The study cohort included a total of 108 male subjects who underwent annual health examinations. Serum biomarkers (high-sensitivity C-reactive protein [hs-CRP], proprotein convertase subtilisin/kexin type 9 [PCSK9], interleukin-6, tumor necrosis factor-α, soluble CD14, myeloperoxidase, matrix metalloproteinase-3, adiponectin, total bilirubin [TBIL], and serum lipids) were analyzed to determine their association (if any) with periodontal parameters. Aortic stiffness was evaluated using the brachial-ankle aortic pulse wave velocity (PWV) index and the cardio-ankle vascular index (CAVI). Results: The concentrations of PCSK9 and hs-CRP were increased (P =.001 and.042, respectively), and the concentration of TBIL was decreased (P =.046), in subjects with periodontal disease (determined as a probing depth of ≥4 mm in at least one site) compared with periodontally healthy subjects. The ratio of low-density lipoprotein cholesterol (LDL-C) to high-density lipoprotein cholesterol and the concentrations of triglycerides, remnant-like particles-cholesterol, and oxidized LDL were elevated in subjects with periodontal disease compared with periodontally healthy subjects (P =.038,.007,.002, and.049, respectively). Multivariate regression analyses indicated that the number of sites with a pocket depth of ≥4 mm was associated with the concentration of PCSK9 and inversely associated with the concentration of TBIL independently (standardized β =.243, P =.040
    standardized β = −.443, P =.0002
    respectively). Analysis of receiver operating characteristic curves of PCSK9 indicated moderate accuracy for predicting the presence of disease sites (probing depth ≥ 4 mm) (area under the curve = 0.740). No significance in the values of PWV and CAVI was observed between subjects with periodontal disease and periodontally healthy subjects. Conclusion: In Japanese male subjects, the concentrations of serum PCSK9 and TBIL were correlated with periodontal parameters. Moreover, PCSK9 could be a candidate biomarker for diagnosing chronic periodontitis, and may also have potential to evaluate the risk for periodontitis to cause ASVD. Longitudinal studies of larger populations are necessary to confirm the exact association of periodontitis with increased serum PCSK9 and decreased TBIL.

    DOI: 10.1111/jre.12533

    Scopus

    PubMed

    researchmap

  • Bardoxolone methylによる腎近位尿細管のメガリン調節機構の検討

    吉澤 優太, 桑原 頌治, 細島 康宏, 蒲澤 秀門, 忰田 亮平, 宇賀村 大亮, 後藤 佐和子, 飯田 倫理, 鈴木 芳樹, 成田 一衛, 斎藤 亮彦

    糖尿病   61 ( Suppl.1 )   S - 383   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • SGLT2阻害薬ダパグリフロジンの腎近位尿細管細胞における血糖値非依存的なメガリン発現抑制作用

    飯田 倫理, 桑原 頌治, 細島 康宏, 石川 友美, 後藤 佐和子, 蒲澤 秀門, 忰田 亮平, 鈴木 芳樹, 成田 一衛, 斎藤 亮彦

    糖尿病   61 ( Suppl.1 )   S - 382   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • 幼少期における米(胚乳)タンパク質の摂取が成熟期の高脂肪食負荷による肥満および肥満関連腎症に及ぼす影響

    樋口 裕樹, 細島 康宏, 蒲澤 秀門, 桑原 頌治, 忰田 亮平, 成田 一衛, 斎藤 亮彦

    糖尿病   61 ( Suppl.1 )   S - 241   2018.4

     More details

    Language:Japanese   Publisher:(一社)日本糖尿病学会  

    researchmap

  • Urinary C-megalin for screening of renal scarring in children after febrile urinary tract infection Reviewed

    Sohsaku Yamanouchi, Takahisa Kimata, Jiro Kino, Tetsuya Kitao, Chikushi Suruda, Shoji Tsuji, Hiroyuki Kurosawa, Yoshiaki Hirayama, Akihiko Saito, Kazunari Kaneko

    Pediatric Research   83 ( 3 )   662 - 668   2018.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Nature Publishing Group  

    BackgroundFebrile urinary tract infection (fUTI) in children may cause renal scarring. This study aimed to investigate the usefulness of urinary biomarkers for diagnosing renal scarring after fUTI.MethodsThirty-seven children (median age: 1.36 years, range: 0.52-12.17 years, 25 boys) with a history of fUTI, who underwent renal scintigraphy for 4 months or longer after the last episode of fUTI, were analyzed. A spot urine sample was obtained on the day of renal scintigraphy to measure levels of total protein, N-acetyl-β-D-glucosaminidase (NAG), β 2 -microglobulin (BMG), neutrophil gelatinase-associated lipocalin (NGAL), liver-type fatty acid binding protein (L-FABP), and C-megalin (full-length megalin). Results were corrected for urinary creatinine (Cr) and compared between the group with renal scarring (n=23) and that without scarring (n=14). Urinary levels of C-megalin were also measured in healthy control subjects.ResultsNo significant differences in total protein, NGAL, L-FABP, NAG, and BMG levels were found between the groups. However, C-megalin levels were significantly higher in the renal scarring group than in the non-renal scarring group and healthy controls (P&lt
    0.001). A cutoff value of 6.5 pmol/nmol of urinary C-megalin/Cr yielded 73.9% of specificity and 92.9% of sensitivity.ConclusionUrinary C-megalin is useful for diagnosing renal scarring caused by fUTI.

    DOI: 10.1038/pr.2017.276

    Web of Science

    Scopus

    PubMed

    researchmap

  • Amnionless-mediated glycosylation is crucial for cell surface targeting of cubilin in renal and intestinal cells. Reviewed International journal

    Tomohiro Udagawa, Yutaka Harita, Kenichiro Miura, Jun Mitsui, Koji L Ode, Shinichi Morishita, Seiya Urae, Shoichiro Kanda, Yuko Kajiho, Haruko Tsurumi, Hiroki R Ueda, Shoji Tsuji, Akihiko Saito, Akira Oka

    Scientific reports   8 ( 1 )   2351 - 2351   2018.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Mutations in either cubilin (CUBN) or amnionless (AMN) genes cause Imerslund-Gräsbeck syndrome (IGS), a hereditary disease characterised by anaemia attributed to selective intestinal malabsorption of cobalamin and low-molecular weight proteinuria. Although cubilin protein does not have a transmembrane segment, it functions as a multi-ligand receptor by binding to the transmembrane protein, amnionless. We established a system to quantitatively analyse membrane targeting of the protein complex in cultured renal and intestinal cells and analysed the pathogenic mechanisms of mutations found in IGS patients. A novel CUBN mutation, several previously reported CUBN missense mutations and all previously reported AMN missense mutations resulted in endoplasmic reticulum (ER) retention and completely inhibited amnionless-dependent plasma membrane expression of cubilin. The ER retention of cubilin and amnionless was confirmed in renal proximal tubular cells of a patient with IGS. Notably, the interaction between cubilin and amnionless was not sufficient, but amnionless-mediated glycosylation of cubilin was necessary for their surface expression. Quantitative mass spectrometry and mutagenesis demonstrated that N-linked glycosylation of at least 4 residues of cubilin protein was required for its surface targeting. These results delineated the molecular mechanisms of membrane trafficking of cubilin in renal and intestinal cells.

    DOI: 10.1038/s41598-018-20731-4

    Web of Science

    PubMed

    researchmap

  • Urinary Iron Excretion is Associated with Urinary Full-Length Megalin and Renal Oxidative Stress in Chronic Kidney Disease. Reviewed

    Nakatani S, Nakatani A, Ishimura E, Toi N, Tsuda A, Mori K, Emoto M, Hirayama Y, Saito A, Inaba M

    Kidney & blood pressure research   43 ( 2 )   458 - 470   2018

  • [Exosomal biomarkers for kidney disease.] Reviewed

    Hosojima M, Kabasawa H, Kuwahara S, Saito A

    Clinical calcium   28 ( 2 )   252 - 259   2018

     More details

  • A Randomized, Double-Blind, Crossover Pilot Trial of Rice Endosperm Protein Supplementation in Maintenance Hemodialysis Patients Reviewed

    Michihiro Hosojima, Hisaki Shimada, Yoshitsugu Obi, Shoji Kuwahara, Ryohei Kaseda, Hideyuki Kabasawa, Hazuki Kondo, Mikio Fujii, Reiko Watanabe, Yoshiki Suzuki, Motoni Kadowaki, Shigeru Miyazaki, Akihiko Saito

    SCIENTIFIC REPORTS   7 ( 1 )   18003   2017.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    In maintenance hemodialysis (MHD) patients, low protein intake is associated with protein-energy wasting, a risk factor that affects outcome. However, increased protein intake may lead to hyperphosphatemia and hyperkalemia, which are also mortality risk factors. Here, we evaluated the safety and effects of purified rice endosperm protein (REP), which contains less phosphorus and potassium than soy and casein proteins, as a supplemental protein source for MHD patients. This randomized, double-blind, placebo-controlled, crossover pilot study of REP supplementation (5 g/day x 4 weeks) was carried out in 50 Japanese adult MHD patients (1 dropped out); the primary outcome was the change in the urea kinetic-based normalized protein catabolic rate (nPCR), an indicator of protein intake in MHD patients. Intention-to-treat analyses of 24 patients in the REP-first group and 25 in the placebo-first group showed that REP supplementation increased nPCR significantly by 0.07 g/kg/day (95% confidence interval, 0.03-0.11), whereas changes in serum phosphorus and potassium concentrations were not different from the placebo. REP supplementation did not show a significant effect on other nutritional or metabolic parameters and no specific complications. In conclusion, purified REP with efficient bioavailability may be safe and useful for dietary supplementation in MHD patients.

    DOI: 10.1038/s41598-017-18340-8

    Web of Science

    PubMed

    researchmap

  • Megalin Blockade with Cilastatin Suppresses Drug-Induced Nephrotoxicity Reviewed

    Yoshihisa Hori, Nobumasa Aoki, Shoji Kuwahara, Michihiro Hosojima, Ryohei Kaseda, Sawako Goto, Tomomichi Iida, Shankhajit De, Hideyuki Kabasawa, Reika Kaneko, Hiroyuki Aoki, Yoshinari Tanabe, Hiroshi Kagamu, Ichiei Narita, Toshiaki Kikuchi, Akihiko Saito

    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY   28 ( 6 )   1783 - 1791   2017.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC NEPHROLOGY  

    Nephrotoxicity induced by antimicrobial or anticancer drugs is a serious clinical problem. Megalin, an endocytic receptor expressed at the apical membranes of proximal tubules, mediates the nephrotoxicity of aminoglycosides and colistin, key antimicrobials for multidrug-resistant organisms. The mechanisms underlying the nephrotoxicity induced by vancomycin, an antimicrobial for methicillin-resistant Staphylococcus aureus, and cisplatin, an important anticancer drug, are unknown, although the nephrotoxicity of these drugs and gentamicin, an aminoglycoside, is suppressed experimentally with cilastatin. In the clinical setting, cilastatin has been used safely to suppress dehydropeptidase-I-mediated renal metabolism of imipenem, a carbapenem antimicrobial, and thereby limit tubular injury. Here, we tested the hypothesis that cilastatin also blocks megalin-mediated uptake of vancomycin, cisplatin, colistin, and aminoglycosides, thereby limiting the nephrotoxicity of these drugs. Quartz crystal microbalance analysis showed that megalin also binds vancomycin and cisplatin and that cilastatin competes with megalin for binding to gentamicin, colistin, vancomycin, and cisplatin. In kidney specific mosaic megalin knockout mice treated with colistin, vancomycin, or cisplatin, the megalin-replete proximal tubule epithelial cells exhibited signs of injury, whereas the megalin-deficient cells did not. Furthermore, concomitant cilastatin administration suppressed colistin-induced nephrotoxicity in C57BL/6J mice. Notably, cilastatin did not inhibit the antibacterial activity of gentamicin, colistin, or vancomycin in vitro, just as cilastatin did not affect the anticancer activity of cisplatin in previous studies. In conclusion, megalin blockade with cilastatin efficiently suppresses the nephrotoxicity induced by gentamicin, colistin, vancomycin, or cisplatin. Cilastatin may be a promising agent for inhibiting various forms of drug-induced nephrotoxicity mediated via megalin in the clinical setting.

    DOI: 10.1681/ASN.2016060606

    Web of Science

    PubMed

    researchmap

  • Differences in the adsorption of nafamostat mesilate between polyester-polymer alloy and polysulfone membranes Reviewed

    Sawako Goto, Susumu Ookawara, Akihiko Saito

    JOURNAL OF ARTIFICIAL ORGANS   20 ( 2 )   138 - 144   2017.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER JAPAN KK  

    We previously experienced severe clot formation in a polyester-polymer alloy (PEPA) dialyzer and hemodialysis (HD) circuit with nafamostat mesilate (NM) as an anticoagulant. The possibility of NM adsorption to the PEPA membrane was taken into consideration, but there was not enough information. In the present study, we evaluated differences in the adsorption of NM between a PEPA membrane (FDX-120 GW, Nikkiso, Tokyo, Japan) and two different polysulfone membranes (FX-140, Fresenius Medical Care, Tokyo, Japan; NV-15U, Toray Medical, Tokyo, Japan). We calculated the NM concentration by measuring absorbance at 241 nm using a spectrometer. NM adsorption was evaluated in three ways. First, we evaluated NM adsorption to hollow fibers. Then, we passed an NM solution through dialyzers and evaluated its adsorption in a single-pass examination. Finally, we circulated an NM solution in an HD circuit using a blood pump and evaluated NM adsorption. In all the experiments, NM adsorption to the PEPA membrane was greater than that to the polysulfone membranes examined. In the blood pump experiment, the estimated adsorption quantities of NM to the PEPA membrane and the FX-140 and NV-15U polysulfone membranes were 12.0 +/- 0.1, 1.0 +/- 0.1, and 4.1 +/- 0.4 mg/m(2), respectively. NM adsorption was confirmed, especially in the early phase, and the PEPA membrane adsorbed greater amounts of NM than the polysulfone membranes. We should pay attention to the choice of dialyzer as well as the appropriate dose of NM administration during the preparation of HD circuits.

    DOI: 10.1007/s10047-016-0937-2

    Web of Science

    PubMed

    researchmap

  • Exocytosis-Mediated Urinary Full-Length Megalin Excretion Is Linked With the Pathogenesis of Diabetic Nephropathy Reviewed

    Shankhajit De, Shoji Kuwahara, Michihiro Hosojima, Tomomi Ishikawa, Ryohei Kaseda, Piyali Sarkar, Yusuke Yoshioka, Hideyuki Kabasawa, Tomomichi Iida, Sawako Goto, Koji Toba, Yuki Higuchi, Yoshiki Suzuki, Masanori Hara, Hiroyuki Kurosawa, Ichiei Narita, Yoshiaki Hirayama, Takahiro Ochiya, Akihiko Saito

    DIABETES   66 ( 5 )   1391 - 1404   2017.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER DIABETES ASSOC  

    Efficient biomarkers for diabetic nephropathy (DN) have not been established. Using ELISA, we found previously that urinary levels of full-length megalin (C-megalin), a multiligand endocytic receptor in proximal tubules, was positively correlated with DN progression in patients with type 2 diabetes mellitus (T2DM). Here, we found that urinary extracellular vesicle (UEV) excretion and C-megalin content in UEVs or in their exosomal fraction increased along with the progression of the albuminuric stages in patients with T2DM. Cultured immortalized rat proximal tubule cells (IRPTCs) treated with fatty acid-free BSA or advanced glycation end product-modified BSA (AGE-BSA), endocytic ligands of megalin, increased EV excretion, and their C-megalin content. C-megalin excretion from IRPTCs via extracellular vesicles was significantly blocked by an exosome-specific inhibitor, GW4869, indicating that this excretion is mainly exocytosis-mediated. AGE-BSA treatment of IRPTCs caused apparent lysosomal dysfunction, which stimulated multivesicular body formation, resulting in increased exosomal C-megalin excretion. In a high-fat diet-induced, megalin-mediated kidney injury model in mice, urinary C-megalin excretion also increased via UEVs. Collectively, exocytosis-mediated urinary C-megalin excretion is associated with the development and progression of DN in patients with T2DM, particularly due to megalin-mediated lysosomal dysfunction in proximal tubules, and hence it could be a candidate biomarker linked with DN pathogenesis.

    DOI: 10.2337/db16-1031

    Web of Science

    PubMed

    researchmap

  • Decreased urinary excretion of the ectodomain form of megalin (A-megalin) in children with OCRL gene mutations Reviewed

    Chikushi Suruda, Shoji Tsuji, Sohsaku Yamanouchi, Takahisa Kimata, Nguyen Thanh Huan, Hiroyuki Kurosawa, Yoshiaki Hirayama, Hiroyasu Tsukaguchi, Akihiko Saito, Kazunari Kaneko

    PEDIATRIC NEPHROLOGY   32 ( 4 )   621 - 625   2017.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    The oculocerebrorenal syndrome of Lowe gene (OCRL) is located on chromosome Xq25-26 and encodes an inositol polyphosphate-5-phosphatase (OCRL-1). Mutations in this gene cause Lowe syndrome (LS) or type 2 Dent disease, of which low-molecular-weight (LMW) proteinuria is a characteristic feature. Megalin is considered to play an important role in the development of renal tubular proteinuria. Two forms of megalin are excreted into the urine: full-length megalin (C-megalin) and megalin ectodomain (A-megalin). We have explored the role of megalin in the development of LMW proteinuria in patients with OCRL mutations by determining urinary megalin fractions.
    We measured A- and C-megalin in spot urine samples from five male patients with OCRL mutations (median age 9 years), using sandwich enzyme-linked immunosorbent assays, and adjusted the obtained values for excreted creatinine. The results were compared with those of 50 control subjects and one patient with type 1 Dent disease (T1D).
    All patients demonstrated normal levels of urinary C-megalin. However, patients with OCRL mutations or T1D showed abnormally low levels of urinary A-megalin, with the exception of one 5-year-old boy with LS, who was the youngest patient enrolled in the study.
    Decreased excretion of urinary A-megalin in four out of five patients with OCRL mutations suggests that LMW proteinuria may be caused by impaired megalin recycling within the proximal tubular cells. Homologous enzymes, similar to inositol polyphosphate-5-phosphatase B in mice, may help to compensate for defective OCRL-1 function during early childhood.

    DOI: 10.1007/s00467-016-3535-x

    Web of Science

    PubMed

    researchmap

  • The Assessment of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Patients with Glucocorticoid-induced Diabetes by Continuous Glucose Monitoring Reviewed

    Yusuke Yata, Michihiro Hosojima, Hideyuki Kabasawa, Tomomi Ishikawa, Ryohei Kaseda, Noriaki Iino, Yoshiki Suzuki, Akihiko Saito, Ichiei Narita

    INTERNAL MEDICINE   56 ( 19 )   2555 - 2562   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    Objective The administration of glucocorticoids usually causes a mild increase in fasting glucose levels and a greater dose-dependent increase in postprandial values in patients without pre-existing diabetes mellitus. Patients with persistent hyperglycemia due to glucocorticoid therapy sometimes require insulin therapy, which might result in increased weight gain and more episodes of hypoglycemia, some of which are severe. On the other hand, scant evidence is available on the efficacy of oral hypoglycemic agents in treating glucocorticoid-induced diabetes. In this study, we evaluated the efficacy of dipeptidyl peptidase (DPP)-4 inhibitors in patients with glucocorticoid-induced diabetes by continuous glucose monitoring (CGM).
    Methods We examined the glycemic profiles using CGM at baseline and 1-4 weeks after initiating DPP-4 inhibitor treatment in patients with newly developed glucocorticoid-induced diabetes.
    Results Eleven patients who had been diagnosed with kidney disease or other diseases with renal involvement were recruited for the present retrospective study. After starting DPP-4 inhibitors, the mean and standard deviation (SD) of the glucose level, and the mean amplitude of glycemic excursion (MAGE) were significantly improved in comparison to baseline. Furthermore, the area over the curve (AOC) for the glucose levels &lt;70 mg/dL was not increased in comparison to baseline after the initiation of DPP-4 inhibitor treatment. The results indicate that the treatment of patients with glucocorticoid-induced diabetes using DPP-4 inhibitors can minimize the risk of hypoglycemia and reduce glucose variability.
    Conclusion DPP-4 inhibitors are potentially useful for blood glucose control in patients with glucocorticoid-induced diabetes.

    DOI: 10.2169/internalmedicine.8296-16

    Web of Science

    PubMed

    researchmap

  • BENEFICIAL EFFECTS OF RICE ENDOSPERM PROTEIN ON CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER (CKD-MBD) IN ZUCKER DIABETIC FATTY RATS Reviewed

    Reiko Watanabe, Masatoshi Kubota, Shogo Sugaki, Michihiro Hosojima, Akihiko Saito, Mikio Fujii, Ichiro Sasagawa, Shinobu Fujimura, Motoni Kadowaki

    ANNALS OF NUTRITION AND METABOLISM   71   1218 - 1218   2017

     More details

    Language:English   Publisher:KARGER  

    Web of Science

    researchmap

  • Glucose Variability Based on Continuous Glucose Monitoring Assessment Is Associated with Postoperative Complications after Cardiovascular Surgery Reviewed

    Hiroki Sato, Michihiro Hosojima, Tomomi Ishikawa, Kenji Aoki, Takeshi Okamoto, Akihiko Saito, Masanori Tsuchida

    ANNALS OF THORACIC AND CARDIOVASCULAR SURGERY   23 ( 5 )   239 - 247   2017

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:MEDICAL TRIBUNE INC  

    Purpose: This purpose of this prospective study was to use a continuous glucose monitoring (CGM) system to evaluate the suitability of our institution's glucose management protocol after cardiovascular surgery and to clarify the impact of glycemic variability on postoperative complications.
    Methods: In all, 76 patients who underwent elective cardiovascular surgery and were monitored perioperatively using a CGM system were evaluated. Postoperative glucose management consisted of continuous intravenous insulin infusion (CIII) in the intensive care unit, and subcutaneous insulin injections (SQII) after oral food intake started. CIII and subcutaneous injections were initiated when blood glucose level exceeded 150 mg/dL. CGM data were used to analyze perioperative glycemic variability and association with postoperative complications.
    Results: Target glucose levels (71-180 mg/dL) were achieved during 97.1 +/- 5.5% and 86.4 +/- 19.0% of the continuous insulin infusion and subcutaneous injection periods, respectively. Major postoperative complications were surgical site infections, found in 6.6% of total patients, and atrial fibrillation, found in 44% of patients with off-pump coronary artery bypass grafting. High glycemic variability during SQII was associated with increased risk for both complications.
    Conclusion: Data analysis revealed that our glucose management protocol during CIII was adequate. However, the management protocol during SQII required improvement.

    DOI: 10.5761/atcs.oa.17-00045

    Web of Science

    PubMed

    researchmap

  • Rice endosperm protein slows progression of fatty liver and diabetic nephropathy in Zucker diabetic fatty rats Reviewed

    Masatoshi Kubota, Reiko Watanabe, Miki Yamaguchi, Michihiro Hosojima, Akihiko Saito, Mikio Fujii, Shinobu Fujimura, Motoni Kadowaki

    BRITISH JOURNAL OF NUTRITION   116 ( 8 )   1326 - 1335   2016.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:CAMBRIDGE UNIV PRESS  

    We previously reported that rice endosperm protein (REP) has renoprotective effects in Goto-Kakizaki rats, a non-obese diabetic model. However, whether these effects occur in obese diabetes remains unclear. This study aimed to clarify the effects of REP on obese diabetes, especially on fatty liver and diabetic nephropathy, using the obese diabetic model Zucker diabetic fatty (ZDF) rats. In total, 7-week-old male ZDF rats were fed diets containing 20 % REP or casein (C) for 8 weeks. Changes in fasting blood glucose levels and urinary markers were monitored during the experimental period. Hepatic lipids and metabolites were measured and renal glomeruli were observed morphologically. HbA1c levels were significantly lower in rats fed REP, compared with C (P &lt; 005). Compared with C in the liver, REP prevented lipid accumulation (total lipid, TAG and total cholesterol, P &lt; 001). Liver metabolome analysis indicated that levels of metabolites associated with glycolysis, the pentose phosphate pathway and carnitine metabolism were significantly greater in the REP group than in the C group (P &lt; 005), suggesting activation of both glucose catabolism and fatty acid oxidation. The metabolite increases promoted by REP may contribute to suppression of liver lipid accumulation. Urinary excretion of albumin and N-acetyl--d-glucosaminidase was significantly reduced in rats fed REP for 8 weeks (P &lt; 001). In addition, there was a distinct suppression of mesangial matrix expansion and glomerular hypertrophy in response to REP (P &lt; 001). Thus, REP had preventive effects on obese diabetes, fatty liver and diabetic nephropathy.

    DOI: 10.1017/S0007114516003512

    Web of Science

    PubMed

    researchmap

  • Megalin-Mediated Tubuloglomerular Alterations in High-Fat Diet-Induced Kidney Disease Reviewed

    Shoji Kuwahara, Michihiro Hosojima, Reika Kaneko, Hiroyuki Aoki, Daisuke Nakano, Taiji Sasagawa, Hideyuki Kabasawa, Ryohei Kaseda, Ryota Yasukawa, Tomomi Ishikawa, Akiyo Suzuki, Hiroyoshi Sato, Shun Kageyama, Takahiro Tanaka, Nobutaka Kitamura, Ichiei Narita, Masaaki Komatsu, Akira Nishiyama, Akihiko Saito

    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY   27 ( 7 )   1996 - 2008   2016.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC NEPHROLOGY  

    Obesity, an important risk factor for metabolic syndrome (MetS) and cardiovascular disease, is often complicated by CKD, which further increases cardiovascular risk and causes ESRD. To elucidate the mechanism underlying this relationship, we investigated the role of the endocytic receptor megalin in proximal tubule epithelial cells (PTECs). We studied a high-fat diet (HFD)-induced obesity/MetS model using kidney-specific mosaic megalin knockout (KO) mice. Compared with control littermates fed a normal-fat diet, control litter mates fed an HFD for 12 weeks showed autolysosomal dysfunction with autophagy impairment and increased expression of hypertrophy, lipid peroxidation, and senescence markers in PTECs of the S2 segment, peritubular capillary rarefaction with localized interstitial fibrosis, and glomerular hypertrophy with mesangial expansion. These were ameliorated in HFD-fed megalin KO mice, even though these mice had the same levels of obesity, dyslipidemia, and hyperglycemia as HFD-fed control mice. Intravital renal imaging of HFD-fed wild-type mice also demonstrated the accumulation of autofluorescent lipofuscin-like substances in PTECs of the S2 segment, accompanied by focal narrowing of tubular lumens and peritubular capillaries. In cultured PTECs, fatty acid-rich albumin induced the increased expression of genes encoding PDGF-B and monocyte chemoattractant protein-1 via megalin, with large (auto)lysosome formation, compared with fatty acid-depleted albumin. Collectively, the megalin-mediated endocytic handling of glomerular-filtered (lipo)toxic substances appears to be involved primarily in hypertrophic and senescent PTEC injury with autophagy impairment, causing peritubular capillary damage and retrograde glomerular alterations in HFD-induced kidney disease. Megalin could be a therapeutic target for obesity/MetS-related CKD, independently of weight, dyslipidemia, and hyperglycemia modification.

    DOI: 10.1681/ASN.2015020190

    Web of Science

    PubMed

    researchmap

  • Beneficial effects of rice endosperm protein intake in Japanese men with risk factors for metabolic syndrome: a randomized, crossover clinical trial

    Michihiro Hosojima, Ryohei Kaseda, Hazuki Kondo, Mikio Fujii, Masatoshi Kubota, Reiko Watanabe, Naohito Tanabe, Motoni Kadowaki, Yoshiki Suzuki, Akihiko Saito

    BMC Nutrition   2 ( 1 )   2016.5

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media LLC  

    DOI: 10.1186/s40795-016-0065-7

    researchmap

  • Protective effect of composite earthworm powder against diabetic complications via increased fibrinolytic function and improvement of lipid metabolism in ZDF rats Reviewed

    Tomoko Kawakami, Airi Fujikawa, Yohei Ishiyama, Michihiro Hosojima, Akihiko Saito, Masatoshi Kubota, Shinobu Fujimura, Motoni Kadowaki

    BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY   80 ( 10 )   1980 - 1989   2016

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:TAYLOR & FRANCIS LTD  

    Thrombosis is the leading cause of mortality globally. It is not only a complication but also a risk factor for progression of diabetes. However, alternative oral therapies and prophylaxis with less adverse effect for thrombosis have not been well studied. In this study, composite powder containing earthworm (CEP) was used and its fibrinolytic activity was measured. CEP was found to have a high urokinase-type plasminogen activator like activity in an in vitro assay. It also had significantly shortened euglobulin clot lysis time (ECLT) at 4 and 24h after ingestion in Sprague Dawley rats. Zucker Diabetic Fatty rats were used to assess the effect of CEP on diabetes and diabetic nephropathy. After 10weeks of feeding, CEP significantly shortened ECLT and attenuated HbA1c, hepatic lipid accumulation, and urinary albumin excretion and improved glomerular mesangial matrix score. Therefore, CEP may have beneficial effects on diabetes and diabetic nephropathy.

    DOI: 10.1080/09168451.2016.1166932

    Web of Science

    PubMed

    researchmap

  • Benefits of a 12-week lifestyle modification program including diet and combined aerobic and resistance exercise on albuminuria in diabetic and non-diabetic Japanese populations Reviewed

    Keiko Yamamoto-Kabasawa, Michihiro Hosojima, Yusuke Yata, Mariko Saito, Noriko Tanaka, Junta Tanaka, Naohito Tanabe, Ichiei Narita, Masaaki Arakawa, Akihiko Saito

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   19 ( 6 )   1079 - 1089   2015.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    Background Albuminuria is a biomarker for chronic kidney disease and an independent predictor of cardiovascular and all-cause mortality. A recent meta-analysis concluded that these risks increase with urinary albumin concentration, even when below the microalbuminuria threshold. Thus, minimizing urinary albumin may be a valuable therapeutic goal regardless of disease status.
    Methods We investigated the benefits and safety of a 12-week lifestyle modification program including diet and combined aerobic and resistance exercise for reducing albuminuria in 295 normoalbuminuric or microalbuminuric Japanese adults, including 30 with type 2 diabetes mellitus (T2DM), 104 with metabolic syndrome (MS), and 145 with hypertension (HT).
    Results In the study population, the urinary albumin:creatinine ratio (UACR) was reduced significantly (Delta UACR -3.8 +/- A 16.8 mg/g, P &lt; 0.001) with no change in estimated glomerular filtration rate (eGFR) (Delta eGFR -0.4 +/- A 7.4 mL/min/1.73 m(2), P = 0.343). The reduction in UACR was associated with decreased fasting plasma glucose (P &lt; 0.05). The UACR was also reduced in the T2DM, MS, and HT groups with no change in eGFR. Reduced UACR was associated with decreased fasting plasma glucose in the MS group and decreased systolic blood pressure in the HT group. The UACR was also reduced in 46 subjects using renin-angiotensin system inhibitors with no change in eGFR. Conclusions Our 12-week lifestyle modification program reduced UACR, maintained eGFR, and improved multiple fitness findings in Japanese subjects including T2DM, MS, and HT patients.

    DOI: 10.1007/s10157-015-1103-5

    Web of Science

    PubMed

    researchmap

  • Reduction of Albuminuria by Sitagliptin Is Associated with Improvement of Renal Proximal Tubular Function in Patients with Type 2 Diabetes Reviewed

    Michihiro Hosojima, Taiji Sasagawa, Hideyuki Kabasawa, Tomomi Ishikawa, Ryohei Kaseda, Yoshiki Suzuki, Ichiei Narita, Hiroyuki Kurosawa, Yoshiaki Hirayama, Akihiko Saito

    DIABETES   64   A151 - A151   2015.6

     More details

    Language:English   Publisher:AMER DIABETES ASSOC  

    Web of Science

    researchmap

  • Drainage patterns of the superficial middle cerebral vein: Effects on perioperative managements of petroclival meningioma. Reviewed

    Fukuda M, Saito A, Takao T, Hiraishi T, Yajima N, Fujii Y

    Surgical neurology international   6   130   2015

  • Significance of Urinary Full-Length Megalin in Patients with IgA Nephropathy Reviewed

    Takuto Seki, Katsuhiko Asanuma, Rin Asao, Kanae Nonaka, Yu Sasaki, Juan Alejandro Oliva Trejo, Hiroyuki Kurosawa, Yoshiaki Hirayama, Satoshi Horikoshi, Yasuhiko Tomino, Akihiko Saito

    PLOS ONE   9 ( 12 )   e114400   2014.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:PUBLIC LIBRARY SCIENCE  

    Background and Objectives: Megalin is highly expressed at the apical membranes of proximal tubular epithelial cells. A urinary full-length megalin (C-megalin) assay is linked to the severity of diabetic nephropathy in type 2 diabetes. This study examined the relationship between levels of urinary C-megalin and histological findings in adult patients with IgA nephropathy (IgAN).
    Design, Setting, Participants, & Measurements: Urine samples voided in the morning on the day of renal biopsy were obtained from 73 patients with IgAN (29 men and 44 women; mean age, 33 years) and 5 patients with membranous nephropathy (MN). Renal pathologic variables were analyzed using the Oxford classification of IgAN, the Shigematsu classification and the Clinical Guidelines of IgAN in Japan. The levels of urinary C-megalin were measured by sandwich ELISA.
    Results: Histological analysis based on the Oxford classification revealed that the levels of urinary C-megalin were correlated with mesangial hypercellularity in IgAN patients (OR=1.76, 95% CI: 1.04-3.27, P&lt;0.05). There was a significant correlation between the levels of urinary C-megalin and the severity of chronic extracapillary abnormalities according to the Shigematsu classification in IgAN patients (beta=0.33, P=0.008). The levels of urinary C-megalin were significantly higher in all risk levels of IgAN patients requiring dialysis using the Clinical Guidelines of IgAN in Japan than in the control group. The levels of urinary C-megalin were significantly higher in the high risk and very high risk grades than in the low risk grade (P&lt;0.05). The levels of urinary C-megalin were significantly higher in MN patients compared to the control group.
    Conclusions: The levels of urinary C-megalin are associated with histological abnormalities in adult IgAN patients. There is a possibility that urinary C-megalin is

    DOI: 10.1371/journal.pone.0114400

    Web of Science

    PubMed

    researchmap

  • The endocytic receptor megalin and its associated proteins in proximal tubule epithelial cells Reviewed

    Shankhajit De, Shoji Kuwahara, Akihiko Saito

    Membranes   4 ( 3 )   333 - 335   2014.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:MDPI AG  

    Receptor-mediated endocytosis in renal proximal tubule epithelial cells (PTECs) is important for the reabsorption and metabolization of proteins and other substances, including carrier-bound vitamins and trace elements, in glomerular filtrates. Impairment of this endocytic process results in the loss of such substances and development of proteinuria, which is an important clinical indicator of kidney diseases and is also a risk marker for cardiovascular disease. Megalin, a member of the low-density lipoprotein receptor gene family, is a multiligand receptor expressed in the apical membrane of PTECs and plays a central role in the endocytic process. Megalin interacts with various intracellular adaptor proteins for intracellular trafficking and cooperatively functions with other membrane molecules, including the cubilin-amnionless complex. Evidence suggests that megalin and the cubilin-amnionless complex are involved in the uptake of toxic substances into PTECs, which leads to the development of kidney disease. Studies of megalin and its associated molecules will be useful for future development of novel strategies for the diagnosis and treatment of kidney diseases. © 2014 by the authors
    licensee MDPI, Basel, Switzerland.

    DOI: 10.3390/membranes4030333

    Scopus

    PubMed

    researchmap

  • RELATIONSHIP BETWEEN LEVELS OF URINARY FULL-LENGTH MEGALIN AND HISTOLOGICAL FINDINGS IN PATIENTS WITH IgA NEPHROPATHY Reviewed

    Seki Takuto, Asanuma Katsuhiko, Asao Rin, Nonaka Kanae, Kodama Fumiko, Sasaki Yu, Akiba-Takagi Miyuki, Hosoe-Nagai Yoshiko, Kurosawa Hiroyuki, Hirayama Yoshiaki, Horikoshi Satoshi, Saito Akihiko, Tomino Yasuhiko

    NEPHROLOGY   19   146 - 146   2014.5

     More details

    Language:English   Publisher:WILEY-BLACKWELL  

    Web of Science

    researchmap

  • Keap1 inhibition attenuates glomerulosclerosis Reviewed

    Yoichi Miyazaki, Akihiro Shimizu, Ira Pastan, Keiko Taguchi, Eriko Naganuma, Takafumi Suzuki, Tatsuo Hosoya, Takashi Yokoo, Akihiko Saito, Toshio Miyata, Masayuki Yamamoto, Taiji Matsusaka

    NEPHROLOGY DIALYSIS TRANSPLANTATION   29 ( 4 )   783 - 791   2014.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:OXFORD UNIV PRESS  

    NFE2-related factor 2 (Nrf2) is a master regulatory transcription factor for antioxidant genes. Inhibition of its adaptor protein, Kelch-like ECH-associated protein 1 (Keap1), activates Nrf2. Podocyte injury triggers the progressive deterioration of glomerular damage toward glomerulosclerosis. We examined whether modulation of the Keap1-Nrf2 system has an impact on this process.
    Methods. Nrf2 null-mutant (KO) and Keap1 hypomorphic knockdown (KD) mice were crossed with NEP25 mice, in which podocyte-specific injury can be induced by an immunotoxin.
    Results. Thiobarbituric acid reactive substances, 8-hydroxy-deoxyguanosine and phosphorylated JNK were increased in the injured NEP25 kidney. Real-time PCR revealed that Keap1 KD upregulated Nrf2 target genes, including Gclc, Gclm, Gstp1, Gstp2 and Nqo1 in the glomerulus. However, podocyte injury did not upregulate these genes in Keap1 wild-type mice, nor did it further increase the expression of those genes in Keap1 KD mice. Three weeks after the induction of podocyte injury, glomerulosclerosis was considerably more attenuated in Keap1 KD mice than in control mice (median sclerosis index, 0.27 versus 3.03, on a 0-4 scale). Keap1 KD mice also showed considerably preserved nephrin staining (median index, 6.76 versus 0.91, on a 0-8 scale) and decreased glomeruli containing desmin-positive injured podocytes (median percentage, 24.5% versus 85.8%), along with a decrease in mRNAs for Fn1, Tgfb1, Col4a4 and Col1a2.
    Conclusions. Thus, podocyte injury cannot effectively activate Nrf2, but Nrf2 activation by Keap1 knockdown attenuates glomerulosclerosis. These results indicate that the Nrf2-Keap1 system is a promising drug target for the treatment of chronic kidney diseases.

    DOI: 10.1093/ndt/gfu002

    Web of Science

    PubMed

    researchmap

  • Upregulation of prolactin receptor in proximal tubular cells was induced in cardiac dysfunction model mice Reviewed

    Yohei Tsuchida, Yoshikatsu Kaneko, Tadashi Otsuka, Kei Goto, Akihiko Saito, Keiko Yamamoto, Tadashi Yamamoto, Ichiei Narita

    CLINICAL AND EXPERIMENTAL NEPHROLOGY   18 ( 1 )   65 - 74   2014.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER  

    In order to clarify the interaction between cardiac dysfunction and sodium homeostasis in the kidney, we used a murine model of cardiac dysfunction and investigated the effect on sodium transporters in renal tubular cells.
    Cardiac function was deteriorated by abdominal aortic banding, and the gene expression of sodium transporters in the kidneys was evaluated by real-time RT-PCR and compared with that in the kidneys of control mice.
    Gene expression of all three variants of the murine prolactin receptor was enhanced by aortic banding. Upregulated prolactin receptor was distributed in the proximal tubular cells of the pars recta in the deep inner cortex and the outer stripe of the outer medulla. Prolactin has been reported to be a natriuretic hormone that inhibits proximal tubular Na+/K+-ATPase activity, resulting in reduced sodium reabsorption and the acceleration of natriuresis. Inhibition of endogenous prolactin secretion by bromocriptine administration decreased the urine sodium excretion in both aortic banding and control mice. On the other hand, excess exogenous prolactin administration enhanced urine potassium excretion in aortic banding mice. Furthermore, a high-sodium diet accelerated urinary sodium excretion, which was also significantly decreased by inhibition of endogenous prolactin secretion in aortic banding mice.
    We reported that the prolactin receptor was upregulated by aortic banding treatment. Prolactin-prolactin receptor interaction in the proximal tubular cells of the pars recta should involve a different mechanism of kaliuresis other than inhibition of Na+/K+-ATPase.

    DOI: 10.1007/s10157-013-0820-x

    Web of Science

    PubMed

    researchmap

  • Erratum to: Decreased urinary calbindin 1 levels in proteinuric rats and humans with distal nephron segment injuries (Clinical and Experimental Nephrology DOI: 10.1007/s10157-013-0835-3) Reviewed

    Tomoko Iida, Hidehiko Fujinaka, Bo Xu, Ying Zhang, Sameh Magdeldin, Masaaki Nameta, Zan Liu, Yutaka Yoshida, Eishin Yaoita, Shuichi Tomizawa, Akihiko Saito, Tadashi Yamamoto

    Clinical and Experimental Nephrology   18 ( 3 )   444   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer-Verlag Tokyo  

    DOI: 10.1007/s10157-013-0846-0

    Scopus

    researchmap

  • Decreased urinary calbindin 1 levels in proteinuric rats and humans with distal nephron segment injuries Reviewed

    Tomoko Iida, Hidehiko Fujinaka, Bo Xu, Ying Zhang, Sameh Magdeldin, Masaaki Nameta, Zan Liu, Yutaka Yoshida, Eishin Yaoita, Shuichi Tomizawa, Akihiko Saito, Tadashi Yamamoto

    Clinical and Experimental Nephrology   18 ( 3 )   432 - 443   2014

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Springer-Verlag Tokyo  

    Background: Several proteins have been proposed as new urinary biomarkers of kidney injuries, but they are not always capable of identifying the kidney nephron segment that has been injured. Since calbindin 1 protein is exclusively localized in the kidney distal nephron segment, it is presumed that its expression is altered during distal nephron segment injuries, resulting in changes in its urinary excretion. Methods: Calbindin 1 expression in normal rat kidneys was compared with that in the kidneys of rats that had suffered distal nephron segment injuries (unilateral ureteral obstruction [UUO] or anti-glomerular basement membrane glomerulonephritis [anti-GBM GN]) using immunohistochemical examinations and real-time polymerase chain reaction. The urinary calbindin 1 protein concentration of normal rats was also compared with that of anti-GBM GN rats and of cisplatin nephropathy rats using Western blotting. We also compared the kidney and urinary calbindin 1 protein concentrations of normal human subjects with those of proteinuric patients [immunoglobulin (Ig)A nephropathy
    IgAN] with distal nephron segment injuries. Results: Calbindin 1 mRNA expression in the renal cortices and calbindin 1 protein expression in the kidney distal nephron segments were decreased in the UUO and anti-GBM GN rat kidneys. The urinary calbindin 1 protein levels of the anti-GBM GN rats were also markedly decreased, whereas those of the cisplatin nephropathy rats were slightly decreased. The human IgAN patients displayed decreased renal calbindin 1 protein expression in their dilated distal tubules, and some patients displayed decreased urinary calbindin 1 levels. Conclusion: Since it has been demonstrated that decreased urinary calbindin 1 levels are indicative of decreased calbindin 1 kidney expression due to distal nephron segment injuries, calbindin 1 might be a useful urinary biomarker for identifying distal nephron segment injuries. © 2013 Japanese Society of Nephrology.

    DOI: 10.1007/s10157-013-0835-3

    Scopus

    PubMed

    researchmap

  • Rice protein ameliorates the progression of diabetic nephropathy in Goto-Kakizaki rats with high-sucrose feeding Reviewed

    Masatoshi Kubota, Reiko Watanabe, Hideyuki Kabasawa, Noriaki Iino, Akihiko Saito, Takehisa Kumagai, Shinobu Fujimura, Motoni Kadowaki

    BRITISH JOURNAL OF NUTRITION   110 ( 7 )   1211 - 1219   2013.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:CAMBRIDGE UNIV PRESS  

    The effect of rice protein (RP) on diabetic nephropathy in non-obese, spontaneous type 2 diabetic Goto-Kakizaki (GK) rats was investigated. GK rats at 7 weeks of age were fed 20% RP or casein (C) in standard or high-sucrose diets for 10 weeks. Plasma total cholesterol, TAG, alkaline phosphatase (ALP), adiponectin, creatinine and urinary albumin excretion (UAE) were measured and renal histology was evaluated. Compared with C, RP lowered plasma TAG and improved plasma adiponectin levels in GK rats fed the standard diet (P&lt;0.05), and also lowered total cholesterol and ALP in high-sucrose-fed GK rats (P&lt;0.05). RP markedly suppressed the sharp increase in UAE when GK rats were fed high-sucrose diets (P&lt;0.05), and prevented glomerular mesangial matrix expansion in the deep renal cortex near the corticomedullary junction (P&lt;0.05). These results strongly indicate that dietary RP can ameliorate the progression of diabetic nephropathy at an early stage compared with C.

    DOI: 10.1017/S0007114513000354

    Web of Science

    PubMed

    researchmap

  • Rice Protein Ameliorates Progression of Diabetic Nephropathy in Goto-Kakizaki Rats with High-Sucrose Feeding Reviewed

    Kubota M, Watanabe R, Kabasawa H, Iino N, Saito A, Kumagai T, Fujimura S, Kadowaki M

    British Journal of Nutrition   110 ( 7 )   1211 - 1219   2013.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    researchmap

  • GFR ESTIMATION BY URINARY SOLUBLE MEGALIN

    Akira Hiwatashi, Masahiro Hagiwara, Syuichi Tsuruoka, Joichi Usui, Kei Nagai, Hirayasu Kai, Naoki Morito, Chie Saito, Keigyo Yoh, Michihiro Hosojima, Akihiko Saito, Kunihiro Yamagata

    NEPHROLOGY DIALYSIS TRANSPLANTATION   28 ( 1 )   145 - 145   2013.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:OXFORD UNIV PRESS  

    Web of Science

    researchmap

  • Dietary alkali-extracted rice protein improves some diabetes-related markers in obese type 2 diabetic rats Reviewed

    Watanabe Reiko, Kubota Masatoshi, Yamaguchi Miki, Saito Akihiko, Fujii Mikio, Fujimura Shinobu, Kadowaki Motoni

    FASEB JOURNAL   27   2013.4

  • Protective effects of alkali-extracted rice protein on diabetic nephropathy in obese type 2 diabetic rats Reviewed

    Masatoshi Kubota, Reiko Watanabe, Miki Yamaguchi, Michihiro Hosojima, Akihiko Saito, Mikio Fujii, Shinobu Fujimura, Motoni Kadowaki

    FASEB JOURNAL   27   2013.4

     More details

    Language:English   Publisher:FEDERATION AMER SOC EXP BIOL  

    Web of Science

    researchmap

  • Intraoperative monitoring of motor evoked potentials during glioma removal Reviewed

    Masafumi Fukuda, Makoto Oishi, Tetsuro Takao, Tetsuya Hiraishi, Tsutomu Kobayashi, Hiroshi Aoki, Ryosuke Ogura, Akihiko Saito, Yukihiko Fujii

    Neurological Surgery   41 ( 3 )   219 - 227   2013.3

     More details

    Language:Japanese   Publishing type:Research paper (scientific journal)  

    Objective : To determine whether motor evoked potentials (MEPs) provide reliable monitoring of the motor system during resection of gliomas in or adjacent to the motor cortex or pyramidal tract. Materials and methods : MEP recording was performed during 64 operations in 55 patients harboring gliomas. Intraoperative MEP findings were classified into 3 groups : Group A was defined as having no significant MEP changes, Group B as having reversible MEP changes (≥50% amplitude decrease or loss), and Group C as having irreversible changes. Postoperative motor function was evaluated according to the presence/absence of deterioration immediately after surgery and 1 month later, as compared to preoperative motor status Results : Immediately after surgery, 13 of 39 (33%) patients in Group A, 6 of 17 (35%) in Group B, and 7 of 8 (88%) in Group C experienced deterioration of motor function. One month after surgery, 4 of 39 (10%) patients in Group A, 3 of 17 (18%) in Group B, and 4 of 8 (50%) showed deterioration of motor function Both immediately (χ2=8.3, p&lt
    0.05) and 1 month (χ2=6.9. p&lt
    0.05) after surgery, MEP alterations correlated significantly with postoperative deterioration of motor function. Despite MEPs being stable throughout surgery (Group A), there were some patients with deterioration of motor function initially appearing to represent false negative monitoring. However, these deteriorations were confirmed to have been caused by secondary hemorrhage, venous return dysfunction, postoperative convulsion, or resection of the supplementary motor area. Conclusions : MEP monitoring provides reliable information on the motor system during glioma surgery. Although false negative MEP results may exist in some patients, most data were not influenced by intraoperative manipulation but rather were attributable to secondary postoperative events.

    Scopus

    PubMed

    researchmap

  • Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: Establishment of a highly sensitive ELISA to detect urinary podocalyxin Reviewed

    M. Hara, K. Yamagata, Y. Tomino, A. Saito, Y. Hirayama, S. Ogasawara, H. Kurosawa, S. Sekine, K. Yan

    Diabetologia   55 ( 11 )   2913 - 2919   2012.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Aims/objective Nephropathy, a major complication of diabetes, is the leading cause of end-stage renal disease. Recent studies have demonstrated that podocyte injury is involved in the onset of and progression to renal insufficiency. Here, we describe a novel, highly sensitive ELISA for detecting urinary podocalyxin, a glycoconjugate on the podocyte apical surface that indicates podocyte injury, particularly in the early phase of diabetic nephropathy. Methods Urine samples from patients with glomerular diseases (n=142) and type 2 diabetes (n=71) were used to quantify urinary podocalyxin by ELISA. Urine samples were obtained from 69 healthy controls for whom laboratory data were within normal values. Podocalyxin was detected in urine by immunofluorescence, immunoelectron microscopy and western blotting. Results Morphologically, urinary podocalyxin was present as a vesicular structure
    western blotting showed it as a positive band at 165-170 kDa. Levels of urinary podocalyxin were elevated in patients with various glomerular diseases and patients with diabetes. In patients with diabetes, urinary podocalyxin was higher than the cut-off value in 53.8% patients at the normoalbuminuric stage, 64.7% at the microalbuminuric stage and 66.7% at the macroalbuminuric stage. Positive correlations were observed between urinary podocalyxin levels and HbA1c, urinary β2 microglobulin, α1 microglobulin and urinary N-acetyl-β-D-glucosaminidase, although urinary podocalyxin levels were not correlated with other laboratory markers such as blood pressure, lipid level, serum creatinine, estimated GFR or proteinuria. Conclusions/interpretation Urinary podocalyxin may be a useful biomarker for detecting early podocyte injury in patients with diabetes. © The Author(s) 2012.

    DOI: 10.1007/s00125-012-2661-7

    Scopus

    PubMed

    researchmap

  • Liver Angiotensinogen Is the Primary Source of Renal Angiotensin II Reviewed

    Taiji Matsusaka, Fumio Niimura, Akihiro Shimizu, Ira Pastan, Akihiko Saito, Hiroyuki Kobori, Akira Nishiyama, Iekuni Ichikawa

    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY   23 ( 7 )   1181 - 1189   2012.7

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC NEPHROLOGY  

    Angiotensin II content in the kidney is much higher than in the plasma, and it increases more in kidney diseases through an uncertain mechanism. Because the kidney abundantly expresses angiotensinogen mRNA, transcriptional dysregulation of angiotensinogen within the kidney is one potential cause of increased renal angiotensin II in the setting of disease. Here, we observed that kidney-specific angiotensinogen knockout mice had levels of renal angiotensinogen protein and angiotensin II that were similar to those levels of control mice. In contrast, liver-specific knockout of angiotensinogen nearly abolished plasma and renal angiotensinogen protein and renal tissue angiotensin II. Immunohistochemical analysis in mosaic proximal tubules of megalin knockout mice revealed that angiotensinogen protein was incorporated selectively in megalin-intact cells of the proximal tubule, indicating that the proximal tubule reabsorbs filtered angiotensinogen through megalin. Disruption of the filtration barrier in a transgenic mouse model of podocyte-selective injury increased renal angiotensin II content and markedly increased both tubular and urinary angiotensinogen protein without an increase in renal renin activity, supporting the dependency of renal angiotensin II generation on filtered angiotensinogen. Taken together, these data suggest that liver-derived angiotensinogen is the primary source of renal angiotensinogen protein and angiotensin II. Furthermore, an abnormal increase in the permeability of the glomerular capillary wall to angiotensinogen, which characterizes proteinuric kidney diseases, enhances the synthesis of renal angiotensin II.

    DOI: 10.1681/ASN.2011121159

    Web of Science

    PubMed

    researchmap

  • Significance of Urinary Full-Length and Ectodomain Forms of Megalin in Patients With Type 2 Diabetes Reviewed

    Shinya Ogasawara, Michihiro Hosojima, Ryohei Kaseda, Hideyuki Kabasawa, Keiko Yamamoto-Kabasawa, Hiroyuki Kurosawa, Hiroyoshi Sato, Noriaki Iino, Tetsuro Takeda, Yoshiki Suzuki, Ichie Narita, Kunihiro Yamagata, Yasuhiko Tomino, Fumitake Gejyo, Yoshiaki Hirayama, Sakari Sekine, Akihiko Saito

    DIABETES CARE   35 ( 5 )   1112 - 1118   2012.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER DIABETES ASSOC  

    OBJECTIVE-Megalin, an endocytic receptor in proximal tubule cells, is involved in the mechanisms of albuminuria in diabetic nephropathy (DN). To develop efficient novel biomarkers associated with the pathogenesis of DN, we investigated urinary megalin excretion in type 2 diabetes.
    RESEARCH DESIGN AND METHODS-Sandwich enzyme-linked immunosorbent assay systems were established with monoclonal antibodies against the NH2 (amino [A]-megalin assay) and CO OH (C-megalin assay) termini of megalin to analyze urinary forms of megalin in 68 patients with type 2 diabetes.
    RESULTS-The A-megalin assay mainly detected a megalin ectodomain form in the soluble urinary fraction, whereas the C-megalin assay identified a full-length form in both soluble and insoluble fractions. Urinary C-megalin levels were significantly high in patients with normoalbuminuria, were elevated in line with increased albuminuria, and showed a better association with estimated glomerular filtration rate (eGFR) (&lt;60 mL/min/1.73 m(2)) than did urinary albumin. In contrast, urinary A-megalin levels were increased in patients with normo- and microalbuminuria but not in those with macroalbuminuria. Urinary C-megalin levels were also positively associated with plasma inorganic phosphate and negatively with hemoglobin levels in those showing no features of bleeding and not taking vitamin D analogs, phosphate binders, or erythropoiesis-stimulating agents.
    CONCLUSIONS-Urinary full-length megalin excretion as measured by the C-megalin assay is well associated with reduced eGFR and linked to the severity of DN, phosphate dysregulation, and anemia, whereas urinary excretion of megalin ectodomain as measured by the A-megalin assay may be associated with distinctive mechanisms of earlier DN in type 2 diabetes.

    DOI: 10.2337/dc11-1684

    Web of Science

    PubMed

    researchmap

  • New beneficial effects of alkali-extracted rice protein in type 2 diabetic Goto-Kakizaki rats Reviewed

    Reiko Watanabe, Masatoshi Kubota, Risa Ito, Akihiko Saito, Mikio Fujii, Motoni Kadowaki

    FASEB JOURNAL   26   2012.4

     More details

    Language:English   Publisher:FEDERATION AMER SOC EXP BIOL  

    Web of Science

    researchmap

  • Effect of alkali-extracted rice protein on the renal function in type 2 diabetic rats Reviewed

    Reiko Watanabe, Masatoshi Kubota, Akihiko Saito, Takehisa Kumagai, Motoni Kadowaki

    AMINO ACIDS   41   S68 - S68   2011.7

     More details

    Language:English   Publisher:SPRINGER WIEN  

    Web of Science

    researchmap

  • Role of Megalin and Cubilin in the Metabolism of Vitamin D-3 Reviewed

    Ryohei Kaseda, Michihiro Hosojima, Hiroyoshi Sato, Akihiko Saito

    THERAPEUTIC APHERESIS AND DIALYSIS   15   14 - 17   2011.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Vitamin D deficiency is associated with various medical conditions including musculoskeletal disorders, infection, metabolic diseases, and cardiovascular disease. Megalin and cubilin, endocytic receptors in proximal tubule cells, are involved in the reabsorption of vitamin D binding protein from glomerular filtrates and the subsequent intracellular conversion of 25-hydroxyvitamin D-3 to biologically active 1 alpha,25-dihydroxyvitamin D-3. Dysfunction of these receptors, which is commonly found in patients with diabetic nephropathy, even at early stages, may explain why vitamin D deficiency is often complicated in these patients. Therapeutic strategies to protect the functions of these receptors from injury could be used to prevent vitamin D deficiency and its related disorders.

    DOI: 10.1111/j.1744-9987.2011.00920.x

    Web of Science

    PubMed

    researchmap

  • Megalin is downregulated via LPS-TNF-alpha-ERK1/2 signaling pathway in proximal tubule cells Reviewed

    Aya Takeyama, Hiroyoshi Sato, Taeko Soma-Nagae, Hideyuki Kabasawa, Akiyo Suzuki, Keiko Yamamoto-Kabasawa, Michihiro Hosojima, Reika Kaneko, Fumie Higuchi, Ryohei Kaseda, Shinya Ogasawara, Ichiei Narita, Akihiko Saito

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   407 ( 1 )   108 - 112   2011.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Expression and function of megalin, an endocytic receptor in proximal tubule cells (PTCs), are reduced in diabetic nephropathy, involved in the development of proteinuria/albuminuria. Lipopolysaccharide (LPS) is chronically increased in diabetic sera, by the mechanism called metabolic endotoxemia. We investigated low-level LPS-mediated signaling that regulates megalin expression in immortalized rat PTCs (IRPTCs). Incubation of the cells with LPS (10 ng/ml) for 48 h suppressed megalin protein expression and its endocytic function. TNF-alpha mRNA expression was increased by LPS treatment, and knockdown of the mRNA with siRNA inhibited LPS-mediated downregulation of megalin mRNA expression at the 24-h time point. Incubation of IRPTCs with exogenous TNF-alpha also suppressed megalin mRNA and protein expression at the 24- and 48-h time points, respectively. MEK1 inhibitor PD98059 competed partially but significantly TNF-alpha-mediated downregulation of megalin mRNA expression. Collectively, low-level LPS-mediated TNF-alpha-ERK1/2 signaling pathway is involved in downregulation of megalin expression in IRPTCs. (C) 2011 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2011.02.118

    Web of Science

    PubMed

    researchmap

  • Proximal tubule cell hypothesis for cardiorenal syndrome in diabetes. Reviewed

    Saito A, Kaseda R, Hosojima M, Sato H

    International journal of nephrology   2011   957164   2010.12

  • Clinicopathological characteristics of patients with IgG4-related tubulointerstitial nephritis Reviewed

    Takako Saeki, Shinichi Nishi, Naofumi Imai, Tomoyuki Ito, Hajime Yamazaki, Mitsuhiro Kawano, Motohisa Yamamoto, Hiroki Takahashi, Shoko Matsui, Shinji Nakada, Tomoki Origuchi, Akira Hirabayashi, Noriyuki Homma, Yutaka Tsubata, Takuma Takata, Yoko Wada, Akihiko Saito, Sachiko Fukase, Kunihiro Ishioka, Kana Miyazaki, Yasufumi Masaki, Hisanori Umehara, Susumu Sugai, Ichiei Narita

    KIDNEY INTERNATIONAL   78 ( 10 )   1016 - 1023   2010.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    IgG4-related disease is a recently recognized multi-organ disorder characterized by high levels of serum IgG4 and dense infiltration of IgG4-positive cells into several organs. Although the pancreas was the first organ recognized to be affected by IgG4-related disorder in the syndrome of autoimmune pancreatitis, we present here clinicopathological features of 23 patients diagnosed as having renal parenchymal lesions. These injuries were associated with a high level of serum IgG4 and abundant IgG4-positive plasma cell infiltration into the renal interstitium with fibrosis. In all patients, tubulointerstitial nephritis was the major finding. Although 14 of the 23 patients did not have any pancreatic lesions, their clinicopathological features were quite uniform and similar to those shown in autoimmune pancreatitis. These included predominance in middle-aged to elderly men, frequent association with IgG4-related conditions in other organs, high levels of serum IgG and IgG4, a high frequency of hypocomplementemia, a high serum IgE level, a patchy and diffuse lesion distribution, a swirling fibrosis in the renal pathology, and a good response to corticosteroids. Thus, we suggest that renal parenchymal lesions actually develop in association with IgG4-related disease, for which we propose the term 'IgG4-related tubulointerstitial nephritis.'

    DOI: 10.1038/ki.2010.271

    Web of Science

    PubMed

    researchmap

  • Molecular Mechanisms of Receptor-Mediated Endocytosis in the Renal Proximal Tubular Epithelium Reviewed

    Akihiko Saito, Hiroyoshi Sato, Noriaki Iino, Tetsuro Takeda

    JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY   2010   403272   2010

     More details

    Language:English   Publisher:HINDAWI PUBLISHING CORPORATION  

    Receptor-mediated endocytosis is a pivotal function of renal proximal tubule epithelial cells (PTECs) to reabsorb and metabolize substantial amounts of proteins and other substances in glomerular filtrates. The function accounts for the conservation of nutrients, including carrier-bound vitamins and trace elements, filtered by glomeruli. Impairment of the process results in a loss of such substances and development of proteinuria, an important clinical sign of kidney disease and a risk marker for cardiovascular disease. Megalin is a multiligand endocytic receptor expressed at clathrin-coated pits of PTEC, playing a central role in the process. Megalin cooperates with various membrane molecules and interacts with many intracellular adaptor proteins for endocytic trafficking. Megalin is also involved in signaling pathways in the cells. Megalin-mediated endocytic overload leads to damage of PTEC. Further studies are needed to elucidate the mechanism of megalin-mediated endocytosis and develop strategies for preventing the damage of PTEC.

    DOI: 10.1155/2010/403272

    Web of Science

    PubMed

    researchmap

  • Megalin and nonmuscle myosin heavy chain IIA interact with the adaptor protein Disabled-2 in proximal tubule cells Reviewed

    Kiyoko Hosaka, Tetsuro Takeda, Noriaki Iino, Michihiro Hosojima, Hiroyoshi Sato, Ryohei Kaseda, Keiko Yamamoto, Asako Kobayashi, Fumitake Gejyo, Akihiko Saito

    KIDNEY INTERNATIONAL   75 ( 12 )   1308 - 1315   2009.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    Megalin plays a critical role in the endocytosis of albumin and other filtered low-molecular-weight proteins. Here we studied the interaction between megalin and Disabled-2 (Dab2), an adaptor protein that binds to the cytoplasmic domain of megalin and appears to control its trafficking. We co-immunoprecipitated megalin and Dab2 from cultured proximal tubule cells and identified the proteins by liquid chromatography and tandem mass spectrometry. We found two proteins associated with the megalin/Dab2 complex, nonmuscle myosin heavy chain IIA (NMHC-IIA) and beta-actin. Subcellular fractionation followed by sucrose velocity gradient separation showed that megalin, Dab2, and NMHC-IIA existed as a complex in the same endosomal fractions. In vitro pull-down assays demonstrated that NMHC-IIA was bound to the carboxyl-terminal region of Dab2, but not to megalin&apos;s cytoplasmic domain. We then transfected COS-7 cells with plasmids that induced the expression of Dab2, NMHC-IIA, and the megalin minireceptor, a truncated form of megalin. Co-immunoprecipitation studies showed that the minireceptor and NMHC-IIA co-immunoprecipitated only with Dab2. Furthermore, the uptake of (125)I-lactoferrin, an endocytic ligand of megalin, by rat yolk sac-derived megalin-expressing L2 cells was inhibited by blebbistatin, a specific inhibitor of nonmuscle myosin II. Our study shows that NMHC-IIA is functionally linked to megalin by interaction with Dab2 and is likely involved in megalin-mediated endocytosis in proximal tubule cells. Kidney International (2009) 75, 1308-1315; doi:10.1038/ki.2009.85; published online 1 April 2009

    DOI: 10.1038/ki.2009.85

    Web of Science

    PubMed

    researchmap

  • Regulation of Megalin Expression in Cultured Proximal Tubule Cells by Angiotensin II Type 1A Receptor- and Insulin-Mediated Signaling Cross Talk Reviewed

    Michihiro Hosojima, Hiroyoshi Sato, Keiko Yamamoto, Ryohei Kaseda, Taeko Soma, Asako Kobayashi, Akiyo Suzuki, Hideyuki Kabasawa, Aya Takeyama, Kenji Ikuyama, Noriaki Iino, Akira Nishiyama, Thomas J. Thekkumkara, Tetsuro Takeda, Yoshiki Suzuki, Fumitake Gejyo, Akihiko Saito

    ENDOCRINOLOGY   150 ( 2 )   871 - 878   2009.2

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ENDOCRINE SOC  

    Impairment of proximal tubular endocytosis of glomerular-filtered proteins including albumin results in the development of proteinuria/albuminuria in patients with chronic kidney disease. However, the mechanisms regulating the proximal tubular function are largely unknown. This study aimed to investigate the role of angiotensin II type 1A receptor (AT(1A)R)- and insulin-mediated signaling pathways in regulating the expression of megalin, a multiligand endocytic receptor in proximal tubule cells (PTCs). Opossum kidney PTC-derived OK cells that stably express rat AT(1A)R but are deficient in endogenous angiotensin II receptors (AT(1A)R-OK cells) were used for this study. Treatment of the cells with angiotensin II suppressed mRNA and protein expression of megalin at 3- and 24-h incubation time points, respectively. Cellular uptake and degradation of albumin and receptor-associated protein, megalin&apos;s endocytic ligands were suppressed 24 h after angiotensin II treatment. The AT(1A)R-mediated decrease in megalin expression was partially prevented by ERK inhibitors. Insulin competed with the AT(1A)R-mediated ERK activation and decrease in megalin expression. Inhibitors of phosphatidylinositol 3- kinase (PI3K), a major component of insulin signaling, also suppressed megalin expression, and activation of the insulin receptor substrate (IRS)/PI3K system was prevented by angiotensin II. Collectively the AT(1A)R-mediated ERK signaling is involved in suppressing megalin expression in the OK cell line, and insulin competes with this pathway. Conversely, the insulin-IRS/PI3K signaling, with which angiotensin II competes, tends to stimulate megalin expression. In conclusion, there is AT(1A)R- and insulin-mediated competitive signaling cross talk to regulate megalin expression in cultured PTCs. (Endocrinology 150: 871 - 878, 2009)

    DOI: 10.1210/en.2008-0886

    Web of Science

    PubMed

    researchmap

  • Megalin contributes to the early injury of proximal tubule cells during nonselective proteinuria Reviewed

    Yaeko Motoyoshi, Taiji Matsusaka, Akihiko Saito, Ira Pastan, Thomas E. Willnow, Shuki Mizutani, Iekuni Ichikawa

    KIDNEY INTERNATIONAL   74 ( 10 )   1262 - 1269   2008.11

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    Megalin, a member of the LDL receptor family, is expressed on the apical membrane of proximal tubules and serves as an endocytic scavenger of filtered proteins and hence might contribute to the tubule injury as a consequence of glomerular disease. To study its role, we crossed megalin knockout mosaic mice (lacking megalin expression in 60% of proximal tubule cells) with NEP25 mice (a transgenic line expressing human CD25 in the podocyte). Treatment of this transgenic mouse with the immunotoxin causes nephrotic syndrome, focal segmental glomerulosclerosis and tubule-interstitial injury. Following this treatment, the double transgenic mice had massive non-selective proteinuria and mild glomerular and tubular injury. Comparison of megalin-containing to megalin-deficient proximal tubule cells within each kidney showed that albumin, immunoglobulin light chain, IgA and IgG were preferentially accumulated in proximal tubule cells expressing megalin. Tubule injury markers such as heme-oxygenase-1, monocyte chemoattractant protein-1 and cellular apoptosis were also preferentially found in these megalin-expressing cells. These results show that megalin plays a pivotal role in the reabsorption of small to large molecular size proteins and provides direct in vivo evidence that reabsorption of filtered proteins triggers events leading to tubule injury.

    DOI: 10.1038/ki.2008.405

    Web of Science

    PubMed

    researchmap

  • Anemia is a predictive factor for the development of CKD only in man, but not in woman, of general Japanese population Reviewed

    Noriaki Iino, Ichiei Narita, Akihiko Saito, Fumitake Gejyo

    NEPHROLOGY   13   A34 - A34   2008.5

     More details

    Language:English   Publisher:BLACKWELL PUBLISHING  

    Web of Science

    researchmap

  • Alterations in serum phosphate levels predict the long-term response to intravenous calcitriol therapy in dialysis patients with secondary hyperparathyroidism Reviewed

    Kiyoko Hosaka, Junichiro James Kazama, Suguru Yamamoto, Yumi Ito, Noriaki Iino, Hiroki Maruyama, Akihiko Saito, Ichiei Narita, Fumitake Gejyo

    JOURNAL OF BONE AND MINERAL METABOLISM   26 ( 2 )   185 - 190   2008.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:SPRINGER TOKYO  

    Calcitriol therapy is a central strategy for the treatment of uremic secondary hyperparathyroidism. Although indiscriminate use of calcitriol may lead to worse outcomes, it is difficult to make a decision to discontinue calcitriol therapy when its parathyroid suppression effect remains unsatisfactory. In this study, intravenous calcitriol was administered to 120 chronic hemodialysis patients. Therapy continued for 48 weeks or until plasma intact parathyroid hormone (iPTH) levels decreased to below 300 pg/ml or until the development of any significant adverse effect. Of the 120 patients, the treatment goal was achieved in 47 patients during the first 4 weeks, in 10 during the next 4 weeks, and in 22 patients thereafter. Logistic regression analysis and stepwise regression analysis revealed that iPTH levels were the only significant predictor of the response to calcitriol therapy at weeks 0 and 4. Besides iPTH, the inorganic phosphate (P) levels were another significant predictor of the ultimate response to calcitriol therapy at week 8. The point of best discrimination for successful treatment was P = 6.0 mg/dl at week 8, or P level at week 8/pretreatment P level = 1.0. In conclusion, the P level at week 8 is a predictor of the response to calcitriol therapy for uremic secondary hyperparathyroidism. Changes in treatment are recommended if patients show unsatisfactory parathyroid suppression with a hyperphosphatemic tendency.

    DOI: 10.1007/s00774-007-0809-1

    Web of Science

    PubMed

    researchmap

  • Localization of megalin in rat vestibular dark cells and endolymphatic sac epithelial cells Reviewed

    Maki Arai, Kunihiro Mizuta, Akihiko Saito, Yasuyuki Hashimoto, Satoshi Iwasaki, Takahiro Watanabe, Hiroyuki Mineta

    ACTA OTO-LARYNGOLOGICA   128 ( 6 )   627 - 633   2008

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:INFORMA HEALTHCARE  

    Conclusion: Megalin immunoreactivity was observed in kidney proximal tubule cells, vestibular dark cells, and epithelial cells of the endolymphatic sac. Endocytic mechanisms appear to differ between the endolymphatic sac and proximal tubule cells. We speculate that megalin is secreted by a certain type of cell into the endolymphatic space, and is then absorbed from the endolymphatic space by another type of cell to maintain endolymphatic sac homeostasis. Objectives: We previously detected megalin immunoreactivity in the rat cochlear duct. Megalin may be involved in endocytosis in the vestibular organ and endolymphatic sac. To examine this possibility, we extended our immunocytochemical investigation to the rat inner ear cells with special attention to vestibular dark cells and endolymphatic sac. Materials and methods: We observed immunoreactivity of megalin under light and electron microscopy. The primary antibody was rabbit polyclonal antibody that had been raised against rat immunoaffmity-purified megalin. Results: The luminal membrane and subapical area of dark cells in the semicircular canal were immunolabeled. The stainable substance in the endolymphatic space was strongly stained. The cytoplasm of epithelial cells was also stained in various patterns.

    DOI: 10.1080/00016480701668531

    Web of Science

    PubMed

    researchmap

  • Role of megalin, a proximal tubular endocytic receptor, in calcium and phosphate homeostasis Reviewed

    Akihiko Saito, Noriaki Iino, Tetsuro Takeda, Fumitake Gejyo

    THERAPEUTIC APHERESIS AND DIALYSIS   11   S23 - S26   2007.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Megalin is expressed at the apical membranes of proximal tubule cells, acting as an endocytic receptor for a variety of ligands filtered by glomeruli. Megalin, also known as a Ca(2+)-binding receptor, is thought to be involved in systemic and intrarenal calcium and phosphate homeostasis. The complex of 25( OH) D(3) and vitamin D-binding protein is endocytosed via megalin into proximal tubule cells, leading to the activation of 25( OH) D3 to 1, 25( OH) D3 in the cells. Megalin knockout mice revealed impaired osteogenesis due to vitamin D deficiency. Megalin is also involved in the metabolism of parathyroid hormone and the regulation of the sodium phosphate cotransporter NaPi-IIa. Decreased expression of megalin may be associated with the pathogenesis of hyperphosphaturia observed in patients with Dent&apos;s disease. Further studies will elucidate more detailed roles of megalin in pathological states and the mechanisms for interacting with other molecules for the endocytic functions.

    DOI: 10.1111/j.1744-9987.2007.00514.x

    Web of Science

    PubMed

    researchmap

  • Tubulointerstitial nephritis associated with IgG4-related systemic disease Reviewed

    Takako Saeki, Akihiko Saito, Hajime Yamazaki, Iwao Emura, Naofumi Imai, Mitsuhiro Ueno, Shinichi Nishi, Syoji Miyamura, Fumitake Gejyo

    Clinical and Experimental Nephrology   11 ( 2 )   168 - 173   2007.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    We report three patients with tubulointerstitial nephritis (TIN) with high serum IgG4 concentrations. None of the patients had notable pancreatic lesions when the TIN developed, although one had a history of autoimmune pancreatitis (AIP). Nevertheless, the clinicopathological findings were quite similar to those of AIP. They were all middle-aged to elderly men. Sialadenitis and lymphadenopathy were often evident. Serum total IgG and IgG4 concentrations were elevated and hypocomplementemia was observed. Although antinuclear antibodies were positive, anti-Ro and anti-La antibodies were negative. Renal biopsy showed dense lymphoplasmacytic infiltration with fibrosis in the renal interstitium, and the infiltrated plasma cells had strong immunoreactivity for IgG4. Furthermore, lymphoplasmacytic infiltration and abundant IgG4-positive plasma cells were observed in the salivary glands of a patient. Steroid therapy was effective for TIN in all three patients. The present findings support the recently proposed concept of IgG4-related systemic disease, and suggest that IgG4 is associated not only with AIP but also with other systemic lymphoplasmacytic diseases, including TIN. The conditions responsible for the pathogenesis of TIN need to be considered, irrespective of the presence of AIP. © 2007 Japanese Society of Nephrology.

    DOI: 10.1007/s10157-007-0464-9

    Scopus

    PubMed

    researchmap

  • Megalin-mediated endocytosis of cystatin C in proximal tubule cells Reviewed

    Ryohei Kaseda, Noriaki Iino, Michihiro Hosojima, Tetsuro Takeda, Kiyoko Hosaka, Asako Kobayashi, Keiko Yamamoto, Akiyo Suzuki, Ayaka Kasai, Yoshiki Suzuki, Fumitake Gejyo, Akihiko Saito

    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS   357 ( 4 )   1130 - 1134   2007.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ACADEMIC PRESS INC ELSEVIER SCIENCE  

    Serum levels of cystatin C, an endogenous cysteine protemase inhibitor, are often used as an indicator of glomerular filtration rate. Although it is known that cystatin C is filtered by glomeruli and metabolized in proximal tubule cells (PTC), the precise molecular mechanism underlying this process is undetermined. Using quartz-crystal microbalance analyses, we demonstrate that cystatin C binds directly to megalin, an endocytic receptor in PTC, in a Ca(+)-dependent manner. We also find that cystatin C is endocytosed specifically via megalin in rat yolk sac epithelium-derived L2 cells which share a variety of characteristics with PTC. Finally, it? vivo studies using kidney-specific megalin knockout mice provide evidence that megalin mediates proximal tubular uptake of cystatin C. We conclude that megalin is an endocytic receptor of cystatin C in PTC. (c) 2007 Elsevier Inc. All rights reserved.

    DOI: 10.1016/j.bbrc.2007.04.072

    Web of Science

    PubMed

    researchmap

  • Functional characterization of a novel missense CLCN5 mutation causing alterations in proximal tubular endocytic machinery in Dent's disease Reviewed

    Atsuhito Tanuma, Hiroyoshi Sato, Tetsuro Takeda, Michihiro Hosojima, Hiroaki Obayashi, Hitomi Hama, Noriaki Iino, Kiyoko Hosaka, Ryohei Kaseda, Naofumi Imai, Mitsuhiro Ueno, Maya Yamazaki, Kenji Sakimura, Fumitake Gejyo, Akihiko Saito

    NEPHRON PHYSIOLOGY   107 ( 4 )   P87 - P97   2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:KARGER  

    Background/Aims: Mutations of the endosomal chloride/ proton exchanger gene, CLCN5, cause Dent's disease, an X-linked recessive proximal tubular disorder. The renal endocytic system was found to be affected in clcn5 knockout mice. However, the impaired endocytic machinery of Dent's disease patients has not been thoroughly investigated. Methods: The CLCN5 gene was sequenced in a Japanese patient with Dent's disease and his family. The loss-of-function phenotype of the missense CLCN5 mutation was investigated by gene expression in Xenopus oocytes and CHO cells. Immunohistochemical analysis was performed on kidney biopsy specimens for endocytic machinery proteins, megalin, cubilin, and disabled-2 (Dab2) in proximal tubules. Results: Genomic analysis revealed a novel G-to-A transition at the first nucleotide of the 333rd codon of CLCN5, causing a substitution of glycine with arginine. Inefficient expression of the mutant gene in Xenopus oocytes resulted in abolished chloride currents. Impaired N-glycosylation of the mutant protein was evident in the DNA-transfected CHO cells. Proximal tubular expression of megalin, cubilin, and Dab2 was markedly reduced and irregular staining in some portions was observed in the patient compared with controls. Conclusions: A novel G333R CLCN5 mutation caused defective expression of megalin, cubilin, and Dab2 in a patient with Dent's disease. Copyright (c) 2007 S. Karger AG, Basel.

    DOI: 10.1159/000111253

    Web of Science

    researchmap

  • Renal lesions in IgG4-related systemic disease Reviewed

    Takako Saeki, Shinichi Nishi, Tomoyuki Ito, Hajime Yamazaki, Syoji Miyamura, Iwao Emura, Naofumi Imai, Mitsuhiro Ueno, Akihiko Saito, Fumitake Gejyo

    INTERNAL MEDICINE   46 ( 17 )   1365 - 1371   2007

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    Objective Recently, a new concept of IgG4-related systemic disease including autoimmune pancreatitis, characterized by a high serum IgG4 level and tissue infiltration by IgG4-positive plasma cells, has been proposed. Our aim was to investigate the renal involvement in this condition.
    Patients and Methods We investigated the results of laboratory and imaging studies of the kidneys in 7 patients with IgG4-related systemic disease, and examined the renal histology in four of them. All patients showed elevated serum IgG4 levels, and 4 had autoimmune pancreatitis. The other three patients showed involvement of various extrapancreatic organs (lymphadenopathy, sialadenitis or renal insufficiency), and abundant IgG4-positive plasma cell infiltration was confirmed in their affected tissues.
    Results Six of the 7 patients showed some renal abnormalities. In one patient, hydronephrosis was observed accompanied by retroperitoneal fibrosis. Another patient showed multiple low-density areas in both kidneys by computed tomography, and gallium citrate scintigraphy showed gallium-67 accumulation in both kidneys, although renal function was normal. Four patients had tubulointerstitial nephritis. In two of them, the tubulointerstitial nephritis was diffuse. In one patient, marked diffuse but patchily distributed lymphoplasmacytic infiltration of the renal interstitium was observed. In another patient, computed tomography showed a tumor-like low-density mass; open biopsy of the mass showed aggregates of lymphocytes and plasma cells in the renal interstitium.
    Conclusion Renal parenchymal lesions in IgG4-related systemic disease are due to dense lymphoplasmacytic infiltration of the renal interstitium, and the lesions vary from diffuse tubulointerstitial nephritis to tumor-like masses according to the distribution patterns of the infiltrating cells.

    DOI: 10.2169/internalmedicine.46.0183

    Web of Science

    PubMed

    researchmap

  • Functional characterization of a novel missense CLCN5 mutation causing alterations in proximal tubular endocytic machinery in Dent's disease. Reviewed

    Tanuma A, Sato H, Takeda T, Hosojima M, Obayashi H, Hama H, Iino N, Hosaka K, Kaseda R, Imai N, Ueno M, Yamazaki M, Sakimura K, Gejyo F, Saito A

    Nephron. Physiology   107 ( 4 )   p87 - 97   2007

  • Current clinical aspects of dialysis-related amyloidosis in chronic dialysis patients Reviewed

    Akihiko Saito, Fumitake Gejyo

    THERAPEUTIC APHERESIS AND DIALYSIS   10 ( 4 )   316 - 320   2006.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BLACKWELL PUBLISHING  

    The current understanding of dialysis-related amyloidosis has evolved over the past two decades. In the early 1980s, several researchers found amyloid deposits in the synovia of carpal tunnel syndrome (CTS), which have been recognized as a complication of chronic hemodialysis. The enigma was resolved in 1985, when beta(2)-microglobulin (beta(2)-m) with a molecular weight of 12 000 Da was identified as the major constitutional protein of this amyloid. Amyloid fibrils of this type that contain the sub-unit protein of human leukocyte antigens (HLA), beta(2)-m, deposit predominantly in osteoarticular tissues, inducing musculoskeletal symptoms such as CTS, polyarthralgia, bone cyst showing radiolucency at X-ray examination and destructive spondyloarthropathy. In addition, extra articular symptoms such as ischemic colitis, megaloglossia, and heart failure, that is, systemic involvement occasionally occur. We confirmed that the prevalence of CTS increases with duration of dialysis. Most patients with CTS associated with beta(2)-m amyloid deposits have undergone hemodialysis for 10 years or more. Up to 50% of patients had developed this complication after 20 years and the percentage was even higher after 25 years. General categories of therapeutic approaches for amyloidosis include prevention of onset or progression, symptomatic therapy (conservative treatment, orthopedic procedures, and physiotherapy), and renal transplantation. It is critical to elucidate the detail mechanisms of the amyloid fibril formation, and establish its radical treatment. It is also important to develop novel therapies such as cell implantation to compensate for normal kidney functions of uremic toxin protein metabolism.

    DOI: 10.1111/j.1744-9987.2006.00383.x

    Web of Science

    PubMed

    researchmap

  • [Megalin and cubilin: protein reabsorption in proximal tubule]. Reviewed

    Takeda T, Saito A, Gejyo F

    Nihon rinsho. Japanese journal of clinical medicine   64 Suppl 2   332 - 338   2006.2

     More details

  • Lymphoplasmacytic infiltration of multiple organs with immunoreactivity for IgG4: IgG4-related systemic disease Reviewed

    Takako Saeki, Akihiko Saito, Tohru Hiura, Hajime Yamazaki, Iwao Emura, Mitsuhiro Ueno, Syoji Miyamura, Fumitake Gejyo

    INTERNAL MEDICINE   45 ( 3 )   163 - 167   2006

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:JAPAN SOC INTERNAL MEDICINE  

    We report three elderly men with high serum IgG4 concentrations and multiple lymphoplasmacytic inflammation of the salivary glands, lymph nodes, pancreas, and renal interstitium. The infiltrating plasma cells had strong immunoreactivity for IgG4, even in patients without pancreatic lesions. These cases show that IgG4 is associated not only with autoimmune pancreatitis, but also with other systemic lymphoplasmacytic disease.

    DOI: 10.2169/internalmedicine.45.1431

    Web of Science

    PubMed

    researchmap

  • Role of megalin, a proximal tubular endocytic receptor, in the pathogenesis of diabetic and metabolic syndrome-related nephropathies: protein metabolic overload hypothesis Reviewed

    A Saito, T Takeda, H Hama, Y Oyama, K Hosaka, A Tanuma, R Kaseda, M Ueno, S Nishi, S Ogasawara, F Gondaira, Y Suzuki, F Gejyo

    NEPHROLOGY   10   S26 - S31   2005.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILEY-BLACKWELL  

    Megalin is an endocytic receptor on the apical membranes of proximal tubule cells (PTC) in the kidney, and is involved in the reabsorption and metabolism of various proteins that have been filtered by glomeruli. Patients with diabetes, especially type 2 diabetes, or metabolic syndrome are likely to have elevated serum levels of advanced glycation end products, liver-type fatty acid binding protein, angiotensin 11, insulin and leptin, and renal metabolism of these proteins is potentially overloaded. Some of these proteins are themselves nephrotoxic, while others are carriers of nephrotoxic molecules. Megalin is involved in the proximal tubular uptake of these proteins. We hypothesize that megalin-mediated metabolic overload in PTC leads to compensatory cellular hypertrophy and sustained Na(+) reabsorption, causing systemic hypertension and glomerular hyperfiltration via tubuloglomerular feedback, and named this as &apos;protein metabolic overload hypothesis&apos;. Impaired metabolism of bioactive proteins such as angiotensin 11 and insulin in PTC may enhance hypertrophy of PTC and/or Na(+) reabsorption. Sleep apnoea syndrome, a frequent complication of diabetes and metabolic syndrome, may cause renal hypoxia and result in relative overload of protein metabolism in the kidneys. The development of strategies to identify patients with diabetes or metabolic syndrome who are at high risk for renal metabolic overload would allow intensive treatment of these patients in an effort to prevent the development of nephropathy. Further studies on the intracellular molecular signalling associated with megalin-mediated metabolic pathways may lead to the development of novel strategies for the treatment of nephropathies related to diabetes and metabolic syndrome.

    DOI: 10.1111/j.1440-1797.2005.00453.x

    Web of Science

    PubMed

    researchmap

  • Evidence for megalin-mediated proximal tubular uptake of L-FABP, a carrier of potentially nephrotoxic molecules Reviewed

    Y Oyama, T Takeda, H Hama, A Tanuma, N Iino, K Sato, R Kaseda, ML Ma, T Yamamoto, H Fujii, JJ Kazama, S Odani, Y Terada, K Mizuta, F Gejyo, A Saito

    LABORATORY INVESTIGATION   85 ( 4 )   522 - 531   2005.4

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATURE PUBLISHING GROUP  

    Liver-type fatty acid binding protein (L-FABP) binds with high affinity to hydrophobic molecules including free fatty acid, bile acid and bilirubin, which are potentially nephrotoxic, and is involved in their metabolism mainly in hepatocytes. L-FABP is released into the circulation, and patients with liver damage have an elevated plasma L-FABP level. L-FABP is also present in renal tubules; however, the precise localization of L-FABP and its potential role in the renal tubules are not known. In this study, we examined the cellular and subcellular localization of L-FABP in the rat kidney and tried to determine from where the L-FABP in kidney tissues had originated. Immunohistochemical studies of kidney sections localized L-FABP in the lysosomes of proximal tubule cells (PTC). In rats with carbon tetrachloride (CCl(4))-induced acute liver injury, we detected high levels of L-FABP in the circulation and in the kidney compared with those in the control rat by immunoblotting, while reverse transcription-polymerase chain reaction showed that the level of L-FABP mRNA expression in the kidney of CCl(4)-treated rats was low and did not differ from that in the control rat. When (35)S-L-FABP was intravenously administered to rats, the kidneys took up (35)S-L-FABP more preferentially than the liver and heart, and histoautoradiography of kidney sections revealed that (35)S-L-FABP was internalized via the apical domains of PTC. Quartz-crystal microbalance analysis revealed that L-FABP bound to megalin, a multiligand endocytotic receptor on PTC, in a Ca(2+)-dependent manner. Degradation assays using megalin-expressing rat yolk sac tumor-derived L2 cells demonstrated that megalin mediated the cellular uptake and catabolism of (125)I-L-FABP. In conclusion, circulatory L-FABP was found to be filtered by glomeruli and internalized by PTC probably via megalin-mediated endocytosis. These results suggest a novel renal uptake pathway for L-FABP, a carrier of hydrophobic molecules, some of which may exert nephrotoxic effects.

    DOI: 10.1038/labinvest.3700240

    Web of Science

    PubMed

    researchmap

  • Significance of proximal ribular metabolism of advanced glycation end products in kidney diseases Reviewed

    A Saito, T Takeda, K Sato, H Hama, A Tanuma, R Kaseda, Y Suzuki, F Gejyo

    MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE   1043   637 - 643   2005

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NEW YORK ACAD SCIENCES  

    Advanced glycation end products (AGEs) are formed by the nonenzymatic Maillard reaction between sugars and proteins. Low-molecular weight AGES are filtered by renal glomeruli and then reabsorbed and metabolized by proximal tubule cells (PTCs). High-molecular weight AGES are also delivered to PTCs in proteinuric states. In patients with diabetes, AGE generation is increased, and the actions of AGES on PTCs are likely involved in the pathogenesis of diabetic nephropathy. In patients with chronic renal failure (CRF), reduced renal metabolism of AGEs likely accounts for the accumulation of AGEs in serum, leading to uremic complications including dialysis-related amyloidosis. AGE precursors such as reactive carbonyl compounds also accumulate in the sera of patients with CRF. It is likely that PTCs take up AGEs and AGE precursors via specific endocytotic receptors or transporters. Megalin is a multiligand endocytotic receptor that is abundantly expressed on PTCs. There is evidence that megalin is involved in the cellular uptake and degradation of AGES. We previously reported a cell therapy model involving implantation of megalin-expressing cells into experimental mice with renal failure for elimination of uremic toxin proteins. Further studies are needed to clarify the molecular mechanisms of the metabolism of AGEs and their precursors to develop a strategy

    DOI: 10.1196/annals.1333.072

    Web of Science

    PubMed

    researchmap

  • Evidence indicating that renal tubular metabolism of leptin is mediated by megalin but not by the leptin receptors

    H Hama, A Saito, T Takeda, A Tanuma, YS Xie, K Sato, JJ Kazama, F Gejyo

    ENDOCRINOLOGY   145 ( 8 )   3935 - 3940   2004.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ENDOCRINE SOC  

    Leptin is secreted by adipocytes and is a circulating factor that regulates food intake and energy expenditure. Its serum level is elevated in patients with renal failure and has been suggested to be associated with malnutritional factors in these patients. Leptin has been suggested to be primarily metabolized by the kidneys, although the precise molecular mechanisms are not known. The purpose of this study was to determine the nephron segments and potential receptors involved in renal leptin metabolism. To determine the segment involved in leptin uptake, we performed histoautoradiography of kidney sections obtained from rats that had been injected iv with I-125-leptin. The ability of megalin, a multiligand endocytic receptor in the proximal tubules, to bind and endocytose leptin was examined by ligand blotting analysis, quartz-crystal microbalance, and degradation assays using megalin-expressing rat yolk sac L2 cells. Immunohistochemistry was performed to localize leptin receptors (LEP-R) in the rat kidney using two antibodies that recognize different epitopes on the LEP-R proteins. Circulating I-125-leptin was filtered by glomeruli and internalized by proximal convoluted tubules. Megalin bound leptin in the presence of Ca2+ and mediated its cellular internalization and degradation. On immunohistochemistry, LEP-R were localized in the proximal straight tubules, loops of Henle, distal tubules, and collecting ducts. In conclusion, circulating leptin was filtered by glomeruli and taken up by proximal convoluted tubules, where megalin likely mediates its binding and uptake. The localization of LEP-R suggests that they are not primarily involved in leptin metabolism in the proximal tubules.

    DOI: 10.1210/en.2004-0074

    Web of Science

    Scopus

    PubMed

    researchmap

  • Differentiation-induced cultured podocytes express endocytically active megalin, a Heymann nephritis antigen

    H Yamazaki, A Saito, H Ooi, N Kobayashi, P Mundel, F Gejyo

    NEPHRON EXPERIMENTAL NEPHROLOGY   96 ( 2 )   E52 - E58   2004

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:KARGER  

    Background/Aims: Megalin is a multiligand endocytic receptor expressed in a number of epithelia. In the Lewis rat kidney, podocytes, as well as proximal tubule cells, express megalin that acts as a pathogenic antigen for Heymann nephritis (HN), an experimental model of membranous nephropathy. To obtain a tool to investigate the molecular mechanisms of megalin-mediated endocytosis and the pathogenesis of HN, we examined whether a differentiation-inducible mouse podocyte cell line expressed endocytically active megalin. Methods: Immunofluorescence and immunoprecipitation analyses with an anti-rat megalin antibody were carried out to investigate whether megalin was expressed in the differentiated and undifferentiated podocytes. Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis was performed to elucidate whether the cells synthesize megalin mRNA. I-125-labeled receptor-associated protein (RAP), an endocytic ligand for megalin, was used for cellular internalization and degradation assays. Results: Immunofluorescence, immunoprecipitation and RT-PCR analyses revealed that megalin was synthesized in both differentiated and undifferentiated cells and localized to the cell surfaces. Effective endocytosis of RAP via megalin was shown under the differentiated condition. Conclusion: Endocytically active megalin is expressed in differentiation-induced cultured podocytes. This cell line could be a useful tool for studies on megalin-mediated endocytosis and the pathogenesis of HN. Copyright (C) 2004 S. Karger AG, Basel.

    DOI: 10.1159/000076404

    Web of Science

    Scopus

    PubMed

    researchmap

  • Different type and localization of CD44 on surface membrane of regenerative renal tubular epithelial cells in vivo

    YS Xie, S Nishi, S Fukase, H Nakamura, XM Chen, N Imai, M Sakatsume, A Saito, M Ueno, Narita, I, T Yamamoto, F Gejyo

    AMERICAN JOURNAL OF NEPHROLOGY   24 ( 2 )   188 - 197   2004

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:KARGER  

    Background: CD44 is a transmembrane glycoprotein comprising an extracellular domain, a transmembrane domain, and a cytoplasmic tail. Previous studies demonstrated that CD44 was generally restricted to lateral- basal plasma membrane ( PM) of epithelial cells, whether it localized on apical PM in vivo has not been clarified. Methods: In this study, we used a gentamicin-induced acute tubular necrosis (ATN) and spontaneous recovery model in rats and two distinct antibodies, an anti-rat distal extracellular domain (OX49) of standard CD44 ( CD44-OX49) and an anti-rat CD44 cytoplasmic tail (CD44CPT), to survey the localization of CD44-OX49 and CD44CPT on the PM in renal tubular epithelial cells in different recovery stages after ATN with immunohistochemistry and immunoelectron-microscopic examinations. Results: CD44-OX49 was localized not only on the lateral-basal PM in tubular epithelial cells, but also on the apical surface membrane in PCNA-positive newly regenerative tubular epithelial cells in early recovery stages after ATN. However, CD44CPT was only localized on the lateral-basal PM. The immunoelectron-microscopic results showed that CD44-OX49 localization was changed from the apical to lateral to basal surface membrane in renal tubular epithelial cells during the recovery process after ATN, finally disappearing from basal PM when normal polarized epithelial cells formed. Conclusions: These results suggest that there were two types of CD44 including CD44 without a cytoplasmic tail localizing on the apical surface membrane related to newly regenerative epithelial cells, and CD44 with a cytoplasmic tail localizing on the lateral-basal PM related to establishment of tubular epithelial cell polarity after ATN in vivo. Copyright (C) 2004 S. Karger AG, Basel.

    DOI: 10.1159/000076758

    Web of Science

    Scopus

    PubMed

    researchmap

  • Bioengineered implantation of megalin-expressing cells: A potential intracorporeal therapeutic model for uremic toxin protein clearance in renal failure Reviewed

    A Saito, JJ Kazama, N Iino, KJ Cho, N Sato, H Yamazaki, Y Oyama, T Takeda, RA Orlando, F Shimizu, Y Tabata, F Gejyo

    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY   14 ( 8 )   2025 - 2032   2003.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Patients who have renal failure and are on dialysis therapy experience serious complications caused by low-molecular-weight uremic toxin proteins normally filtered by glomeruli and metabolized by proximal tubule cells (PTC). Dialysis-related amyloidosis is one such complication induced by systemic deposition of amyloid proteins derived from 12-kD beta(2)-microglobulin (beta(2)-M). Despite the use of high-flux membrane hemodialysis devices and direct absorbent columns, the removal of beta(2)-M is suboptimal, because the effects are transient and insufficient. Megalin is expressed in the apical membranes of PTC and recognized as a multiligand endocytic receptor that binds numerous low-molecular-weight proteins, including, beta(2)-M. This study tested the feasibility of an intra corporeal therapeutic model of continuous beta(2)-m removal using megalin-expressing cell implantation. By cell association and degradation assays, rat yolk sac-derived L2 cells were identified to internalize and degrade beta(2)-M via megalin. The cells were effectively implanted within the subcutaneous tissues of nude mice using a type I collagen scaffold and a method inducing local angiogenesis. After nephrectomy and intraperitoneal injection with I-125-beta(2)-m, it was found that the implanted cells took up the labeled ligand, efficiently removing it from the blood. Bioengineered implantation of megalin-expressing cells may represent a new supportive therapy for dialysis patients to compensate for the loss of renal protein metabolism and remove uremic toxin proteins.

    DOI: 10.1097/01.ASN.0000078804.98322.4A

    Web of Science

    PubMed

    researchmap

  • Infection-associated hemophagocytic syndrome in a diabetic patient undergoing chronic hemodialysis Reviewed

    Yoko Wada, Maki Sato, Akihiko Saito, Fumitake Gejyo

    Clinical and Experimental Nephrology   7 ( 2 )   163 - 166   2003.6

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Hemophagocytic syndrome (HPS) is an uncommon but severe illness associated with a variety of infections, malignant tumors, and autoimmune diseases. We report a case of infection-associated HPS in a patient receiving chronic hemodialysis. Peptostreptococcus-induced sepsis and abscess formation in the left iliopsoas muscle led to the onset of infection-associated HPS in this patient. The patient had diabetes mellitus and end-stage renal disease, and it is likely that immunological dysfunctions from these disorders played a part in the onset of both severe bacterial infections and HPS.

    DOI: 10.1007/s10157-003-0230-6

    Scopus

    PubMed

    researchmap

  • Role of megalin in endocytosis of advanced glycation end products: Implications for a novel protein binding to both megalin and advanced glycation end products Reviewed

    A Saito, R Nagai, A Tanuma, H Hama, KJ Cho, T Takeda, Y Yoshida, T Toda, F Shimizu, S Horiuchi, F Gejyo

    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY   14 ( 5 )   1123 - 1131   2003.5

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:AMER SOC NEPHROLOGY  

    Advanced glycation end products (AGE) are filtered by glomeruli and reabsorbed and metabolized by proximal tubule cells (PTC). In renal failure, decreased renal AGE metabolism likely accounts for the accumulation in serum that is related to uremic complications. In diabetes, AGE generation is increased, and the handling mechanisms in PTC are likely associated with the pathogenesis of tubulointerstitial injury. It is therefore important to clarify the mechanisms of the AGE metabolism to develop a strategy for removing AGE in uremia and to elucidate the pathogenesis of diabetic nephropathy. To this end, this study focused on the molecular analysis of megalin, a multi-ligand endocytic receptor, in PTC. AGE uptake analysis was performed using the rat yolk sac-derived L2 cell line system established for the analysis of megalin's endocytic functions. The cells mediated specific internalization and degradation of AGE, which were significantly blocked by anti-megalin IgG, indicating that megalin is involved in the cellular processes. However, cell surface AGE-binding assays and ligand blot analysis revealed no evidence that megalin is a direct AGE receptor. Affinity chromatography and ligand blot analysis originally revealed that 200-kD and 400-kD proteins in the cells bind to AGE and the 200-kD protein to megalin in a Ca2+-dependent manner. The binding of megalin with the 200-kD protein was suppressed by receptor-associated protein (RAP), a ligand for megalin. In conclusion, megalin functions for endocytosis of AGE via an indirect mechanism. L2 cells express novel AGE-binding proteins, one of which may interact with megalin.

    DOI: 10.1097/01.ASN.0000062962.51879.F8

    Web of Science

    PubMed

    researchmap

  • IgA腎症の進展におけるACE及びAngiotensinogen(AGT)遺伝子多型の検討

    後藤 眞, 成田 一衛, 斉藤 徳子, 坂爪 実, 飯野 則昭, 斉藤 亮彦, 西 慎一, 上野 光博, 下条 文武

    日本腎臓学会誌   43 ( 3 )   270 - 270   2001.4

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • メサンギウム増殖性糸球体腎炎(MesPGN)におけるLRP遺伝子多型の検討

    齋藤 徳子, 成田 一衛, 後藤 眞, 坂爪 実, 斎藤 亮彦, 大森 健太郎, 上野 光博, 下条 文武

    日本腎臓学会誌   43 ( 3 )   271 - 271   2001.4

     More details

    Language:Japanese   Publisher:(一社)日本腎臓学会  

    researchmap

  • IgA腎症の進展におけるレニン・アンギオテンシン系遺伝子多型の検討

    後藤 眞, 成田 一衛, 斉藤 徳子, 坂爪 実, 飯野 則昭, 斉藤 亮彦, 西 慎一, 上野 光博, 今井 直史, 下条 文武

    日本内科学会雑誌   90 ( 臨増 )   211 - 211   2001.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • Association of Gene Polymorphism of Polymeric Immunoglobulin Receptor and IgA Nephropathy

    Ichiei Narita, Daisuke Kondo, Shin Goto, Noriko Saito, Yasuo Watanabe, Hajime Yamazaki, Minoru Sakatsume, Akihiko Saito, Fumitake Gejyo

    Internal Medicine   40 ( 9 )   867 - 872   2001

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Objective In order to explore the possibility that genetic predisposition to dysfunction of mucosal immunity and the IgA processing pathway plays a role in the pathogenesis of mesangial IgA1 deposition in IgAN, we examined the possible association of the gene polymorphism of plgR in the patients with and without IgAN. Subjects and Methods Genomic DNA of peripheral blood cells was isolated from 372 individuals including 172 histologically confirmed IgAN patients. Segments of the pIgR gene were PCR amplified and restriction fragment length polymorphism was determined as Al and A2 with and without Pvu II site, respectively. Results The pIgR genotype distribution was significantly different between the patients with IgAN and those without IgAN. Allele frequency of A2 was higher in IgAN than in other renal diseases (Al and A2
    0.516 and 0.484 in IgAN, 0.641 and 0.359 in others, X2=9.84, P=0.0017, Odds ratio=1.71). Moreover, the subjects with A2A2 genotype were associated with a relatively low level of serum IgA only in the patients with IgAN but not in other renal diseases. The difference of allele frequencies was more remarkable in the patients with a serum IgA level of less than 300 mg/dl (Al and A2
    0.439 and 0.561 in IgAN, 0.702 and 0.298 in others, X2=12.44, P=0.0004, Odds ratio=3.01). Conclusion This is the first demonstration of the pIgR gene polymorphisms in IgAN which are associated with its clinical phenotype. Gene polymorphisms of pIgR may be candidate genetic markers of susceptibility to IgAN. (Internal Medicine 40: 867-872, 2001). © 2001, The Japanese Society of Internal Medicine. All rights reserved.

    DOI: 10.2169/internalmedicine.40.867

    Scopus

    PubMed

    researchmap

  • Expression of osteopontin in gentamicin-induced acute tubular necrosis and its recovery process

    Yuansheng Xie, Shinichi Nishi, Seitaro Iguchi, Naofumi Imai, Minoru Sakatsume, Akihiko Saito, Mika Ikegame, Noriaki Iino, Hisaki Shimada, Mitsuhiro Ueno, H. Kawashima, M. Arakawa, Fumitake Gejyo

    Kidney International   59 ( 3 )   959 - 974   2001

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Background. There is controversy regarding the exact localization and roles of osteopontin (OPN), a multipotential chemokine, in renal injury. There is little information on the expression and role of OPN in gentamicin-induced acute tubular necrosis (ATN) and its recovery process. Methods. A severe ATN model was made using male Wistar rats by injecting gentamicin (150 mg/kg/day) for five days and limiting the provision of water. The expression and localization of OPN mRNA and protein, ED1 as a macrophage marker, proliferating cellular nuclear antigen (PCNA), CD44 as an OPN receptor, megalin as a proximal tubule marker, and their relationships to each other were examined from the early tubular necrotic period to the late recovery period by Northern blotting, in situ hybridization, and double immunohistochemical staining. Results. In the gentamicin group, OPN mRNA and protein were expressed in only the PCNA-positive proliferating cortical distal tubules, not in the necrotic proximal tubules, until day 6 after the first administration, but were found markedly in PCNA-positive regenerative proximal and distal tubules on days 10, 15, and 30. The localization of PCNA-positive cells was almost always accompanied with the up-regulated expression of OPN using quantitative analysis (P &lt
    0.01). CD44 expression was markedly up-regulated in the renal cortical tubular epithelium from days 6 to 30. In the control group, no expression of OPN and CD44 in the cortical area was found throughout the experimental period. Conclusions. These results suggested that OPN is related to the proliferation and regeneration of tubular epithelial cells after tubular damage.

    DOI: 10.1046/j.1523-1755.2001.059003959.x

    Scopus

    PubMed

    researchmap

  • IgA腎症におけるpIgR,TGF-β1,MCP-1及びRAA系遺伝子多型の検討

    後藤 眞, 成田 一衛, 斉藤 徳子, 山崎 肇, 坂爪 実, 島田 久基, 斉藤 亮彦, 西 慎一, 上野 光博, 下条 文武

    日本内科学会雑誌   89 ( 臨増 )   144 - 144   2000.2

     More details

    Language:Japanese   Publisher:(一社)日本内科学会  

    researchmap

  • The prevention of glomerulosclerosis in rats using traditional Chinese medicine, Sairei-to

    Ping Li, Hiroshi Kawachi, Yasuhito Suzuki, Akihiko Saito, Michiaki Orikasa, Zhen Sheng Shi, Fujio Shimizu

    Nephrology   5 ( 1-2 )   83 - 89   2000

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The effects of Sairei-to on chronic irreversible lesions were examined by the administration of drugs after the initiation of irreversible renal lesions by uninephrectomy and anti-thy-1 antibody injection. Twenty-one female Wistar rats were divided into three groups. Group 1 was treated with phosphate-buffered saline (PBS) as a control and groups 2 and 3 were treated with Sairei-to 400 mg/kg bodyweight per day on a daily basis beginning on day 1 (group 2) and day 7 (group 3) to day 42 after the intravenous administration of 500 μg anti-thy-1 monoclonal antibody (MoAb) into uninephrectomized rats, respectively. Statistically significant effects of Sairei-to on proteinuria were observed on days 3, 7, 14, and 21 in group 2 and on day 21 in group 3 as compared with the PBS controls. On day 42, light microscopy showed that Sairei-to ameliorated morphological lesions (Matrix score: 133.7±50.35 for group 1 vs 40.02±24.0 for group 2, P&lt
    0.05). The weight of the kidneys in groups given Sairei-to was also lower than that in the PBS control. In addition, immunofluorescent findings showed that Sairei- to suppressed the expression of transforming growth factor-beta (TGF-β), alpha-smooth muscle actin (α-SMA) and collagen type I in glomeruli and decreased the number of ED1- and OX8-positive cells in tubulo-interstitium as well as in glomeruli. In conclusion, Sairei-to blocked the progression of renal lesions in this model even when it was administered after the initiation of the disease. In addition, earlier treatment more effectively prevented the progression of the renal lesions.

    DOI: 10.1046/j.1440-1797.2000.00503.x

    Scopus

    researchmap

  • Severe proteinuria, sustained for 6 months, induces tubular epithelial cell injury and cell infiltration in rats but not progressive interstitial fibrosis

    Hiroshi Kikuchi, Hiroshi Kawachi, Yumi Ito, Katsuyuki Matsui, Hitonari Nosaka, Akihiko Saito, Michiaki Orikasa, Masaaki Arakawa, Fujio Shimizu

    Nephrology Dialysis Transplantation   15 ( 6 )   799 - 810   2000

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Oxford University Press  

    Background. Sustained proteinuria is reported to be very harmful to the tubulointerstitium, leading to severe interstitial injury. However, it remains unclear whether sustained proteinuria itself is responsible for severe interstitial injury because, in the previously reported models, the development of factors other than proteinuria in tubulointerstitial lesions could not be excluded completely. Methods. After treatment to induce immune tolerance to mouse immunoglobulin, 20 rats were injected with anti-rat slit diaphragm monoclonal antibody (mAb) 5-1-6 twice a week for 6 months and were then sacrificed. Results. mAb 5-1-6 induced massive proteinuria in 11 rats. In nine rats with mild proteinuria, no histological alteration could be detected with light microscopy and immunofluorescence. In nephrotic rats, light microscopy showed minor glomerular abnormalities, with interstitial oedema, tubular epithelial cell degeneration and interstitial cell infiltration. Immunofluorescence revealed increased expression of vimentin and an increased number of OX1-, OX19- and ED1-positive cells. However, we could not detect any accumulation of type I and IV collagen or laminin in the tubulointerstitium. RT-PCR showed that the expression of mRNA for type I collagen was not increased, compared with that in control rats. Conclusions. We succeeded in developing a model of persistent nephrosis without severe glomerular abnormalities, nephrectomy or other manoeuvres known to induce disturbed haemodynamics, using an agent without tubulointerstitial toxicity, and considered it to be suitable for investigating the direct toxicity of proteinuria. In this model, isolated massive proteinuria induced interstitial injury. However, the degree of injury was suggested to be much less than that observed in other previously developed models.

    DOI: 10.1093/ndt/15.6.799

    Scopus

    PubMed

    researchmap

  • Down-regulation of interferon-γ signaling by gene transfer of Stat1 mutant in mesangial cells

    Minoru Sakatsume, Ichiei Narita, Hajime Yamazaki, Akihiko Saito, Yoichi Nakagawa, Hideyuki Kuriyama, Ryozo Kuwano, Fumitake Gejyo, Masaaki Arakawa

    Kidney International   57 ( 2 )   455 - 463   2000

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Blackwell Publishing Inc.  

    Background. Interferon-γ (IFN-γ) is secreted by T lymphocytes and natural killer (NK) cells in the cellular immunity-mediated inflammatory lesion, including endocapillary or extracapillary proliferative glomerulonephritis. It induces and/or enhances multiple histocompatibility complex (MHC) class I and II, intercellular adhesion molecule-1 (ICAM-1), inducible nitric oxide synthase (iNOS), and Fc receptor expression in renal resident cells, resulting in the initiation and promotion of inflammation. Recently, the signaling mechanism of IFN-γ has been investigated, and it appears that Stat1α is essential for signaling. We investigated Stat1α activation by IFN-γ in mesangial cells and attempted to regulate the signal transduction by gene transfer. Methods. Western blot with anti-Stat1 and antiphosphotyrosine after immunoprecipitation of Stat1 and Northern blot for detection of Stat1 mRNA were performed. The dominant negative form of Flag- tagged Stat1 was expressed in cultured rat mesangial cells. Flag was immunostained in transfectants, and luciferase reporter assay was carried out to measure the transcriptional activity of Stat1α. The expression of IFN-γ- inducible genes such as MHC class II (Ia-Aα) and MHC class II transactivator (CIITA) was detected by reverse transcriptase-polymerase chain reaction (RT- PCR). Results. Stat1α was tyrosine phosphorylated and activated by IFN-γ in mesangial cells, and the mRNA and protein level of Stat1α increased upon stimulation by IFN-γ. Overexpression of Stat1-mutant lacking 35 C-terminal amino acids strongly suppressed the IFN-γ-induced signal transduction and inhibited the expression of MHC class II and CIITA genes in mesangial cells. Conclusions. Stat1α is a critical molecule in the signal transduction of IFN-γ in mesangial cells. The inhibition of an endogenous function of Stat1α by gene transfer of the Stat1 mutant may be a new method to reduce the inflammatory effects of IFN-γ in localized inflammation of the kidney.

    DOI: 10.1046/j.1523-1755.2000.00865.x

    Scopus

    PubMed

    researchmap

  • Ultrastructural localization of megalin in the rat cochlear duct

    K Mizuta, A Saito, T Watanabe, M Nagura, M Arakawa, F Shimizu, T Hoshino

    HEARING RESEARCH   129 ( 1-2 )   83 - 91   1999.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:ELSEVIER SCIENCE BV  

    Megalin is an endocytic receptor predominantly expressed in the kidney proximal tubule cells. In the present study, localization of megalin was examined using a post-embedding immunogold method in the rat cochlear duct. Marginal cells of the stria vascularis were labeled on the apical surface, but not on the basolateral surface. This localization pattern resembles kidney proximal tubule cells. Immunoreactivity was also detected on various other cells, including epithelial cells of the spiral prominence and epithelial cells of Reissner&apos;s membrane. In contrast, virtually no gold particles were seen on intermediate cells and basal cells of the stria vascularis, mesothelial cells of Reissner&apos;s membrane or fibrocytes in the lateral wall. Also unlabeled were cells in the tympanic wall of the cochlear duct, including sensory cells and supporting cells of the organ of Corti. The present findings show the involvement of megalin in endocytosis of marginal cells and are suggestive of different uptake mechanisms for aminoglycosides in the kidney proximal tubule cells and in the cochlear sensory cells. (C) 1999 Elsevier Science B.V. All rights reserved.

    DOI: 10.1016/S0378-5955(98)00221-4

    Web of Science

    Scopus

    PubMed

    researchmap

  • All four putative ligand-binding domains in megalin contain pathogenic epitopes capable of inducing passive Heymann nephritis

    H Yamazaki, R Ullrich, M Exner, A Saito, RA Orlando, D Kerjaschki, MG Farquhar

    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY   9 ( 9 )   1638 - 1644   1998.9

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:LIPPINCOTT WILLIAMS & WILKINS  

    Megalin (gp330) is the main target antigen involved in the induction of Heymann nephritis (HN), a rat model of human membranous nephropathy. Its large extracellular region contains four putative ligand-binding domains separated by spacer regions. Previously, it was reported that the second ligand-binding domain (LBD II) of megalin is involved in the pathogenesis of passive HN because it is capable of binding antibodies in vivo and initiating formation of immune deposits (ID). This study explores the possibility that pathogenic epitopes might also be present in the other putative ligand-binding domains. Recombinant fragments of ligand-binding domains (LBD)I through IV expressed in a baculovirus system were used to generate polyclonal domain-specific antibodies. Antibodies raised against each of the recombinant megalin fragments reacted preferentially with its respective antigen and with whole megalin by immunoblotting. Each of the antibodies also gave a characteristic brush-border staining for megalin by indirect immunofluorescence on rat kidney. When rats were injected with the domain-specific antibodies to test their ability to produce passive HN, glomerular ID were present in kidneys of all injected animals. The staining pattern in glomeruli of rats injected with LED I, III, or IV was similar to that obtained with antibodies to LED II. It is concluded that passive HN can be induced with antibodies against LED I, III, and IV, as well as LED II, and that each of the ligand-binding domains contains a pathogenic epitope. These findings provide further evidence for the multiple epitope model of HN.

    Web of Science

    Scopus

    PubMed

    researchmap

  • Identification of genes specifically expressed in chronic and progressive glomerulosclerosis Reviewed

    Narita, I, H Nakayama, S Goto, T Takeda, M Sakatsume, A Saito, Y Nakagawa, M Arakawa

    KIDNEY INTERNATIONAL   S215 - S217   1997.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:BLACKWELL SCIENCE INC  

    To identify genes expressed predominantly in the kidney with chronic and progressive glomerulosclerosis but not in acute and transient form of glomerulonephritis, we induced progressive glomerulosclerosis in rats by applying unilateral nephrectomy prior to injection of monoclonal anti-Thy1.1 antibody (OX-7), which cause acute and transient glomerulonephritis with single injection. In rats with nephrectomy and OX-7 injection (Nx group), proteinuria increased with time and mesangial expansion accompanied with interstitial fibrosis was recognized, whereas transient proteinuria and mesangiolysis followed by mesangial hypercellularity were seen in rats with sham operation and OX-7 injection (Sham group). Four weeks after the induction of glomerulonephritis, mRNAs were isolated from kidney cortex of both groups and used for cDNA synthesis. By subtraction hybridization of cDNAs from Nx with excess amount of those from Sham, we isolated and sequenced several genes expressed specifically in the Nx group. These included genes, which contain identical sequences with serine protease inhibitors, cytokine receptors, osteopontin as well as genes with unknown function. These genes may play important roles in the process which promotes acute glomerular damage advance to chronic and progressive glomerulosclerosis.

    Web of Science

    researchmap

  • Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions

    RA Orlando, M Exner, RP Czekay, H Yamazaki, A Saito, R Ullrich, D Kerjaschki, MG Farquhar

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   94 ( 6 )   2368 - 2373   1997.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATL ACAD SCIENCES  

    Megalin is a large cell surface receptor that mediates the binding and internalization of a number of structurally and functionally distinct ligands from the lipoprotein and protease:protease inhibitor families, To begin to address how megalin is able to bind ligands with unique structurally properties, we have mapped a binding site for apolipoprotein E (apoE)-beta very low density lipoprotein (beta VLDL), lipoprotein lipase, aprotinin, lactoferrin, and the receptor-associated protein (RAP) within the primary sequence of the receptor, RAP is known to inhibit the binding of all ligands to megalin, We identified a ligand-binding site on megalin by raising mAb against purified megalin, selected for a mAb whose binding to megalin is inhibited by RAP, and mapped the epitope for this mAb, mAb AC10 inhibited the binding of apoE-beta VLDL, lipoprotein Lipase, aprotinin, and lactoferrin to megalin in a concentration-dependent manner. When cDNA fragments encoding the four cysteine-rich ligand-binding repeats in megalin were expressed in a baculovirus system and immunoblotted with AC10, it recognized only the second cluster of ligand-binding repeats. The location of the epitope recognized by mAb AC10 within this domain was pinpointed to amino acids 1111-1210. From these studies we conclude that the binding of apoE-beta VLDL, lactoferrin, aprotinin, lipoprotein lipase, and RAP to megalin is either competitively or sterically inhibited by mAb AC10 suggesting that these ligands bind to the same or closely overlapping sites within the second cluster of ligand-binding repeats.

    DOI: 10.1073/pnas.94.6.2368

    Web of Science

    Scopus

    PubMed

    CiNii Article

    researchmap

  • Identification of genes specifically expressed in chronic and progressive glomerulosclerosis

    I. Narita, H. Nakayama, S. Goto, T. Takeda, M. Sakatsume, A. Saito, Y. Nakagawa, M. Arakawa

    Kidney International, Supplement   51 ( 63 )   S215 - S217   1997

     More details

    Language:English   Publishing type:Research paper (international conference proceedings)  

    To identify genes expressed predominantly in the kidney with chronic and progressive glomerulosclerosis but not in acute and transient form of glomerulonephritis, we induced progressive glomerulosclerosis in rats by applying unilateral nephrectomy prior to injection of monoclonal anti-Thy1.1 antibody (OX-7), which cause acute and transient glomerulonephritis with single injection. In rats with nephrectomy and OX-7 injection (Nx group), proteinuria increased with time and mesangial expansion accompanied with interstitial fibrosis was recognized, whereas transient proteinuria and mesangiolysis followed by mesangial hypercellularity were seen in rats with sham operation and OX-7 injection (Sham group). Four weeks after the induction of glomerulonephritis, mRNAs were isolated from kidney cortex of both groups and used for cDNA synthesis. By subtraction hybridization of cDNAs from Nx with excess amount of those from Sham, we isolated and sequenced several genes expressed specifically in the Nx group. These included genes, which contain identical sequences with serine protease inhibitors, cytokine receptors, osteopontin as well as genes with unknown function. These genes may play important roles in the process which promotes acute glomerular damage advance to chronic and progressive glomerulosclerosis.

    Scopus

    PubMed

    researchmap

  • Molecular Genetics of Renal Diseases

    Akihiko Saito, Hajime Yamazaki, Yoichi Nakagawa, Masaaki Arakawa

    Internal Medicine   36 ( 2 )   81 - 86   1997

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:Japanese Society of Internal Medicine  

    Recent progress in molecular genetics has strongly influenced nephrology. Gene mutations have been identified which cause various monogenic hereditary renal diseases including Alport syndrome, autosomal dominant polycystic kidney disease, and tubular transporter disorders. The data obtained will be useful not only to develop new methods of diagnosis and treatment of such particular diseases but also to expand the knowledge of renal physiology and pathophysiology. In addition, genetic factors have been investigated which are involved in the development and progression of more common renal diseases such as IgA nephropathy and diabetic nephropathy. There have also been great advances in molecular studies of experimental renal diseases such as Heymann nephritis and in the use of transgenic and knockout mice. In this review we focused on the important achievements made recently in the field of molecular nephrology.

    DOI: 10.2169/internalmedicine.36.81

    Scopus

    PubMed

    CiNii Article

    researchmap

  • Mapping rat megalin: The second cluster of ligand binding repeats contains a 46-amino acid pathogenic epitope involved in the formation of immune deposits in Heymann nephritis

    A Saito, H Yamazaki, K Rader, A Nakatani, R Ullrich, D Kerjaschki, RA Orlando, MG Farquhar

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   93 ( 16 )   8601 - 8605   1996.8

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATL ACAD SCIENCES  

    Megalin (gp330), an epithelial endocytic receptor, is a major target antigen of Heymann nephritis (HN), an autoimmune disease in rats. To elucidate the mechanisms of HN, we have mapped a pathogenic epitope in megalin that binds anti-megalin antibodies. We focused our attention on four clusters of cysteine-rich, low density lipoprotein receptor (LDLR) ligand binding repeats in the extracellular domain of megalin because they represent putative ligand binding regions and therefore would be expected to be exposed in vivo and to be able to bind circulating antibodies. Rat megalin cDNA fragments I through IV encoding the first through fourth clusters of ligand-binding repeats, respectively, were expressed in a baculovirus system. All four expression products were detected by immunoblotting with two antisera capable of inducing passive HN (pHN). When antibodies eluted from glomeruli of rats with pHN were used for immunoblotting, only the expression product encoded by fragment II was detected. This indicates that the second cluster of LDLR ligand binding repeats is directly involved in binding anti-megalin antibodies and in the induction of pHN. To narrow the major epitope in this domain, fragment II was used to prepare proteins sequentially truncated from the C- and N-terminal ends by in vitro translation. Analysis of the truncated translation products by immunoprecipitation with anti-megalin IgG revealed that the fifth ligand-binding repeat (amino acids 1160-1205) contains the major epitope recognized. This suggests that a 46-amino acid sequence in the second cluster of LDLR ligand binding repeats contains a major pathogenic epitope that plays a key role in pHN. Identification of this epitope will facilitate studies on the pathogenesis of HN.

    DOI: 10.1073/pnas.93.16.8601

    Web of Science

    Scopus

    PubMed

    CiNii Article

    researchmap

  • THE HEYMANN NEPHRITIS ANTIGENIC COMPLEX - MEGALIN (GP330) AND RAP

    MG FARQUHAR, A SAITO, D KERJASCHKI, RA ORLANDO

    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY   6 ( 1 )   35 - 47   1995.7

     More details

    Language:English   Publisher:WILLIAMS & WILKINS  

    Heymann nephritis (HN) has been extensively studied as a model of human membranous nephropathy since it was first described by Heymann in 1959, HN was induced in active form by the immunization of rats with antigens derived from the proximal tubule brush border, resulting in subepithelial glomerular immune deposits. HN was also induced passively by the injection of antibrush border antibodies into normal rats, A breakthrough in the understanding of the pathogenesis of HN was made in the 1970s, when it was established that the disease was due to the binding of circulating antibodies to glomerular components. This in turn led to a search to identify the endogenous antigen(s), In 1982, gp330 (now called megalin), a glycoprotein located in clathrin-coated pits of glomerular and proximal tubular epithelia, was identified as a target antigen, In 1990, a second protein (44 kd), now known as RAP (for receptor associated protein), that binds to megalin was also shown to be a target antigen. Both molecules have been cloned and sequenced, and their role in normal epithelial cells has been explored. It has come to light that megalin (gp330) is a member of the low-density lipoprotein receptor gene family and functions as a multiligand receptor for the uptake of a variety of macromolecules (plasminogen, protease: protease inhibitor complexes, apolipoprotein E-enriched very low-density lipoproteins, lactoferrin, among others). RAP associates with megalin and appears to function as a chaperone assisting in the folding of megalin in the endoplasmic reticulum and its transport to the cell surface. This review considers what is now known about the structure, function, and trafficking of megalin and RAP and the role of these two molecules in the pathogenesis of HN.

    Web of Science

    Scopus

    PubMed

    researchmap

  • No linkage to the COL4A3 gene locus in Japanese thin basement membrane disease families

    Hajime YAMAZAKI, Yoichi NAKAGAWA, Akihiko SAITO, Shinichi NISHI, Shiminoru SAKATSUME, Tetsuro TAKEDA, Yuichiro MARUYAMA, Sojiro OGINO, Shiro MARUYAMA, Toshio MOCHIZUKI, Stephen T REEDERS, Masaaki ARAKAWA

    Nephrology   1 ( 4 )   315 - 321   1995

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Summary: Patients with thin basement membrane disease (TBMD) exhibit persistent haematuria with a diffuse thinning of the glomerular basement membrane (GBM), especially of the lamina densa. It appears to be an autosomal dominant trait. It has been reported that the Goodpasture epitope, which is located in the non‐collagenous domain of type IV collagen α 3 chain, may be reduced in patients with TBMD. We speculated that the candidate gene for TBMD could be the type IV collagen α 3 chain gene (COL4A3), which is present closely to type IV collagen α 4 chain gene (COL4A4) on chromosome 2q35–37. We conducted a linkage analysis to investigate the relationship between familial TBMD and COL4A3 gene, using COL4A3 cDNA polymorphism and a (CA)n microsatellite marker located in the COL4A3 gene. We examined 32 individuals from four Japanese families with TBMD. There were no associations between the patients with haematuria and certain alleles of the two markers in the pedigrees of three families. It has been reported that type IV collagen α 1 chain gene (COL4A1) and α 2 chain gene (COL4A2) are not involved in TBMD, and that α 5 chain gene (COL4A5) and a 6 chain gene (COL4A6) map to chromosome X. In conclusion, our findings suggested that familial TBMD is not caused by the genetic abnormalities of type IV collagen genes isolated thus far. Copyright © 1995, Wiley Blackwell. All rights reserved

    DOI: 10.1111/j.1440-1797.1995.tb00046.x

    Scopus

    researchmap

  • Mesangial cell-matrix interactions: Modulation of matrix expression in mesangial cells by extracellular matrices

    M. Sakatsume, A. Saito, T. Takeda, H. Yamazaki, I. Narita, S. I. Nishi, Y. Nakagawa, M. Arakawa

    Experimental Nephrology   3 ( 6 )   362 - 368   1995

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Aberrant extracellular matrices (ECMs) observed in mesangial areas during the progression of glomerulonephropathy could be produced by mesangial cells (MCs), interacting with altered ECM components, under the influence of various mediators. We studied the interaction between MCs and ECMs, especially focusing on matrix expression of MCs in contact with ECMs. We analyzed mRNA expression and protein synthesis of ECM components by cultured rat MCs which were plated on different types of ECMs, basement membrane-type matrix (BMM), type IV collagen and type I collagen. The level of mRNA for ECM components (α1 type I collagen, α1 type IV collagen, fribronectin and laminin B2) increased in MCs on the two types of collagen compared with BMM. The relative increase of α1 type I collagen mRNA expression in MCs on type I collagen was greater than that of α1 type IV collagen expression. At the protein level, type I collagen production by MCs on coated type I collagen showed a 2.2-fold increase relative to that on BMM. MCs on type IV collagen produced it at an intermediate level. The phenomena were not associated with differences of proliferative activity, but were accompanied by minor morphological differences. These results indicate that ECMs can modulate the phenotype of MCs in terms of matrix expression and suggest that MC-matrix interaction may in part contribute to abnormal ECM accumulation in diseased glomeruli.

    Scopus

    PubMed

    researchmap

  • COMPLETE CLONING AND SEQUENCING OF RAT GP330 MEGALIN, A DISTINCTIVE MEMBER OF THE LOW-DENSITY-LIPOPROTEIN RECEPTOR GENE FAMILY

    A SAITO, S PIETROMONACO, AKC LOO, MG FARQUHAR

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   91 ( 21 )   9725 - 9729   1994.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATL ACAD SCIENCES  

    We completed the cDNA cloning and sequencing of gp330, the major kidney glomerular antigen for rat Heymann nephritis. The deduced 4660-aa sequence, expected to constitute a mature protein of M(r) 516,715, consists of a probable N-terminal signal peptide sequence (25 aa), an extracellular region (4400 aa), a single transmembrane domain (22 aa), and a C-terminal cytoplasmic tail (213 aa), The extracellular region contains three types of cysteine-rich repeats characteristic of the low density lipoprotein receptor (LDLR) gene family-36 LDLR ligand-binding repeats forming four clusters of putative ligand-binding domains, 16 growth factor repeats separated by 8 YWTD spacer regions, and 1 C-terminal epidermal growth factor repeat. The cytoplasmic tail contains two copies of the (FX)NPXY moth, which represents a signal for coated pit-mediated internalization and an additional similar moth. The overall structure of gp330 is similar to that of the LDLR-related protein (LRP)/alpha(2)-macroglobulin receptor and shows even greater similarity to the Caenorhabditis elegans protein, reported as a homologue of LRP. However, gp330 differs from these proteins in (i) the cysteine-rich repeat arrangements found in the extreme extracellular N- and C-terminal regions, (ii) the distribution pattern of cysteine residues in the YWTD spacer regions, (iii) the location of the RX(K/R)R consensus recognition sequence of furin, a precursor processing endoprotease, and (iv) the length and structure of the cytoplasmic tail. We suggest the name megalin (from Greek mega) for gp330, the largest plasma membrane protein identified so far in vertebrates. The cloned cDNA will be useful for studies on the physiological functions of gp330/megalin and for determining its role in Heymann nephritis.

    DOI: 10.1073/pnas.91.21.9725

    Web of Science

    Scopus

    PubMed

    CiNii Article

    researchmap

  • A DELETION MUTATION IN THE 3' END OF THE ALPHA-5(IV) COLLAGEN GENE IN JUVENILE-ONSET ALPORT SYNDROME

    A SAITO, M SAKATSUME, H YAMAZAKI, F OGATA, Y HIRASAWA, M ARAKAWA

    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY   4 ( 9 )   1649 - 1653   1994.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:WILLIAMS & WILKINS  

    Alport syndrome is a hereditary progressive glomerular basement membrane disorder in which juvenile-or adult-onset renal failure is often accompanied by sensorineural deafness and ocular abnormalities. Recently, mutations have been found in the type IV collagen alpha 5 chain gene in patients with X-linked Alport syndrome. This study searched for gene mutations in seven unrelated Japanese patients by the use of conventional Southern blot analysis with cDNA probes for the carboxyl-terminal noncollagenous domain that is encoded by exons 46 to 51. A deletion mutation was found in a patient who developed juvenile-onset (age 15) ESRD with typical ultrastructural glomerular basement membrane destruction and sensorineural hearing loss but no characteristic ocular abnormalities. His mother showed hematuria and proteinuria with nomal renal function, suggesting that she may be the heterozygous carrier. Exon-specific polymerase chain reaction amplified the coding sequence of exon 48 but not exons 49 to 51. Analysis with pulsed-field gel electrophoresis revealed that the deletion is approximately 10 kb in length and does not involve the CpG island, which is located in the 3' distal site of the gene. Identification of this novel deletion causing juvenile-type Alport syndrome would contribute to elucidating the mechanisms of renal failure progression in the syndrome.

    Web of Science

    Scopus

    PubMed

    researchmap

  • Alternative splicing in the α5(IV) collagen gene in human kidney and skin tissues

    Akihiko Saito, Minoru Sakatsume, Hajime Yamazaki, Masaaki Arakawa

    The Japanese Journal of Nephrology   36 ( 1 )   19 - 24   1994

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Type IV collagen is a complex molecule composed of three α chains that can be of types αl(IV) to α5(IV). Each α chain contains an amino-terminal collagenous domain and a carboxyl-terminal noncol-lagenous (NC) domain consisting of 229 amino acids, which is involved in intermolecular cross-linking to construct the basement membrane network. Specific localization of α5(IV) collagen in glomerular basement membranes (GBM) in the kidney indicates its crucial role for that construction. In human kidney cortex and skin RNA, we found an alternative splicing transcript which skips exon 50 of the α5(IV) collagen gene using reverse transcription-polymerase chain reaction and direct sequencing of the PCR products. This alternative splicing introduces a stop codon at the first codon of exon 51, resulting in an mRNA encoding a protein lacking the 84 NC domain carboxylterminal amino acid residues encoded by exons 50 and 51. Recently, gene mutations affecting the α5(IV) collagen NC domain have been reported in patients with X-linked Alport syndrome who display GBM destruction and progressive renal failure, which are usually milder in female patients. Therefore, the alternative splicing, if its truncated products are dominantly expressed in glomeruli, may cause GBM impairment and renal failure progression. © 1994, Japanese Society of Nephrology. All rights reserved.

    DOI: 10.14842/jpnjnephrol1959.36.19

    Scopus

    PubMed

    researchmap

  • Clinical Significance of Urinary Methylguanidine in Non-Dialyzed Patients with Chronic Renal Failure —Prediction of Progression Rate of Renal Dysfunction—

    Yutaka Koda, Akihiko Saito, Katsunobu Shinohara, Ran Ei, Shigeru Miyazaki, Yasuko Yuasa, Shinji Sakai, Masashi Suzuki, Sachio Takahashi, Yoshihei Hirasawa, Motoo Nakajima

    Japanese Journal of Nephrology   35 ( 3 )   203 - 208   1993

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    To clarify a clinical significance of urinary methylguanidine (U-MG, dl) in non-dialyzed patients with chronic renal failure, we measured U-MG, urinry creatinine (U-Cr, mg/ dl) and serum creatinine (S-Cr, mg/dl), concurrently and continually in 36 out-patients whose S-Cr was over 4. 0 mg/dl. Fresh urine sample was obtained and U-MG was measured by an enzymic method. © 1993, Japanese Society of Nephrology. All rights reserved.

    DOI: 10.14842/jpnjnephrol1959.35.203

    Scopus

    PubMed

    researchmap

  • Molecular genetics of Alport syndrome

    H. Yamazaki, A. Saito, Y. Nakagawa, M. Arakawa

    Nippon rinsho. Japanese journal of clinical medicine   50   3021 - 3026   1992.12

     More details

    Alport syndrome is a hereditary glomerulonephritis in which progressive loss of kidney function is often accompanied by sensorineural deafness. Ultrastructural studies in glomerular basement membranes (GBM) of Alport syndrome patients implicate an altered GBM protein structure as the cause of nephritis. The product of COL4A5, the alpha 5 (IV) collagen chain, is a specific component of GBM of the kidney. Various mutations in the COL4A5 gene have been identified in X-linked dominant Alport syndrome, and these aberrations of the alpha 5 (IV) can account for at least a part of X-linked Alport syndrome.

    Scopus

    PubMed

    researchmap

  • LONG-DISTANCE RESTRICTION MAPPING OF THE PROXIMAL LONG ARM OF HUMAN CHROMOSOME-21 WITH NOT-I LINKING CLONES

    H ICHIKAWA, K SHIMIZU, A SAITO, D WANG, R OLIVA, H KOBAYASHI, Y KANEKO, H MIYOSHI, CL SMITH, CR CANTOR, M OHKI

    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA   89 ( 1 )   23 - 27   1992.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)   Publisher:NATL ACAD PRESS  

    Human chromosome 21 is the smallest of the 22 autosomes and 2 sex chromosomes. Hybridization of the human repetitive sequence Alu to pulsed-field gel-fractionated Not I-digested genomic DNA from a human-mouse hybrid cell line containing chromosome 21 as the sole human component identified chromosome 21 Not I restriction fragments. A Not I restriction map of regions of the chromosome was constructed, by identifying neighboring Alu bands with Not I linking clones. This approach simplifies the task of physical mapping and avoids ambiguities in Not I fragment assignments that arise from gel-to-gel mobility variations. A contiguous map was constructed with six Not I linking clones that covers at least the proximal one-third of the long arm of chromosome 21 and spans 20 megabases. A more detailed restriction map revealed 11 likely CpG islands in this region and localized 11 additional DNA markers.

    DOI: 10.1073/pnas.89.1.23

    Web of Science

    Scopus

    PubMed

    CiNii Article

    researchmap

  • Single dialysis system

    T. Kawasaki, A. Saito, H. Yamazaki, H. Ichikawa

    Nippon rinsho. Japanese journal of clinical medicine   49 Suppl   196 - 204   1991.12

  • Central dialysate supply system

    T. Kawasaki, A. Saito, H. Yamazaki, H. Ichikawa

    Nippon rinsho. Japanese journal of clinical medicine   49 Suppl   205 - 211   1991.12

  • Construction and characterization of a NotI linking library of human chromosome 21

    Akihiko Saito, Jose P. Abad, Denan Wang, Misao Ohki, Charles R. Cantor, Cassandra L. Smith

    Genomics   10 ( 3 )   618 - 630   1991

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    Effective procedures have been developed for constructing NotI linking libraries starting from chromosome-specific genomic libraries. Fifteen different single copy and two rDNA NotI linking clones from human chromosome 21 were identified in two libraries. Their chromosomal origin was confirmed, and regional location established using hybrid cell panels. Hybridization experiments with these probes revealed pairs of genomic NotI fragments, each ranging in size from &lt
    0.05 to 4.0 Mb. Many fragments displayed cell type variation. The total size of the NolI fragments detected in a human fibroblast cell line (GM6167) and mouse hybrid cell containing chromosome 21 as its only human component (WAV17) were approximately 32 and 34 Mb, respectively. If these fragments were all nonoverlapping, this would correspond to about 70% of the 50-Mb content estimated for the whole chromosome. The linking clones will be enormously useful in the subsequent construction of a NotI restriction map of this chromosome. Characterization of these clones indicates the presence of numerous additional sites for other enzymes that recognize sequences containing CpG. Thus most NotI linking clones appear to derive from CpG islands and probably identify the 5′ end of genes. © 1991.

    DOI: 10.1016/0888-7543(91)90444-J

    Scopus

    PubMed

    CiNii Article

    researchmap

▶ display all

MISC

▶ display all

Presentations

  • Megalin-targeted translational research on kidney diseases

    SAITO Akihiko

    2018.12 

     More details

    Language:English  

    researchmap

  • 腎保護を目指した糖尿病治療:SGLT2阻害剤およびメガリン研究の観点から

    斎藤 亮彦

    Diabetic Kidney Diseaseの未来  2018.12 

     More details

    Language:Japanese  

    researchmap

  • LC/MCによるアンジオテンシンペプチドの定量法を用いた腎内RAS調節におけるメガリンの役割の検証

    後藤佐和子, 細島康宏, 桑原頌治, 蒲澤秀門, 忰田亮平, 鈴木芳樹, 成田一衛, 吉田豊, 斎藤亮彦

    第30回日本糖尿病性腎症研究会プログラム  2018.12 

     More details

    Language:Japanese  

    researchmap

  • 自記式食事歴質問票(DHQ)を用いたSGLT2阻害薬使用時の食事内容の検討

    村山稔子, 細島康宏, 蒲澤秀門, 桑原頌治, 田中崇裕, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第30回日本糖尿病性腎症研究会プログラム  2018.12 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンを標的とした新しい診断・予防・治療戦略

    細島康宏, 蒲澤秀門, 桑原頌治, 斎藤亮彦

    第30回日本糖尿病性腎症研究会プログラム  2018.12 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病を合併した維持血液透析患者におけるオマリグリプチンの有用性に関するランダム化比較試験

    吉澤優太, 細島康宏, 蒲澤秀門, 田邊直仁, 甲田豊, 島田久基, 髙澤哲也, 伊藤孝仁, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第30回日本糖尿病性腎症研究会プログラム  2018.12 

     More details

    Language:Japanese  

    researchmap

  • Rice Bran Protein Affects Urinary Metabolome Profile in Obese Type2 Diabetic Rats International conference

    Watanabe R, Yamaguchi M, Kubota M, Hashimoto H, Harada Y, Hosojima M, Saito A, Fujimura S, Kadowaki M

    The 3rd International Symposium on Rice Science in Global Health  2018.11 

     More details

    Language:English  

    researchmap

  • Rice Bran Protein Suppresses Deterioration of Bone Microstructure and Strength in Obese Type 2 Diabetic Rats International conference

    Kubota M, Sugaki S, Komori E, Watanabe R, Hashimoto H, Harada Y, Hosojima M, Saito A, Aoyagi S, Fujimura S, Kadowaki M

    The 3rd International Symposium on Rice Science in Global Health  2018.11 

     More details

    Language:English  

    researchmap

  • メガリンと自己免疫性腎疾患

    斎藤 亮彦

    第15回免疫学セミナー  2018.10 

     More details

    Language:Japanese  

    researchmap

  • Multicenter randomized controlled study of the efficacy of low-protein rice for dietary protein restriction in patients with CKD International conference

    Hosojima M, Kabasawa H, Kaseda R, Ishikawa T, Obi Y, Maruyama T, Kuwahara S, Suzuki Y, Narita I, Saito A

    American Society of Nephrology Kidney Week 2018  2018.10 

     More details

    Language:English  

    researchmap

  • The role of Megalin in the Regulation of Renal RAS: Investigation Using LC/MS-Based Multiple-Reaction Monitoring Quantification of Angiotensin Peptides International conference

    Goto S, Yoshida Y, Hosojima M, Kuwahara S, Iida T, Kabasawa H, Kaseda R, Narita I, Saito A

    American Society of Nephrology Kidney Week 2018  2018.10 

     More details

    Language:English  

    researchmap

  • Sodium Glucose Transporter 2 inhibition With Dapagliflozin Downregulates Megalin in Proximal Convoluted Tubules for Renoprotection International conference

    Iida T, Kuwahara S, Hosojima M, Tanaka-Ishikawa T, Wada E, Kabasawa H, Goto S, Ugamura D, Yoshizawa Y, Kaseda R, Narita I, Saito A

    American Society of Nephrology Kidney Week 2018  2018.10 

     More details

    Language:English  

    researchmap

  • 腎保護を目指した糖尿病治療:SGLT2阻害薬およびメガリン研究に関連して

    斎藤 亮彦

    Meeting Experts Conference 〜心・腎保護を見据えて〜  2018.9 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンを標的とした腎臓病のトランスレーショナルリサーチ

    斎藤 亮彦

    第22回腎間質障害研究会  2018.9 

     More details

    Language:Japanese  

    researchmap

  • 腎保護治療を目指した糖尿病治療:メガリン研究からの視点

    斎藤 亮彦

    Scientific Exchange Meeting in Kagawa  2018.9 

     More details

    Language:Japanese  

    researchmap

  • メガリン/LRP2を標的とした腎臓病のトランスレーショナルリサーチ

    斎藤 亮彦

    腎研究センター主催 第3回腎研究セミナー  2018.9 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病の薬物療法

    斎藤 亮彦

    腎・呼吸器Clinical Conference  2018.7 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎臓病(DKD)の病態と治療

    斎藤 亮彦

    第10回これからの糖尿病治療を考える会  2018.7 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療:SGLT2阻害薬およびメガリン研究の観点から

    斎藤 亮彦

    糖尿病治療戦略を考える会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎臓病に対する摂取たんぱく質の違いによる「腸—腎連関」を介した発症・進展機序の解明

    細島康宏, 樋口裕樹, 蒲澤秀門, 桑原頌治, 成田一衛, 斎藤亮彦

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • 12週間の生活習慣改善プログラムの腎障害に与える影響

    蒲澤佳子, 細島康宏, 成田一衛, 斎藤亮彦, 荒川正昭

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • メガリンを介するシスプラチン腎症の発症機序とその予防戦略

    桑原頌治, 斎藤亮彦

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • CKDにおける治療用特殊食品の有用性

    蒲澤秀門, 細島康宏, 村山稔子, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • 保存期CKD患者における尿中メガリン排泄とビタミンD代謝の関連

    都井律和, 山田真介, 石村栄治, 津川尚子, 平山吉朗, 仲谷慎也, 森克人, 斎藤亮彦, 稲葉雅明

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • 低たんぱく質米の使用がCKD患者におけるたんぱく質摂取量に与える効果に関する多施設共同無作為化比較試験

    細島康宏, 蒲澤秀門, 忰田亮平, 石川友美, 小尾佳嗣, 樋口裕樹, 村山稔子, 桑原頌治, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • 食事性酸負荷とCKDの進行との関連

    蒲澤秀門, 細島康宏, 村山稔子, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • 尿中A-メガリンはシスプラチン腎症の発症予測マーカーとなりうる

    蒲澤秀門, 飯田倫理, 細島康宏, 桑原頌治, 成田一衛, 斎藤亮彦

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • 血液透析中における栄養補助法

    細島康宏, 蒲澤秀門, 斎藤亮彦

    第63回日本透析医学会学術集会・総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • Investigation of the role of megalin in the renal RAS by LC/MS-based multiple-reaction monitoring quantification of angiotensin peptides

    Goto S, Yoshida Y, Hosojima M, Kuwahara S, Kabasawa H, Kaseda R, Suzuki Y, Narita I, Saito A

    2018.6 

     More details

    Language:English  

    researchmap

  • 腎・心保護を目指した糖尿病治療:SGLT2阻害剤およびメガリン研究に関連して

    斎藤 亮彦

    第61回日本腎臓学会学術総会_LS18  2018.6 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンをターゲットとした腎臓病の新しい診断・予防・治療戦略

    斎藤 亮彦

    第61回日本腎臓学会学術総会  2018.6 

     More details

    Language:Japanese  

    researchmap

  • Plant versus animal protein improves anti-inflammatory effects of HDL and lessens CKD-induced atherosclerosis

    Kaseda R, Hosojima M, Kuwahara S, Kabasawa H, Aoki H, Higuchi Y, Kon V, Maruyama K, Narita I, Saito A

    2018.6 

     More details

    Language:English  

    researchmap

  • Rice endosperm protein intake in childhood suppresses development of high-fat diet-induced metabolic disorders and kidney disease in adulthood in mice

    Higuchi Y, Hosojima M, Kabasawa H, Kuwahara S, Kaseda R, Maruyama K, Narita I, Saito A

    2018.6 

     More details

    Language:English  

    researchmap

  • Inhibition of sodium glucose transporter 2 with depagliflozin downregulates megalin expression in proximal tubular epithelial cells

    Iida T, Kuwahara S, Hosojima M, Ishikawa T, Goto S, Kabasawa H, Kaseda R, Suzuki Y, Narita I, Saito A

    2018.6 

     More details

    Language:English  

    researchmap

  • In vitro analysis of the regulation of megalin expression by bardoxolone methyl in proximal tubular epithelial cells

    Yoshizawa Y, Kuwahara S, Hosojima M, Kabasawa H, Kaseda R, Ugamura D, Goto S, Iida T, Suzuki Y, Narita I, Saito A

    2018.6 

     More details

    Language:English  

    researchmap

  • 腎保護を目指した糖尿病治療:SGLT2阻害薬およびメガリン研究に関連して

    斎藤 亮彦

    T2DM Forum in Tochigi  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病を合併した腎移植後患者におけるSGLT2阻害薬の使用経験

    蒲澤秀門, 細島康宏, 亀田茂美, 宇賀村大亮, 吉澤優太, 飯田倫理, 後藤佐和子, 忰田亮平, 保坂 聖子, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第60回新潟透析医学会学術集会  2018.5 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療〜SGLT2阻害薬およびメガリン研究に関連して〜

    斎藤 亮彦

    Kidney&Cardiovascular Symposium in Funabashi / Ichihara  2018.4 

     More details

    Language:Japanese  

    researchmap

  • どのような薬がよいでしょうか?

    斎藤 亮彦

    第29回日本糖尿病性腎症研究会 新潟サテライト市民公開講演会  2018.4 

     More details

    Language:Japanese  

    researchmap

  • Bardoxolone methylによる腎近位尿細管のメガリン調節機能の検討

    吉澤優太, 桑原頌治, 細島康宏, 蒲澤秀門, 忰田亮平, 宇賀村大亮, 後藤佐和子, 飯田倫理, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第61回日本糖尿病学会年次学術集会  2018.4 

     More details

    Language:Japanese  

    researchmap

  • 幼少期における米(胚乳)タンパク質の摂取が成熟期の高脂肪食負荷による肥満および肥満関連腎症に及ぼす影響

    樋口裕樹, 細島康宏, 蒲澤秀門, 桑原頌治, 忰田亮平, 成田一衛, 斎藤亮彦

    第61回日本糖尿病学会年次学術集会  2018.4 

     More details

    Language:Japanese  

    researchmap

  • SGLT2阻害薬ダパグリフロジンの腎近位尿細管細胞における血糖値非依存的なメガリン発現抑制作用

    飯田倫理, 桑原頌治, 細島康宏, 石川友美, 後藤佐和子, 蒲澤秀門, 忰田亮平, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第61回日本糖尿病学会年次学術集会  2018.4 

     More details

    Language:Japanese  

    researchmap

  • メガリンに着目した腎臓病の診断・予防・治療法の開発

    斎藤 亮彦

    平成29年度4事業合同成果報告会  2018.2 

     More details

    Language:Japanese   Presentation type:Poster presentation  

    researchmap

  • 腎保護を目指した糖尿病治療:SGLT2阻害薬およびメガリンの観点から

    斎藤 亮彦

    T2DM Forum in 郡山  2018.2 

     More details

    Language:Japanese  

    researchmap

  • メガリンを標的とした腎機能温存・再生療法の開発

    斎藤 亮彦

    平成29年度JSN公的研究班研究成果合同発表会  2018.2 

     More details

    Language:Japanese   Presentation type:Oral presentation (general)  

    researchmap

  • 糖尿病性腎症の進展予防にむけた病期分類−病理−バイオマーカーを統合した診断法の開発「早期診断と進展予防のためのバイオマーカー開発」分科会

    斎藤亮彦, 和田隆志

    平成29年度JSN公的研究班研究成果合同発表会  2018.2 

     More details

    Language:Japanese  

    researchmap

  • Sodium glucose transporter 2 inhibition with dapagliflozin downregulates megalin expression in proximal tubule epithelial cells International conference

    Iida T, Kuwahara S, Hosojima M, Ishikawa T, Goto S, Kabasawa H, Kaseda R, Suzuki Y, Narita I, Saito A

    ISN FRONTIERS MEETINGS 2018  2018.2 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • Intracellular trafficking of cubilin is crucial for renal and intestinal endocytosis International conference

    Udagawa T, Harita Y, Miura K, Urae S, Kanda S, Saito A, Oka A

    ISN FRONTIERS MEETINGS 2018  2018.2 

     More details

    Language:English  

    researchmap

  • Rice endosperm protein intake in childhood suppresses the development of high-fat diet-induced metabolic disorders and kidney disease in adulthood in mice International conference

    Higuchi Y, Hosojima M, Kabasawa H, Kuwahara S, Kaseda R, Maruyama K, Narita I, Saito A

    ISN FRONTIERS MEETINGS 2018  2018.2 

     More details

    Language:English  

    researchmap

  • Two forms of urinary megalin excretion are novel predictors of the progression of early-stage diabetic kidney disease in type 2 diabetes International conference

    Iida T, Hosojima M, Kabasawa K, Nakamura K, Kuwahara S, Ishikawa T, Kaseda R, Kurosawa H, Hirayama Y, Narita I, Saito A

    ISN FRONTIERS MEETINGS 2018  2018.2 

     More details

    Language:English  

    researchmap

  • Higher estimated net endogenous acid production with lower intake of fruits and vegetables is associated with the progression of chronic kidney disease in Japan International conference

    Kabasawa H, Hosojima M, Toba K, Kuwahara S, Tanabe N, Kaseda R, Suzuki Y, Narita I, Saito A

    ISN FRONTIERS MEETINGS 2018  2018.2 

     More details

    Language:English  

    researchmap

  • Effectiveness of DPP-4inhibitors for blood glucose variability in type 2 diabetes patients undergoing maintenance hemodialysis International conference

    Ishikawa T, Hosojima M, Kabasawa H, Kaseda R, Kuwahara S, Iino N, Tanaka T, Kitamura N, Suzuki Y, Narita I, Saito A

    ISN FRONTIERS MEETINGS 2018  2018.2 

     More details

    Language:English  

    researchmap

  • Plant protein compared to animal protein improves anti-inflammatory effects of HDL and lessens CKD-induced atherosclerosis International conference

    Kaseda R, Hosojima M, Kuwahara S, Kabasawa H, Aoki H, Higuchi Y, Kon V, Maruyama K, Narita I, Saito A

    ISN FRONTIERS MEETINGS 2018  2018.2 

     More details

    Language:English  

    researchmap

  • 近位尿細管におけるSGLT2阻害薬のメガリン発現抑制作用

    飯田倫理, 桑原頌治, 細島康宏, 石川友美, 後藤佐和子, 蒲澤秀門, 忰田亮平, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第60回(最終回)新潟腎臓懇話会  2018.1 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管におけるSGLT2阻害薬ダパグリフロジンのメガリン発現抑制作用

    飯田倫理, 桑原頌治, 細島康宏, 石川友美, 後藤佐和子, 蒲澤秀門, 忰田亮平, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第29回日本糖尿病性腎症研究会  2017.12 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • Proximal tubular endocytic reseptor megalin is a diagnostic and therapeutic target for diabetic kidney disease

    Saito A

    2017.12 

     More details

    Language:English   Presentation type:Oral presentation (general)  

    researchmap

  • Nrf活性化薬バルドキソロンメチルによる近位尿細管のメガリン発現抑制機序の解析

    桑原頌治, 細島康宏, 蒲澤秀門, 忰田亮平, 宇賀村大亮, 吉澤優太, 後藤佐和子, 飯田倫理, 成田一衛, 斎藤亮彦

    第29回日本糖尿病性腎症研究会  2017.12 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • LC/MSによる生体試料の内因性アンジオテンシンペプチドの定量法の開発

    後藤佐和子, 吉田豊, 斎藤亮彦

    平成29年度新技術説明会  2017.12 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病合併血液透析患者のCGMによる血糖変動と低血糖の評価: DPP-4阻害薬の血糖変動幅縮小の可能性

    石川友美, 細島康宏, 忰田亮平, 蒲澤秀門, 桑原頌治, 飯野則昭, 田中崇裕, 北村信隆, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第29回日本糖尿病性腎症研究会  2017.12 

     More details

    Language:Japanese  

    researchmap

  • 新潟市の糖尿病性腎症重症化予防事業における栄養指導プログラムの構築について

    村山稔子, 細島康宏, 牧野令子, 佐藤純子, 水野佐智子, 蒲澤秀門, 斎藤亮彦, 鈴木芳樹, 成田一衛

    第29回日本糖尿病性腎症研究会  2017.12 

     More details

    Language:Japanese  

    researchmap

  • 新潟県燕市における糖尿病性腎症重症化予防における取り組み

    細島康宏, 蒲澤秀門, 本間修, 甲田豊, 原田隆, 斎藤亮彦, 鈴木芳樹, 成田一衛

    第29回日本糖尿病性腎症研究会  2017.12 

     More details

    Language:Japanese  

    researchmap

  • CKD患者では野菜や果実の摂取不足にともなう食事性酸負荷がCKD の進行と関連する 〈臨床〉

    蒲澤秀門, 鳥羽宏司, 細島 康宏, 忰田亮平, 石川友美, 桑原頌治, 渡邊令子, 田邊直仁, 鈴木芳樹, 斎藤亮彦, 成田一衛

    Advans研究会2017  2017.12 

     More details

    Language:Japanese  

    researchmap

  • SGLT2阻害薬により蛋白尿が寛解に至った2型糖尿病を合併した肥満関連腎症の1例

    蒲澤秀門, 細島康宏, 羽深将人, 山本卓, 後藤眞, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第29回日本糖尿病性腎症研究会  2017.12 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療:メガリン研究からの視点

    斎藤 亮彦

    水戸病診連携講演会〜心腎連関を考える〜  2017.11 

     More details

    Language:Japanese  

    researchmap

  • 腎・心保護を目指した糖尿病治療

    斎藤 亮彦

    東北信糖尿病合併症治療研究会2017  2017.11 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病とその合併症を予防するために

    斎藤 亮彦

    第10回市民公開講座 新潟「食と健康」フォーラム  2017.11 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療:メガリン研究からの視点

    斎藤 亮彦

    Scientific Exchange Meeting in 岡山  2017.10 

     More details

    Language:Japanese  

    researchmap

  • メガリンとSGLT2阻害薬

    斎藤 亮彦

    Scientific Exchange Meeting for Young Investigators  2017.10 

     More details

    Language:Japanese  

    researchmap

  • 腎・心保護を目指した糖尿病治療

    斎藤 亮彦

    糖尿病トータルケアを考える会in仙台  2017.10 

     More details

    Language:Japanese  

    researchmap

  • 新規糖尿病治療薬による腎保護効果

    細島康宏, 蒲澤秀門, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第47回日本腎臓学会東部学術大会  2017.10 

     More details

    Language:Japanese  

    researchmap

  • Urinary Iron and Oxidative Stress: Association with Megalin in CKD International conference

    Nakatani S, Nakatani A, Ishimura E, Toi N, Tsuda A, Yamada S, Mori K, Hirayama Y, Saito A, Inaba M

    American Society of Nephrology Kidney Week 2017  2017.10 

     More details

    Language:English  

    researchmap

  • Association between Urinary Full-Length Megalin and Serum Vitamin D Metabolites in CKD International conference

    Toi N, Yamada S, Ishimura E, Nakatani A, Nakatani S, Hirayama Y, Tsugawa N, Saito A, Inaba M

    American Society of Nephrology Kidney Week 2017  2017.10 

     More details

    Language:English  

    researchmap

  • Plant versus Animal Protein Improves Anti-Inflammatory Effects of HDL and Lessens CKD-Induced Atherosclerosis International conference

    Kaseda R, Hosojima M, Kuwahara S, Kabasawa H, Aoki H, Higuchi Y, Kon V, Maruyama K, Narita Î, Saito A

    American Society of Nephrology Kidney Week 2017  2017.10 

     More details

    Language:English  

    researchmap

  • Beneficial effects of rice endosperm protein on chronic kidney disease-mineral and bone disorder(CKD-MBD) in Zucker diabetic fatty rats International conference

    Watanabe R, Kubota M, Sugaki S, Hosojima M, Saito A, Fujii M, Sasagawa I, Fujimura S, Kadowaki M

    IUNS 21st International Congress of Nutrition  2017.10 

     More details

    Language:English  

    researchmap

  • メガリン研究に基づく腎臓病のトランスレーショナルリサーチ

    斎藤 亮彦

    第15回BRB Nephrology Conference  2017.9 

     More details

    Language:Japanese  

    researchmap

  • 自記式食事歴質問票(DHQ)を用いた高齢CKD患者における食事性酸負荷の評価

    鳥羽宏司, 細島康宏, 蒲澤秀門, 桑原頌治, 忰田亮平, 石川友美, 渡邊令子, 田邊直仁, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第44回東北腎不全研究会  2017.9 

     More details

    Language:Japanese  

    researchmap

  • レーザーアブレーション誘導結合プラズマ質量分析装置を用いた生体試料のPtイメージング分析

    堀孝太郎, 坂下明子, 花田一利, 井田巌, 藤本京子, 後藤佐和子, 斎藤亮彦

    第42回日本医用マススペクトル学会年会  2017.9 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療:SGLT2阻害薬およびメガリンの観点から International conference

    斎藤 亮彦

    T2DM Forum in Nagoya  2017.7 

     More details

    Language:Japanese  

    researchmap

  • メガリン研究と糖尿病性腎症

    斎藤 亮彦

    第8回Diabetic Complication Frontier Forum in Hyogo  2017.6 

     More details

    Language:Japanese  

    researchmap

  • 腎臓内科領域から見たSGLT2阻害薬:メガリン研究との関連

    斎藤 亮彦

    T2DM Forum in SENDAI  2017.6 

     More details

    Language:Japanese  

    researchmap

  • SGLT2阻害薬により蛋白尿の明らかな減少を認めた2型糖尿病を合併した肥満関連腎症の1例

    神林昂宏, 細島康宏, 蒲澤秀門, 佐々木健太, 羽深将人, 山本卓, 後藤眞, 鈴木芳樹, 斎藤亮彦, 成田一衛

    日本内科学会第140回信越地方会  2017.6 

     More details

    Language:Japanese  

    researchmap

  • 腎・心保護を目指した糖尿病治療

    斎藤 亮彦

    小千谷市魚沼市医師会学術講演会 地域連携の会IN小千谷  2017.6 

     More details

    Language:Japanese  

    researchmap

  • Effectiveness of DPP-4 Inhibitors on Blood Glucose Variability in Type 2 Diabetes Patients Undergoing Hemodialysis International conference

    Ishikawa T, Hosojima M, Kabasawa H, Kaseda R, Kuwahara S, Iino N, Tanaka T, Kitamura N, Suzuki Y, Narita I, Saito A

    American Diabetes Association 77th scientific sessions  2017.6 

     More details

    Language:English  

    researchmap

  • 2型糖尿病を合併した腎移植後患者におけるSGLT2阻害薬の使用経験

    蒲澤秀門, 細島康宏, 亀田茂美, 宇賀村大亮, 吉澤優太, 飯田倫理, 後藤佐和子, 忰田亮平, 保坂 聖子, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第60回新潟透析医学会学術集会  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療:SGLT2阻害薬およびメガリン研究の観点から

    斎藤 亮彦

    T2DM Forum in Chiba  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 早期の糖尿病腎症における腎予後予測マーカーとしての尿中メガリン測定の意義

    飯田倫理, 細島康宏, 蒲澤佳子, 桑原頌治, 石川友美, 忰田亮平, 中村和利, 鈴木芳樹, 成田一衛, 黒澤寛之, 蒲澤秀門, 平山吉朗, 斎藤亮彦

    第60回日本糖尿病学会年次学術集会  2017.5 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • 近位尿細管におけるダパグリフロジンによるメガリン機能調整作用

    飯田倫理, 桑原頌治, 細島康宏, 石川友美, 後藤佐和子, 蒲澤秀門, 忰田亮平, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第60回日本腎臓学会学術総会  2017.5 

     More details

    Presentation type:Oral presentation (general)  

    researchmap

  • 週1回GLP-1受容体作動薬デュラグルチドを使用し血糖変動を抑制できた経管栄養中高齢2型糖尿病患者の1例

    蒲澤秀門, 土田雅史, 飯田倫理, 細島康宏, 忰田亮平, 保坂聖子, 金子佳賢, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第71回日本栄養・食糧学会大会  2017.5 

     More details

    Language:Japanese  

    researchmap

  • ステージ別による慢性腎臓病(CKD)患者のたんぱく質およびリン摂取量とその食品群の関連

    村松芳多子, 渡邊令子, 林祐美, 細島康宏, 門脇基二, 斎藤亮彦

    第71回日本栄養・食糧学会大会  2017.5 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療:SGLT2阻害薬およびメガリン研究の観点から

    斎藤 亮彦

    T2DM Forum in Maebashi  2017.4 

     More details

    Language:Japanese  

    researchmap

  • 腎臓内科領域から見たSGLT2阻害薬〜メガリン研究との関連〜

    斎藤 亮彦

    T2DM Forum in県北  2017.4 

     More details

    Language:Japanese  

    researchmap

  • 腎臓内科領域から見たSGLT2阻害薬腎・心保護を目指した糖尿病治療

    斎藤 亮彦

    T2DM Forum in 西多摩〜心臓・腎臓保護の観点から〜  2017.3 

     More details

    Language:Japanese  

    researchmap

  • メガリン研究に基づく糖尿病性腎症の診断・治療法の開発

    斎藤 亮彦

    糖尿病治療検討会in 富士  2017.3 

     More details

    Language:Japanese  

    researchmap

  • 週1回GLP-1受容体作動薬デュラグルチドを使用し血糖変動を抑制できた経管栄養中高齢2型糖尿病患者の1例

    蒲澤秀門, 土田雅史, 飯田倫理, 細島康宏, 忰田亮平, 保坂聖子, 金子佳賢, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第65回日本老年医学会関東甲信越地方会  2017.3 

     More details

    Language:Japanese  

    researchmap

  • 自記式食事歴質問票(DHQ)を用いた高齢CKD患者における食事性酸負荷の評価

    鳥羽宏司, 細島康宏, 蒲澤秀門, 忰田亮平, 渡邊令子, 田邊直仁, 金子佳賢, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第65回 日本老年医学会関東甲信越地方会  2017.3 

     More details

    Language:Japanese  

    researchmap

  • 高齢者のフレイル,骨粗鬆症と血糖管理について考える

    斎藤 亮彦

    WORLD KIDNEY DAY シンポジウム 2017  2017.3 

     More details

    Language:Japanese  

    researchmap

  • 生活習慣と腎臓病

    斎藤 亮彦

    平成28年度新潟大学ラジオ公開講座 元気に長生き腎臓は大切なパートナー  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 他の腎臓病を疑って腎生検を行い糖尿病性腎症と診断した2例

    蒲澤秀門, 細島康宏, 飯田倫理, 後藤佐和子, 石川友美, 忰田亮平, 今井直史, 伊藤由実, 谷長行, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第46回新潟糖尿病談話会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 週1回のGLP-1受容体作動薬エキセナチド開始後に腸管気腫症の増悪を来した一例

    石川友美, 細島康宏, 佐藤健, 塩谷基, 蒲澤秀門, 忰田亮平, 中枝武司, 和田庸子, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第46回新潟糖尿病談話会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 栄養指導がSGLT2阻害薬内服症例に及ぼす影響について

    和田恵梨, 細島康宏, 蒲澤秀門, 石川友美, 桑原頌治, 忰田亮平, 成田一衛, 本間則行, 鈴木芳樹, 斎藤亮彦

    第7回日本腎臓リハビリテーション学会学術集会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 自記式食事歴質問票(DHQ)を用いたCKD患者における食事性酸負荷の評価と腎予後との関連

    鳥羽宏司, 細島康宏, 蒲澤秀門, 桑原頌治, 忰田亮平, 石川友美, 和田恵梨, 渡邊令子, 田邊直仁, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第7回日本腎臓リハビリテーション学会学術集会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 保存期CKD患者に対する運動処方

    細島康宏, 蒲澤佳子, 蒲澤秀門, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第7回日本腎臓リハビリテーション学会学術集会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者における食塩摂取量と生命予後の検討

    河野恵美子, 高田琢磨, 細島康宏, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第7回日本腎臓リハビリテーション学会学術集会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 推定食塩摂取量を用いて診察直後に行う個別減塩指導がCKD合併高血圧患者の降圧効果に及ぼす影響

    蒲澤秀門, 細島康宏, 忰田亮平, 山崎肇, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第7回日本腎臓リハビリテーション学会学術集会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 12週間の生活習慣改善プログラムにおける食事評価と尿中アルブミン排泄量の関連についての検討

    蒲澤佳子, 細島康宏, 斎藤麻里子, 田中典子, 田中純太, 中村和利, 成田一衛, 荒川正昭, 斎藤亮彦

    第7回日本腎臓リハビリテーション学会学術集会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • 実臨床における新規糖尿病治療薬のインパクト~持続血糖モニター(CGM)から見えるもの~

    細島康宏, 蒲澤秀門, 石川友美, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第7回日本腎臓リハビリテーション学会学術集会  2017.2 

     More details

    Language:Japanese  

    researchmap

  • AMED 腎疾患実用化研究事業 メガリンを標的とした腎機能温存・再生療法の開発

    斎藤亮彦, 桑原頌治, 細島康宏, 忰田亮平, 成田一衛, 田邊嘉也, 各務博, 上田隆宏, 田中崇裕, 平山吉朗

    平成28年度 JSN 公的研究班研究成果合同発表会  2017.1 

     More details

    Language:Japanese  

    researchmap

  • 週1回のGLP-1受容体作動薬エキセナチド使用中に腸管気腫症の増悪を来した1例

    石川友美, 細島康宏, 佐藤健, 塩谷基, 蒲澤秀門, 忰田亮平, 中枝武司, 和田庸子, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第54回日本糖尿病学会関東甲信越地方会  2017.1 

     More details

    Language:Japanese  

    researchmap

  • 代謝性アシドーシスと栄養

    村山稔子, 細島康宏, 鳥羽宏司, 蒲澤秀門, 桑原頌治, 忰田亮平, 石川友美, 和田恵梨, 渡邊令子, 田邊直仁, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第20回日本病態栄養学会年次学術集会  2017.1 

     More details

    Language:Japanese  

    researchmap

  • 慢性腎臓病患者に対するたんぱく質摂取制限指導の検証(栄養士の立場から):SOFT-J study

    村山稔子, 細島康宏, 青野直美, 岩原由美子, 大滝智子, 川村美和子, 佐藤美代子, 宗田敬子, 田宮之子, 西村美貴, 廣川玲子, 山田邦子, 牧野令子, 忰田亮平, 斎藤亮彦, 鈴木芳樹, 山縣邦弘, 成田一衛

    第20回新潟栄養・食生活学会学術集会  2016.12 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病患者における尿中メガリンの腎予後予測能の検討

    飯田倫理, 細島康宏, 蒲澤佳子, 桑原頌治, 石川友美, 忰田亮平, 中村和利, 鈴木芳樹, 成田一衛, 平山吉朗, 斎藤亮彦

    第28回日本糖尿病性腎症研究会  2016.12 

     More details

    Language:Japanese  

    researchmap

  • 腎・心保護を目指した糖尿病治療

    斎藤 亮彦

    医師会胎内支部 学術講演会  2016.11 

     More details

    Language:Japanese  

    researchmap

  • Study on the mechanism of renal tubular proteinuria in children with OCRL gene mutations International conference

    Kuwahara S, Hosojima M, Kaseda R, Goto S, Iida T, Saito A

    49th Annual Meeting of American Society of Nephrology  2016.11 

     More details

    Language:English  

    researchmap

  • Net endogenous acid production, an index of dietary acid load, is associated with the progression of CKD International conference

    Toba K, Hosojima M, Kuwahara S, Kaseda R, Iida T, Goto S, Tanabe N, Suzuki S, Narita I, Saito A

    49th Annual Meeting of American Society of Nephrology  2016.11 

     More details

    Language:English  

    researchmap

  • Defects in N-Glycosylation of cubilin result in tubular proteinuria International conference

    Udagawa T, Miura K, Saito A, Harita Y

    49th Annual Meeting of American Society of Nephrology  2016.11 

     More details

    Language:English  

    researchmap

  • Megalin blockade with cilastatin suppresses drug-induced nephrotoxicity International conference

    Kuwahara S, Hosojima M, Kaseda R, Goto S, Iida T, Saito A

    49th Annual Meeting of American Society of Nephrology  2016.11 

     More details

    Language:English  

    researchmap

  • Two forms of urinary megalin excretion are novel predictors of the progression of early-stage diabetic nephropathy in Type 2 diabetes mellitus International conference

    Iida T, Hosojima M, Kabasawa K, Nakamura K, Kuwahara S, Ishikawa T, Kaseda R, Suzuki Y, Kurosawa H, Hirayama Y, Narita I, Saito A

    49th Annual Meeting of American Society of Nephrology  2016.11 

     More details

    Language:English  

    researchmap

  • メガリンを標的とした腎臓病の新しい診断・治療法の開発

    斎藤 亮彦

    第718回新潟医学会次第  2016.10 

     More details

    Language:Japanese  

    researchmap

  • 腎・心保護を目指した糖尿病治療

    斎藤 亮彦

    糖尿病学術講演会in三条  2016.10 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病患者における尿中メガリンの腎予後予測能の検討

    飯田倫理, 細島康宏, 蒲澤佳子, 桑原頌治, 石川友美, 忰田亮平, 中村和利, 鈴木芳樹, 成田一衛, 黒澤寛之, 平山吉朗, 斎藤亮彦

    第27回新潟糖尿病臨床研究会  2016.10 

     More details

    Language:Japanese  

    researchmap

  • Rice bran protein has beneficial effects on diabetes, fatty liver and diabetic nephropathy International conference

    Kubota M, Yamaguchi M, Watanabe R, Hashimoto H, Harada Y, Hosojima M, Saito A, Fujimura S, Kadowaki M

    The 3rd International Conference on Rice Bran Oil  2016.10 

     More details

    Language:English  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンと腎臓病の診断・治療

    斎藤 亮彦

    平成28年度 日臨技北日本支部医学検査学会<第5回>  2016.10 

     More details

    Language:Japanese  

    researchmap

  • Rice Bran Protein has Beneficial Effects on Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) ㏌ Type 2 Diabetic ZDF Rats International conference

    Sugaki S, Komori E, Kubota M, Watanabe R, Hashimoto H, Harada Y, Hosojima M, Saito A, Aoyagi S, Fujimura S, Kadowaki M

    The 3rd International Conference on Rice Bran Oil  2016.10 

     More details

    Language:English  

    researchmap

  • 腎臓領域からみたSGLT2阻害薬とDPP-4阻害薬

    斎藤 亮彦

    第5回腎を守る糖尿病治療の会  2016.9 

     More details

    Language:Japanese  

    researchmap

  • SGLT2阻害薬開始後に腎機能障害の増悪を認めた1例

    羽深将人, 細島康宏, 永野淳嗣, 石川友美, 蒲澤秀門, 山本卓, 風間順一郎, 鈴木芳樹, 斎藤亮彦, 成田一衛

    老年医学会 第64回関東甲信越地方会  2016.9 

     More details

    Language:Japanese  

    researchmap

  • The role of megalin in the generation of angiotensinⅡ from angiotensinogen in the kidney Invited International conference

    SAITO Akihiko

    ISH 2016 satellite symposium, Renin-angiotensin-aldosterone system(RAAS 2016)  2016.9 

     More details

    Language:English  

    researchmap

  • CKDの食事療法・生活指導

    斎藤 亮彦

    市民公開メディカルセミナーin新発田 第八回 天地腎  2016.8 

     More details

    Language:Japanese  

    researchmap

  • SGLT2阻害薬の腎・心に対する可能性〜腎臓内科の立場から〜

    斎藤 亮彦

    心腎は今何を語り合う〜腎臓から心臓へのクロスファンクション〜  2016.7 

     More details

    Language:Japanese  

    researchmap

  • Cubilin糖鎖修飾異常は近位尿細管再吸収機能障害を起こし蛋白尿の原因となる

    宇田川智宏, 斎藤亮彦

    第51回日本小児腎臓病学会学術集会  2016.7 

     More details

    Language:Japanese  

    researchmap

  • メガリン研究に基づく糖尿病性腎症の診断・治療法の開発

    斎藤 亮彦

    山梨糖尿病セミナー  2016.6 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の病態と治療

    斎藤 亮彦

    第138回日本内科学会信越地方会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • Blue Native-PAGE法を用いたメガリンをめぐる分子間相互作用の検討

    佐藤博慶, 塩田友也, 保坂聖子, 蒲澤秀門, 山本佳子, 鈴木哲世, 相馬多恵子, 飯野則昭, 竹田徹朗, 成田一衛, 斎藤亮彦

    第53回日本腎臓学会学術総会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • メガリンを介する薬剤性腎障害とその予防

    桑原頌治, 青木信将, 堀好寿, 金子麗華, 青木弘行, 細島康宏, 忰田亮平, 斎藤亮彦

    第59回日本腎臓学会学術総会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • Mechanisms underlying urinary excretion of full-length and extracellular domain forms of megalin

    De S, Kuwahara S, Hosojima M, Ishikawa T, Kaseda R, Yoshioka Y, Suzuki Y, Narita I, Ochiya T, Kurosawa H, Hirayama Y, Saito A

    The 59th Annual Meeting of the Japanese Society of Nephrology  2016.6 

     More details

    Language:English  

    researchmap

  • 2型糖尿病患者における尿中メガリンの腎予後予測能の検討

    飯田倫理, 細島康宏, 蒲澤佳子, 桑原頌治, 石川友美, 忰田亮平, 中村和則, 鈴木芳樹, 成田一衛, 黒澤寛之, 平山吉朗, 斎藤亮彦

    第59回日本腎臓学会学術総会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • Cubilin依存的近位尿細管再吸収の分子機構

    宇田川智宏, 三浦健一郎, 斎藤亮彦, 張田豊

    第59回日本腎臓学会学術総会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • 腎瘢痕のバイオマーカーとしての尿中メガリンの有用性

    山内壮作, 木全貴久, 辻章志, 斎藤亮彦, 金子一成

    第59回日本腎臓学会学術総会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • OCRL1遺伝子変異による2型Dent病患者の尿細管性蛋白尿の出現メカニズム

    駿田竹紫, 木全貴久, 山内壮作, 辻章志, 斎藤亮彦, 金子一成

    第59回日本腎臓学会学術総会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • ポドサイト傷害後の腎内Angiotensin Ⅱ増加はmegalinに依存する

    小泉賢洋, 新村文男, 西山成, 斎藤亮彦, 柳田素子, 深川雅史, 松阪泰二

    第59回日本腎臓学会学術総会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • CKD患者における自記式食事歴質問票(DHQ)を用いた食事性酸負荷の評価と腎予後との関連

    鳥羽宏司, 細島康宏, 忰田亮平, 石川友美, 和田恵梨, 桑原頌治, 渡邊令子, 田邊直仁, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第59回日本腎臓学会学術総会  2016.6 

     More details

    Language:Japanese  

    researchmap

  • 慢性腎臓病(CKD)患者におけるたんぱく質およびリン摂取量とその食品群の関連

    村松芳多子, 渡邊令子, 曽我杏里, 細島康宏, 門脇基二, 斎藤亮彦

    第70回日本栄養・食糧学会大会  2016.5 

     More details

    Language:Japanese  

    researchmap

  • 米胚乳タンパク質の特性と糖尿病合併症に対する有効性

    久保田真敏, 渡邊令子, 藤井幹夫, 斎藤亮彦, 門脇基二

    第70回日本栄養・食糧学会大会  2016.5 

     More details

    Language:Japanese  

    researchmap

  • シスプラチン腎症発症予測マーカーとしての尿中メガリン

    近藤利恵, 各務博, 渡辺聡, 阿部徹哉, 細島康宏, 忰田亮平, 小屋俊之, 菊地利明, 成田一衛, 斎藤亮彦

    第113回日本内科学会総会・講演会  2016.4 

     More details

    Language:Japanese  

    researchmap

  • ポドサイト傷害後の腎内AngiotensinⅡ増加はmegalinに依存する

    小泉賢洋, 新村文男, 西山成, 斎藤亮彦, 柳田素子, 深川雅史, 松阪泰二

    第11回弥彦ポドサイトセミナー  2016.3 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療

    斎藤 亮彦

    県央地区nephrologistDM講演会  2016.3 

     More details

    Language:Japanese  

    researchmap

  • 12週間の生活習慣改善プログラムにおける食事評価と尿中アルブミン排泄量の関連についての検討

    蒲澤佳子, 細島康宏, 齋藤麻里子, 田中典子, 田中純太, 中村和利, 成田一衛, 荒川正昭, 斎藤亮彦

    第6回腎臓リハビリテーション学会学術集会  2016.3 

     More details

    Language:Japanese  

    researchmap

  • 腎・心保護を目指した糖尿病治療

    斎藤 亮彦

    糖尿病学術講演会in秋葉  2016.2 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病患者におけるシタグリプチンによるアルブミン尿減少効果は近位尿細管機能の改善と関連する

    細島康宏, 笹川泰司, 蒲澤秀門, 石川友美, 桑原頌治, 忰田亮平, 鈴木芳樹, 成田一衛, 黒澤寛之, 平山吉朗, 斎藤亮彦

    第27回日本糖尿病性腎症研究会  2015.12 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病腎症患者における尿中細胞外小胞の解析:全長型メガリンの尿中排泄機序

    De Shankhajit, 桑原頌治, 細島康宏, 石川友美, 忰田亮平, 吉岡祐亮, 鈴木芳樹, 成田一衛, 落谷孝広, 斎藤亮彦

    第27回日本糖尿病性腎症研究会  2015.12 

     More details

  • メガリン研究と糖尿病性腎症

    斎藤 亮彦

    第24回Rokko Nephrology Research Forum  2015.11 

     More details

    Language:Japanese  

    researchmap

  • Efficiency of nutrition counseling on protein intake restriction in chronic kidney disease patients –Niigata part of SOFT-J (Study on regional variation of FROM-J intervention by JSN) International conference

    Kaseda R, Hosojima M, Murayama T, Saito A, Suzuki Y, Yamagata K, Narita I

    48th Annual Meeting of American Society of Nephrology  2015.11 

     More details

    Language:English  

    researchmap

  • Prospective cross-sectional and longitudinal observational study of urinary podocyte markers and urinary megalin in kidney disease of ANCA-associated vasculitis International conference

    Kajiyama H, Hiromura K, Lkuma D, Suwa J, Ikenouchi H, Kurosawa H, Hirayama Y, Hara M, Saito A, Nojima Y, Miura T

    48th Annual Meeting of American Society of Nephrology  2015.11 

     More details

    Language:English  

    researchmap

  • Novel urinary biomarkers for detecting renal scar in children with febrile urinary tract infection International conference

    Kimata T, Kaito T, Yamanouchi S, Kino J, Kurosawa H, Hirayama Y, Saito A, Kaneko K

    48th Annual Meeting of American Society of Nephrology  2015.11 

     More details

    Language:English  

    researchmap

  • Defect of interdependent membrane targeting and endocytosis of cubilin and amnionless leads toImerslund-Gräsbeck syndrome International conference

    Udagawa T, Miura K, Saito A, Harita Y

    48th Annual Meeting of American Society of Nephrology  2015.11 

     More details

    Language:English  

    researchmap

  • Megalin-dependent intrarenal generation of angiotensin Ⅱ induced by podocyte injury International conference

    Matsusaka T, Niimura F, Nishiyama A, Saito A, Yanagida M, Ichikawa I

    48th Annual Meeting of American Society of Nephrology  2015.11 

     More details

    Language:English  

    researchmap

  • Mechanism of increased urinary full-length megalin excretion in type 2 diabetes mellitus patients with nephropathy International conference

    De S, Kuwahara S, Hosojima M, Ishikawa T, Kaseda R, Yoshioka Y, Suzuki Y, Narita I, Ochiya T, Saito A

    48th Annual Meeting of American Society of Nephrology  2015.11 

     More details

    Language:English  

    researchmap

  • Weight reduction with low calorie diet improves albuminuria but increases urinary megalin International conference

    Takeda T, Saito A

    48th Annual Meeting of American Society of Nephrology  2015.11 

     More details

    Language:English  

    researchmap

  • Randomized, double-blind, cross over crinical trial on oral rice endosperm protein supplementation to patients on maintenance hemodialysis International conference

    Hosojima M, Shimada H, Miyazaki S, Obi Y, Kondo H, Fujii M, Watanabe R, Kuwahara S, Kaseda R, Narita I, Suzuki Y, Kadowaki M, Saito A

    48th Annual Meeting of American Society of Nephrology  2015.11 

     More details

    Language:English  

    researchmap

  • 腎・心保護を目指した糖尿病治療

    斎藤 亮彦

    新潟臨港糖尿病を考える会  2015.10 

     More details

    Language:Japanese  

    researchmap

  • グルベス配合錠の有効性の検討

    吉澤優太, 宇賀村大亮, 石川友美, 飯田倫理, 後藤佐和子, 桑原頌治, 忰田亮平, 細島康宏, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第26回新潟糖尿病臨床研究会  2015.10 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病患者におけるシタグリプチンによるアルブミン尿減少効果は近位尿細管機能の改善と関連する

    細島康宏, 笹川泰司, 蒲澤秀門, 石川友美, 桑原頌治, 忰田亮平, 鈴木芳樹, 成田一衛, 黒澤寛之, 平山吉朗, 斎藤亮彦

    第26回新潟糖尿病臨床研究会  2015.10 

     More details

    Language:Japanese  

    researchmap

  • SGLT2阻害薬使用患者における栄養摂取状況の検討

    和田恵理, 細島康宏, 忰田亮平, 鈴木裕美, 石川友美, 桑原頌治, 鈴木芳樹, 斎藤亮彦, 本間則行

    第26回新潟糖尿病臨床研究会  2015.10 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者における食塩摂取量調査

    河野恵美子, 細島康宏, 高田琢磨, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第38回日本高血圧学会総会  2015.10 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療

    斎藤 亮彦

    加茂市医師会学術講演会  2015.9 

     More details

    Language:Japanese  

    researchmap

  • CKD患者に対するたんぱく質制限の指導の検証:SOFT-J study(新潟県)

    忰田亮平, 細島康宏, 村山稔子, 斎藤亮彦, 鈴木芳樹, 山縣邦弘, 成田一衛

    第2回腎と栄養研究会  2015.9 

     More details

    Language:Japanese  

    researchmap

  • 慢性腎臓病患者における自記式食事歴質問票(DHQ)を用いた食事性酸負荷の評価

    細島康宏, 鳥羽宏司, 石川友美, 忰田亮平, 成田一衛, 和田恵梨, 桑原頌治, 斎藤亮彦, 渡邊令子, 鈴木芳樹

    第2回腎と栄養研究会  2015.9 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症患者における尿中細胞外小胞の解析:全長型メガリンの尿中排泄機序

    De Shankhajit, 桑原頌治, 細島康宏, 忰田亮平, 吉岡祐亮, 落合孝広, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第22回新潟糖尿病性腎症研究会  2015.9 

     More details

  • 肥満2型糖尿病モデルZDFラットの骨・ミネラル代謝に与える米糠タンパク質の影響

    菅木省吾, 小森絵里香, 久保田真敏, 渡邊令子, 原田幸和, 橋本博之, 細島康宏, 斎藤亮彦, 藤村忍, 門脇基二

    第22回新潟糖尿病性腎症研究会  2015.9 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症患者における尿中EV解析:全長型メガリンの尿中排泄機序

    斎藤亮彦, Shankhajit De, 桑原頌治, 細島康宏, 石川友美, 忰田亮平, 吉岡祐亮, 鈴木芳樹, 成田一衛, 落合孝広

    第7回日本RNAi研究会・第2回日本細胞外小胞学会  2015.8 

     More details

    Language:Japanese  

    researchmap

  • メガリン研究と糖尿病性腎症

    斎藤 亮彦

    東埼玉糖尿病治療フォーラム  2015.7 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病と腎臓をめぐる最近の動向

    斎藤 亮彦

    上越地区腎機能を考える会  2015.7 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療

    斎藤 亮彦

    糖尿病セミナー2015〜腎臓領域における糖尿病治療〜  2015.7 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療

    斎藤 亮彦

    Diabetes Symposium in Fukui  2015.6 

     More details

    Language:Japanese  

    researchmap

  • メガリン研究と糖尿病性腎症

    斎藤 亮彦

    第5回Cardio-Renal Metabolic Meeting in Tokatsu  2015.6 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病患者におけるシタグリプチンによるアルブミン尿減少効果は近位尿細管機能の改善と関連する

    笹川泰司, 細島康宏, 蒲澤秀門, 石川友美, 桑原頌治, 忰田亮平, 鈴木芳樹, 成田一衛, 黒澤寛之, 平山吉朗, 斎藤亮彦

    第58回日本腎臓学会学術総会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者における食塩摂取量に関する検討

    河野恵美子, 高田琢磨, 細島康宏, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第60回日本透析医学会学術集会・総会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • 非糖尿病血液透析患者における血糖変動のCGMによる評価

    石川友美, 細島康宏, 忰田亮平, 蒲澤秀門, 飯野則昭, 鈴木芳樹, 斎藤亮彦

    第60回日本透析医学会学術集会・総会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症患者における尿中エクソソーム解析:全長型メガリンの排泄機序

    De Shankhajit, 桑原頌治, 細島康宏, 忰田亮平, 吉岡祐亮, 鈴木芳樹, 成田一衛, 落谷孝広, 斎藤亮彦

    第58回日本腎臓学会学術総会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • Reduction of Albuminuria by Sitagliptin Is Associated with Improvement of Renal Proximal Tubular Function in Patients with Type 2 Diabetes International conference

    Hosojima M, Sasagawa T, Kabasawa H, Ishikawa T, Kaseda R, Suzuki Y, Narita I, Kurosawa H, Hirayama Y, Saito A

    American Diabetes Association’s 75th Scientific Sessions  2015.6 

     More details

    Language:English  

    researchmap

  • 腎瘢痕のバイオメーカーとしての尿中メガリンの有用性

    山内壮作, 木全貴久, 北尾哲也, 木野仁郎, 加藤正吾, 辻章志, 黒澤寛之, 平山吉郎, 斎藤亮彦, 金子一成

    日本小児腎臓病学会学術集会 第50回記念大会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • CKD患者に対するたんぱく質摂取制限指導の検証:SOFT-J study

    忰田亮平, 細島康宏, 村山稔子, 斎藤亮彦, 鈴木芳樹, 山縣邦弘, 成田一衛

    第58回日本腎臓学会学術総会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷マウスの腎臓におけるメガリンを介する老化関連物質の蓄積

    桑原頌治, 細島康宏, 金子麗華, 青木弘行, 中野大介, 忰田亮平, 西山成, 成田一衛, 斎藤亮彦

    第58回日本腎臓学会学術総会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • ループス腎炎における新規尿中バイオマーカーmegalinの解析

    井熊大輔, 梶山浩, 黒澤寛之, 平山吉朗, 池内秀和, 廣村桂樹, 野島美久, 斎藤亮彦, 三村俊英

    第58回日本腎臓学会学術総会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • ANCA関連血管炎における尿中メガリンの横断的検討

    梶山浩, 井熊大輔, 黒澤寛之, 平山吉朗, 池内秀和, 廣村桂樹, 野島美久, 斎藤亮彦, 三村俊英

    第58回日本腎臓学会学術総会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • デント病における尿中メガリン分画の検討

    木野仁郎, 木全貴久, 山内壮作, 北尾哲也, 加藤正吾, 辻章志, 黒澤寛之, 平山吉郎, 斎藤亮彦, 金子一成

    日本小児腎臓病学会学術集会 第50回記念大会  2015.6 

     More details

    Language:Japanese  

    researchmap

  • Effect of rice bran protein on chronic kidney disease-mineral and bone disorder(CKD-MBD)in type-2 diabetic ZDF rats International conference

    Sugaki S, Komori E, Kubota M, Watanabe R, Hashimoto H, Harada Y, Hosojima M, Saito A, Fujimura S, Kadowaki M

    ACN2015 12th Asian Congress of Nutrition  2015.5 

     More details

    Language:English  

    researchmap

  • Beneficial effects of rice endosperm protein intake in Japanese men with obesity or metabolic syndorome: a fundamental crossover clinical trial International conference

    Hosojima M, Kaseda R, Kondo H, Fujii M, Kubota M, Watanabe R, Kadowaki M, Saito A

    ACN2015 12th Asian Congress of Nutrition  2015.5 

     More details

    Language:English  

    researchmap

  • 2型糖尿病患者(腎症1期〜3期)におけるシタグリプチンの有効性についての観察研究:JUMP study

    細島康宏, 笹川泰司, 蒲澤秀門, 石川友美, 桑原頌治, 忰田亮平, 鈴木芳樹, 成田一衛, 黒澤寛之, 平山吉朗, 斎藤亮彦

    第58回日本糖尿病学会年次学術集会  2015.5 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症患者におけるエクソサイトーシスを介した尿中全長型メガリンの排泄機序

    De Shankhajit, 頌治, 細島康宏, 石川友美, 忰田亮平, 吉岡祐亮, 落合孝広, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第58回日本糖尿病学会年次学術集会  2015.5 

     More details

  • 持続グルコースモニタによる心臓周術期における術前の血糖変動の評価と術後高血糖の予測について

    石川友美, 細島康宏, 桑原頌治, 忰田亮平, 佐藤裕喜, 青木賢治, 土田正則, 鈴木芳樹, 斎藤亮彦

    第58回日本糖尿病学会年次学術集会  2015.5 

     More details

    Language:Japanese  

    researchmap

  • SGLT2阻害薬使用患者の食事療法

    和田恵梨, 三浦隆義, 中村元, 白石友信, 鈴木裕美, 石川友美, 桑原頌治, 細島康宏, 忰田亮平, 鈴木芳樹, 斎藤亮彦, 本間則行

    第58回日本糖尿病学会年次学術集会  2015.5 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療-SGLT2阻害薬及びDPP4阻害薬を中心に-

    斎藤 亮彦

    県央地区nephrologist DM講演会  2015.4 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者における食塩摂取量に関する検討

    河野恵美子, 高田琢磨, 細島康宏, 忰田亮平, 鈴木芳樹, 斎藤亮彦, 成田一衛

    腎臓病と栄養・代謝・食事フォーラム2015  2015.3 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療-SGLT2阻害薬を中心に-

    斎藤 亮彦

    第88回日本薬理学会年会  2015.3 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療-SGLT2阻害薬を中心に-

    斎藤 亮彦

    中越地区SGLT-2阻害剤に関する勉強会〜腎・糖尿病セミナー〜  2015.3 

     More details

    Language:Japanese  

    researchmap

  • 米胚乳タンパク質の血清尿酸値低下効果(第2報)

    近藤葉月, 樋口裕紀, 藤井幹夫, 丸山健太郎, 北原祐樹, 山本哲郎, 齋藤次郎, 近藤澄夫, 門脇基二, 細島康宏, 斎藤亮彦

    日本農芸化学会2015年度大会  2015.3 

     More details

    Language:Japanese  

    researchmap

  • 保存期CKD患者における運動療法—有酸素運動とレジスタンス運動の併用によるアルブミン尿の減少効果—

    細島康宏, 蒲澤佳子, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第5回日本腎臓リハビリテーション学会学術集会  2015.3 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者において米胚乳たんぱく質補給は血清リン,カリウム値を上昇させずにnPCRを増加させる

    細島康宏, 島田久基, 宮崎滋, 小尾佳嗣, 渡邊令子, 門脇基二, 近藤葉月, 藤井幹夫, 忰田亮平, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第18回日本病態栄養学会年次学術集会  2015.1 

     More details

    Language:Japanese  

    researchmap

  • ネフローゼ症候群の発症を契機に行われた腎生検で初めて糖尿病性腎症と診断された一例

    石川友美, 細島康宏, 保川亮太, 忰田亮平, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第52回日本糖尿病学会関東甲信越地方会  2015.1 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷マウスにおけるメガリンを介する腎臓の老化所見

    桑原頌治, 細島康宏, 金子麗華, 青木弘行, 中野大介, 忰田亮平, 西山成, 成田一衛, 斎藤亮彦

    第26回日本糖尿病性腎症研究会  2014.12 

     More details

  • 持続グルコースモニタ(CGM) による糖尿病合併維持血液透析患者の血糖変動とDPP-4阻害薬の有効性の検討

    石川友美, 細島康宏, 忰田亮平, 蒲澤秀門, 桑原頌治, 飯野則昭, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第26回日本糖尿病性腎症研究会  2014.12 

     More details

    Language:Japanese  

    researchmap

  • Beneficial effects of supplementary rice endosperm protein intake in maintenance hemodialysis patients Invited International conference

    SAITO Akihiko

    East Asia Conference on Standardization of Rice Function  2014.12 

     More details

    Language:English  

    researchmap

  • 腎保護を目指した糖尿病治療—SGLT2阻害薬の話題を中心に—

    斎藤 亮彦

    加茂・田上地区糖尿病治療セミナー  2014.11 

     More details

    Language:Japanese  

    researchmap

  • Relationship between levels of urinary full-length megalin and histological findings in patients with IgA nephropathy International conference

    Seki T, Asanuma K, Asao R, Nonaka K, Kodama F, Sasaki Y, Takagi M, Kurosawa H, Hirayama Y, Horikoshi S, Saito A, Tomino Y

    47th Annual Meeting of American Society of Nephrology  2014.11 

     More details

    Language:English  

    researchmap

  • Efficiency of dipeptidyl peptidase-4 inhibitors in hemodialysis patients with type2 International conference

    Ishikawa T, Hosojima M, Kaseda R, Kabasawa H, Kuwahara S, Iino N, Suzuki Y, Narita I, Saito A

    47th Annual Meeting of American Society of Nephrology  2014.11 

     More details

    Language:English  

    researchmap

  • 肥満2型糖尿病モデルZDFラットの骨代謝に対する米糠タンパク質摂取の有効性

    久保田真敏, 小森絵理香, 渡邊令子, 橋本博之, 原田幸和, 細島康宏, 斎藤亮彦, 藤村忍, 門脇基二

    日本アミノ酸学会  2014.11 

     More details

    Language:Japanese  

    researchmap

  • 心臓手術期におけるCGMによる血糖変動の評価

    石川友美, 細島康宏, 忰田亮平, 佐藤祐喜, 青木賢治, 土田正則, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第25回新潟糖尿病臨床研究会  2014.10 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療〜SGLT2阻害薬を中心に〜

    斎藤 亮彦

    十日町市中魚沼郡医師会学術講演会  2014.10 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンと腎臓病研究

    斎藤 亮彦

    第46回日本臨床分子形態学会総会・学術集会  2014.10 

     More details

    Language:Japanese  

    researchmap

  • 薬剤性腎障害とメガリン

    斎藤 亮彦

    第44回日本腎臓学会東部学術大会  2014.10 

     More details

    Language:Japanese  

    researchmap

  • 自記式食事歴法質問表(DHQ)を用いた慢性腎臓病患者における摂取たんぱく質の種類と量の検討

    細島康宏, 忰田亮平, 石川友美, 山本卓, 金子佳賢, 後藤眞, 成田一衛, 村松芳多子, 渡邊令子, 鈴木芳樹, 斎藤亮彦

    第1回腎と栄養研究会  2014.9 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病治療と腎臓〜SGLT2阻害薬を中心に〜

    斎藤 亮彦

    新潟病院薬剤師会学術講演会  2014.8 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症とメガリン

    斎藤 亮彦

    Diabetes Forum in 東京  2014.8 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の病態と治療

    斎藤 亮彦

    第699回新潟医学会次第「糖尿病の合併症」  2014.7 

     More details

    Language:Japanese  

    researchmap

  • IgA腎症患者における尿中メガリンの重要性

    関卓人, 淺沼亮彦, 浅尾りん, 野中香苗, 黒澤寛之, 平山吉郎, 斎藤亮彦, 富野康日己

    第57回日本腎臓学会学術総会  2014.7 

     More details

    Language:Japanese  

    researchmap

  • 薬剤等による腎障害の早期診断法と治療法の開発

    成田一衛, 寺田典生, 横山仁, 和田隆志, 山縣邦弘, 斎藤亮彦

    第57回日本腎臓学会学術総会  2014.7 

     More details

    Language:Japanese  

    researchmap

  • DPP-4阻害薬による血液透析時の血中総GIPと血糖値の変動への影響

    細島康宏, 石川友美, 飯野則昭, 佐藤隆之, 桑原頌治, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第57回日本腎臓学会学術総会  2014.7 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管における蛋白再吸収・代謝機構

    斎藤 亮彦

    第57回日本腎臓学会学術総会  2014.7 

     More details

    Language:Japanese  

    researchmap

  • 培養近位尿細管細胞を用いたGLP-1受容体作動薬による腎保護作用機序の解析

    和田恵梨, 桑原頌治, 細島康宏, 成田一衛, 斎藤亮彦

    第57回日本腎臓学会学術総会  2014.7 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病合併血液透析患者におけるDPP-4阻害薬によるGIPへの影響と血糖変動について

    細島康宏, 石川友美, 飯野則昭, 佐藤隆之, 桑原頌治, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第59回日本透析医学会学術集会・総会  2014.6 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病合併維持血液透析患者における透析時の血糖変動と夜間低血糖のCGMによる評価〜DDP-4阻害薬の低血糖抑制効果の可能性〜

    石川友美, 細島康宏, 蒲澤秀門, 保川亮太, 矢田雄介, 河野恵美子, 桑原頌治, 秋山史大, 飯野則昭, 鈴木芳樹, 斎藤亮彦

    第59回日本透析医学会学術集会・総会  2014.6 

     More details

    Language:Japanese  

    researchmap

  • DPP-4阻害薬が原因と考えられる水疱性類天疱瘡を発症した腹膜透析患者の一例

    河野恵美子, 細島康宏, 荻野宗次郎, 稲晃市郎, 斎藤亮彦, 成田一衛

    第59回日本透析医学会学術集会・総会  2014.6 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者における米胚乳たんぱく質によるnPNA増加効果

    細島康宏, 島田久基, 宮崎滋, 小尾佳嗣, 渡邊令子, 門脇基二, 藤井幹夫, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第59回日本透析医学会学術集会・総会  2014.6 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析中の2型糖尿病患者におけるDPP-4阻害薬によるGIPへの影響と血糖変動について

    細島康宏, 石川友美, 飯野則昭, 佐藤隆之, 桑原頌治, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第57回日本糖尿病学会年次学術集会  2014.5 

     More details

    Language:Japanese  

    researchmap

  • 米胚乳タンパク質が肥満2型糖尿病ZDFラットの肝臓中代謝物質に与える影響

    山口実希, 久保田真敏, 渡邉令子, 細島康宏, 斎藤亮彦, 藤井幹夫, 藤村忍, 門脇基二

    第68回日本栄養・食糧学会大会  2014.5 

     More details

    Language:Japanese  

    researchmap

  • ミミズEisenia Fetida粉末による糖尿病性腎症進行の抑制作用

    川上智子, 渡邉望美, 藤川愛里, 細島康宏, 斎藤亮彦, 久保田真敏, 藤村忍, 門脇基二

    第68回日本栄養・食糧学会大会  2014.5 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者におけるCGMによる血糖変動と低血糖の評価:DPP-4阻害薬による血糖変動幅縮小効果の可能性

    石川友美, 細島康宏, 蒲澤秀門, 保川亮太, 矢田雄介, 河野恵美子, 桑原頌治, 飯野則昭, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第57回日本糖尿病学会年次学術集会  2014.5 

     More details

    Language:Japanese  

    researchmap

  • 米糠タンパク質摂取が肥満2型糖尿病ZDFラットの骨およびCa・P代謝に与える影響

    小森絵里香, 久保田真敏, 杉山稔恵, 渡邊令子, 橋本博之, 原田幸和, 細島康宏, 斎藤亮彦, 藤村忍, 門脇基二

    第68回日本栄養・食糧学会大会  2014.5 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者において米胚乳タンパク質補給は血清リン,カリウム値を上昇させずにnPNAを増加させる

    細島康宏, 成田一衛, 島田久基, 宮崎滋, 小尾佳嗣, 渡辺令子, 門脇基二, 近藤葉月, 藤井幹夫, 鈴木芳樹, 斎藤亮彦

    第56回新潟透析懇話会学術集会  2014.4 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病合併維持血液透析患者におけるDPP-4阻害薬の無自覚低血糖抑制効果の可能性〜CGMによる評価から〜

    石川友美, 細島康宏, 蒲澤秀門, 保川亮太, 矢田雄介, 河野恵美子, 飯野則昭, 成田一衛, 桑原頌治, 斎藤亮彦, 秋山史大, 鈴木芳樹

    第56回新潟透析懇話会学術集会  2014.4 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病治療と腎臓

    斎藤 亮彦

    長岡市学術講演会〜より良い糖尿病診療の扉を開く〜  2014.4 

     More details

    Language:Japanese  

    researchmap

  • 新規糖尿病治療薬と腎臓

    斎藤 亮彦

    腎・糖尿病セミナー  2014.4 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症を予防するために

    斎藤 亮彦

    新潟大学医学部医学科第2回学外講義2014  2014.3 

     More details

    Language:Japanese  

    researchmap

  • 様々な臓器障害の影響で血液透析継続に難渋したミトコンドリア異常症の一例

    蒲澤秀門, 栗原太郎, 近藤大介, 長谷川尚, 細島康宏, 斎藤亮彦

    第50回日本糖尿病学会 関東甲信越地方会  2014.1 

     More details

    Language:Japanese  

    researchmap

  • HIV感染症の経過中に膵臓関連自己抗体が陽性となった3例

    保川亮太, 細島康宏, 青木信将, 若松拓也, 石川友美, 茂呂寛, 田邊嘉也, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第51回日本糖尿病学会関東甲信越地方大会  2014.1 

     More details

    Language:Japanese  

    researchmap

  • 培養近尿細管細胞を用いたin vitro検証系の確立

    保川亮太, 細島康宏, 青木信将, 若松拓也, 石川友美, 茂呂寛, 田邊嘉也, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第17回日本病態栄養学会年次学術集会  2014.1 

     More details

    Language:Japanese  

    researchmap

  • CGMを用いた維持血液透析患者における血糖変動と低血糖の評価:DPP-4阻害薬における血糖変動幅縮小効果の可能性

    石川友美, 細島康宏, 保川亮太, 飯野則昭, 鈴木芳樹, 成田一衛, 斎藤亮彦

    2014 

     More details

    Language:Japanese  

    researchmap

  • 血液透析患者中の2型糖尿病患者におけるビルダグリブチンを中心としたDPP-4阻害薬によるグルカゴンへの影響と血糖変動について

    細島康宏, 佐藤隆之, 飯野則昭, 桑原頌治, 鈴木芳樹, 成田一衛, 斎藤亮彦

    E-Qualityサミット2013  2013.12 

     More details

    Language:Japanese  

    researchmap

  • メガリンを介する高脂肪食誘発性腎症の発症機序

    細島康宏, 桑原頌治, 蒲澤秀門, 笹川泰司, 青木弘行, 金子麗華, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第25回日本糖尿病性腎症研究会  2013.12 

     More details

    Language:Japanese  

    researchmap

  • Megalin-mediated mechanism of high fat diet-induced kidney disease International conference

    Hosojima M, Kuwahara S, Kabasawa H, Aoki H, Kaneko R, Narita I, Saito A

    46th Annual Meeting of American Society of Nephrology  2013.11 

     More details

    Language:English  

    researchmap

  • 糖尿病性腎症とDPP-4阻害薬

    斎藤 亮彦

    CKD学術講演会 —慢性腎臓病悪化予防の戦略研究 (FROM-J) –  2013.10 

     More details

    Language:Japanese  

    researchmap

  • HIV感染症の経過中に膵島関連自己抗体が陽性となった3例

    細島康宏, 青木信将, 保川亮太, 石川友美, 茂呂寛, 田邊嘉也, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第24回新潟糖尿病臨床研究会  2013.10 

     More details

    Language:Japanese  

    researchmap

  • 腎臓病の新しい診断・治療法の開発を目指して

    斎藤 亮彦

    機能分子医学寄附講座 開設10周年記念講演会  2013.9 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドローム関連腎症モデルにおけるメガリンの病的役割

    桑原頌治, 細島康宏, 青木弘行, 金子麗華, 蒲澤秀門, 笹川泰司, 鈴木哲世, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第20回新潟糖尿病性腎症研究会  2013.9 

     More details

    Language:Japanese  

    researchmap

  • CKD合併2型糖尿病症例におけるシタグリプチンの有効性

    細島康宏, 保川亮太, 石川友美, 河野恵美子, 飯野則昭, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第20回新潟糖尿病性腎症研究会  2013.9 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷モデルの腎障害機序におけるメガリンの役割

    細島康宏, 桑原頌治, 青木弘行, 金子麗華, 鈴木哲世, 蒲澤秀門, 笹川泰司, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第28回日本糖尿病合併症学会  2013.9 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療

    斎藤 亮彦

    安中市医師会学術講演会  2013.8 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドローム・糖尿病などの生活習慣病

    斎藤 亮彦

    にいがた市民大学 生命自然科学コース 講座「中高年を元気に生き抜く」第2回講義  2013.6 

     More details

    Language:Japanese  

    researchmap

  • 生体腎移植患者に対する持続血糖測定(CGM)を用いた血糖評価

    矢田雄介, 細島康宏, 石川友美, 池田正博, 中川由紀, 斎藤和英, 髙橋公太, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第97回新潟内分泌代謝同好会  2013.6 

     More details

    Language:Japanese  

    researchmap

  • エンドサイトーシス受容体メガリンとメタボリックシンドローム関連腎症

    斎藤 亮彦

    Scientific Presentation in Niigata  2013.6 

     More details

    Language:Japanese  

    researchmap

  • 肥満・メタボリックシンドローム関連腎症の病態機序

    斎藤 亮彦

    第25回新潟臨床腎セミナー「肥満関連腎症」  2013.6 

     More details

    Language:Japanese  

    researchmap

  • 血液透析患者におけるDPPVI阻害薬の血糖調節効果の検討

    佐藤隆之, 細島康宏, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 成田一衛

    第58回日本透析医学会学術集会  2013.6 

     More details

    Language:Japanese  

    researchmap

  • 透析時の糖代謝指標の変動についての検討

    青池郁夫, 細島康宏, 斎藤亮彦

    第58回日本透析医学会学術集会  2013.6 

     More details

    Language:Japanese  

    researchmap

  • HIV感染症の経過中に緩徐進行1型血糖病を発症した1例

    若松拓也, 細島康宏, 青木信将, 月岡啓輔, 岡島正明, 森山寛史, 小屋俊之, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第132回信越地方会  2013.6 

     More details

    Language:Japanese  

    researchmap

  • Megalin–mediated autophagolysomal dysfunction in proximal tubule cells is primarily associated with the development of high-fat diet-induced kidney International conference

    Hosojima M, Kuwahara S, Aoki H, Sasagawa T, Kabasawa H, Kaneko R, Suzuki A, Narita I, Saito A

    WCN 2013 Satellite Symposium Kidney and Lipids  2013.6 

     More details

    Language:English  

    researchmap

  • 維持血液透析患者における精製米たんぱく質摂取の安全性の評価

    細島康宏, 青池郁夫, 渡邊令子, 田邊直仁, 門脇基二, 藤井幹夫, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第58回日本透析医学会学術集会  2013.6 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷モデルの腎障害機序におけるメガリンの役割

    細島康宏, 蒲澤秀門, 笹川泰司, 鈴木哲世, 青木弘行, 金子麗華, 桑原頌治, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第56回日本糖尿病学会年次学術集会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • ステロイド糖尿病を発症した慢性腎臓病患者におけるDPP-4阻害剤の有用性の検討

    矢田雄介, 細島康宏, 石川友美, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第56回日本腎臓学会学術総会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 虚血・再環流モデルマウス腎におけるメガリン切断の検討

    保川亮太, 細島康宏, 保坂聖子, 矢田雄介, 青木弘行, 桑原頌治, 成田一衛, 黒澤寛之, 平山吉朗, 斎藤亮彦

    第56回日本腎臓学会学術総会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷モデルの腎障害機序におけるメガリンの役割

    細島康宏, 蒲澤秀門, 笹川泰司, 鈴木哲世, 青木弘行, 金子麗華, 桑原頌治, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第56回日本腎臓学会学術総会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 新規ARBアジルサルタンの臨床的効果

    細島康宏, 河野恵美子, 斎藤亮彦, 成田一衛

    第二回臨床高血圧フォーラム【臨床高血圧ノススメ】  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 心不全モデルマウスにおける近位尿細管プロラクチン受容体の発現増加

    土田陽平, 金子佳賢, 大塚忠司, 後藤慧, 斎藤亮彦, 山本格, 成田一衛

    第56回日本腎臓学会学術総会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • ミトコンドリアDNA A3243G変異を有する保存期腎不全患者4例における腎疾患の臨床経過の検討

    蒲澤秀門, 近藤大介, 栗原太郎, 長谷川尚, 宗田聡, 太田隆志, 今井直史, 細島康宏, 斎藤亮彦

    第56回日本糖尿病学会年次学術集会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • DHQを用いた慢性腎臓病患者における摂取たんぱく質の種類と量の検討

    細島康宏, 山本卓, 金子佳賢, 後藤眞, 村松芳多子, 渡邉令子, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第56回日本腎臓学会学術総会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病モデルラットに対する米タンパク質の腎症進行遅延効果

    久保田真敏, 渡邉令子, 細島康宏, 藤井幹夫, 斎藤亮彦, 門脇基二

    第56回日本腎臓学会学術総会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 腎産生タンパク質の尿中排泄量を基にした腎機能推測法の検討

    樋渡昭, 萩原正大, 臼井丈一, 永井恵, 甲斐平康, 森戸直記, 楊景堯, 斎藤知栄, 細島康宏, 原正則, 斎藤亮彦, 山縣邦弘

    第56回日本腎臓学会学術総会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 米タンパク質および大豆タンパク質摂取が肥満型糖尿病モデルZDFラットの糖尿病や腎症の進行に与える影響

    久保田真敏, 渡邊令子, 山口実希, 小林奨, 斎藤亮彦, 藤井幹夫, 藤森忍, 門脇基二

    日本栄養・食糧学会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • ステロイド糖尿病を発症した慢性腎臓病患者におけるCGMを用いたDPP-4阻害薬の有用性の検討

    矢田雄介, 細島康宏, 石川友美, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第56回日本糖尿病学会年次学術集会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 米糠タンパク質摂取による糖尿病性腎症の進行遅延効果

    渡邊令子, 久保田真敏, 橋本博之, 原田幸和, 細島康宏, 斎藤亮彦, 門脇基二

    日本栄養・食糧学会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • 米胚乳タンパク質摂取による糖尿病性腎症進行遅延効果の作用メカニズム解明

    久保田真敏, 渡邊令子, 山口実希, 小林奨, 斎藤亮彦, 藤井幹夫, 藤森忍, 門脇基二

    日本栄養・食糧学会  2013.5 

     More details

    Language:Japanese  

    researchmap

  • CGM(持続血糖モニター)による透析患者における低血糖の頻度の検討

    石川友美, 秋山史大, 細島康宏, 飯野則昭, 矢田雄介, 成田一衛, 斎藤亮彦

    第55回新潟透析懇話会学術集会  2013.4 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者における精製米タンパク質摂取の安全性の評価

    細島康宏, 門脇基二, 成田一衛, 青池郁夫, 渡邊令子, 田邊直仁, 藤井幹夫, 鈴木芳樹, 斎藤亮彦

    第55回新潟透析懇話会学術集会  2013.4 

     More details

    Language:Japanese  

    researchmap

  • 血液透析患者における透析時間中のレジスタンス運動の試み

    河野恵美子, 細島康宏, 飯野則昭, 風間順一郎, 成田一衛, 張替徹, 斎藤亮彦

    第55回新潟透析懇話会学術集会  2013.4 

     More details

    Language:Japanese  

    researchmap

  • 生体腎移植患者に対する持続血糖走測定(CGM)を用いた血糖評価

    矢田雄介, 細島康宏, 成田一衛, 石川友美, 池田正博, 斎藤和英, 高橋公太, 鈴木芳樹, 斎藤亮彦

    第55回新潟透析懇話会学術集会  2013.4 

     More details

    Language:Japanese  

    researchmap

  • Examination of urinary podocalyxin and megalin in patients with IgA nephropathy International conference

    Seki T, Asanuma K, Asao R, Kodama F, Akiba-Takagi M, Nagai-Hosoe Y, Nonaka K, Sasaki Y, Hidaka T, Takeda Y, Saito A, Tomino Y

    1st Juntendo University- Taipei Medical University Nephrology Conference  2013.4 

     More details

    Language:English  

    researchmap

  • IgA腎症における尿中ポドカリキシン・尿中メガリンの検討

    関卓人, 淺沼克彦, 浅尾りん, 細江佳子, 野中香苗, 黒澤寛之, 平山吉朗, 原正則, 斎藤亮彦, 富野康日己

    第110回日本内科学会総会・講演会  2013.4 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者における精製米たんぱく質摂取の安全性の評価

    細島康宏, 青池郁夫, 渡邊令子, 田邊直仁, 門脇基二, 藤井幹夫, 成田一衛, 鈴木芳樹, 斎藤亮彦

    腎臓病と栄養・代謝・食事フォーラム2013  2013.3 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症症例に対するDPP-IV阻害剤の使い方

    斎藤 亮彦

    第4回Expert Meeting in Niigata  2013.3 

     More details

    Language:Japanese  

    researchmap

  • 維持血液透析患者における精製米たんぱく質摂取の安全性の評価

    細島康宏, 青池郁夫, 渡邊令子, 田邊直仁, 門脇基二, 藤井幹夫, 成田一衛, 鈴木芳樹, 斎藤亮彦

    第3回日本腎臓リハビリテーション学会学術集会  2013.3 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷マウスの腎障害機序におけるメガリンの役割

    細島康宏, 蒲澤秀門, 笹川泰司, 矢田雄介, 保川亮太, 青木弘行, 金子麗華, 鈴木哲世, 桑原頌治, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第42回新潟糖尿病談話会  2013.2 

     More details

    Language:Japanese  

    researchmap

  • Klinefelter症候群が疑われ高度なインスリン抵抗性を示した糖尿病の一例

    矢田雄介, 細島康宏, 金子佳賢, 風間順一郎, 鈴木芳樹, 成田一衛

    第42回新潟糖尿病談話会  2013.2 

     More details

    Language:Japanese  

    researchmap

  • 様々な臓器障害の影響で血液透析継続に難渋したミトコンドリア異常症の一剖検例

    蒲澤秀門, 栗原太郎, 近藤大介, 長谷川尚, 細島康宏, 斎藤亮彦

    第42回新潟糖尿病談話会  2013.2 

     More details

    Language:Japanese  

    researchmap

  • シタグリプチンとグリメピリドの隔日内服中にCGMにより血糖変動を確認できた一例

    矢田雄介, 細島康宏, 金子佳賢, 風間順一郎, 鈴木芳樹, 成田一衛

    第50回日本糖尿病学会 関東甲信越地方会  2013.1 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病モデルラットの腎症に対する米タンパク質摂取の有効性

    久保田真敏, 渡邉令子, 細島康宏, 飯野則昭, 斎藤亮彦, 藤村忍, 門脇基二

    第24回日本糖尿病性腎症研究会  2012.12 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症とメガリンに関する研究の展開

    斎藤 亮彦

    友腎会特別講演会  2012.11 

     More details

    Language:Japanese  

    researchmap

  • 腹膜透析患者におけるCGM(持続血糖モニター)による血糖変動の評価

    細島康宏, 飯野則昭, 山本卓, 河野恵美子, 矢田雄介, 丸山弘樹, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第28回新潟CAPDセミナー  2012.11 

     More details

    Language:Japanese  

    researchmap

  • 腎保護を目指した糖尿病治療

    斎藤 亮彦

    上越糖尿病学術講演会(ネテリア新発売講演会)  2012.11 

     More details

    Language:Japanese  

    researchmap

  • CKDの疾患病態と治療について

    斎藤 亮彦

    村上市岩船郡医師会学術講演会  2012.11 

     More details

    Language:Japanese  

    researchmap

  • メガリンとCKD

    斎藤 亮彦

    第7回代謝異常とCKDを考える会  2012.10 

     More details

    Language:Japanese  

    researchmap

  • 慢性腎臓病患者におけるCGMを用いた血糖評価

    細島康宏, 飯野則昭, 矢田雄介, 石川友美, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第23回新潟糖尿病臨床研究会  2012.10 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症と心腎関連

    斎藤 亮彦

    第94回新潟動脈硬化性疾患研究会総会  2012.10 

     More details

    Language:Japanese  

    researchmap

  • 医学と栄養学の視点から健康と食の機能を考える

    斎藤 亮彦

    食と花の世界フォーラムにいがた2012  2012.10 

     More details

    Language:Japanese  

    researchmap

  • Irbesartan decreases serum and urinary MCP-1 levels in patients with metablolic syndrome-related nephrology International conference

    Hosojima M, Kabasawa H, Suzuki Y, Narita I, Saito A

    ISN FOREFRONTS 2012 - Forefronts in Nephrology  2012.10 

     More details

    Language:English  

    researchmap

  • 新潟大学発の脳死膵腎同時移植の1例

    細島康宏, 土田陽平, 山本卓, 飯野則昭, 後藤眞, 斎藤亮彦, 成田一衛, 山本智, 大矢洋, 佐藤好信, 鈴木芳樹, 斉藤和英, 高橋公太

    第19回新潟糖尿病性腎症研究会  2012.9 

     More details

    Language:Japanese  

    researchmap

  • 腎臓とアンジオテンシンⅡ受容体拮抗薬

    斎藤 亮彦

    Expert Meeting  2012.7 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷マウスにおける近位尿細管上皮細胞障害とメガリンの関与

    細島康宏, 蒲澤秀門, 笹川泰司, 矢田雄介, 保川亮太, 青木弘行, 金子麗華, 佐藤博慶, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第55回日本腎臓学会学術総会  2012.6 

     More details

    Language:Japanese  

    researchmap

  • Protective effect of isolated soy proteinfeeding on renal tubules in the early stage of diabetic nephropathy International conference

    Asanoma M, Ota S, Sato H, Hosojima M, Kohno M, Saito A

    The 16th International Congress on Renal Nutrition and Metabolism (ICRNM) in Honolulu  2012.6 

     More details

    Language:English  

    researchmap

  • 近位尿細管細胞内におけるアンジオテンシノーゲンのレニン反応性の検討

    矢田雄介, 佐藤博慶, 細島康宏, 青木弘行, 成田一衛, 斎藤亮彦

    第55回日本腎臓学会学術総会  2012.6 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドローム関連腎症患者におけるイルベサルタンによる血中・尿中MCP-1減少効果

    細島康宏, 酒巻裕一, 蒲澤秀門, 蒲澤佳子, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第55回日本腎臓学会学術総会  2012.6 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症におけるメガリンの病的役割と尿中バイオマーカーとしての意義

    斎藤 亮彦

    第55回日本腎臓学会学術総会  2012.6 

     More details

    Language:Japanese  

    researchmap

  • 虚血性急性腎障害モデルマウスにおけるメガリンの切断の検討

    保川亮太, 保坂聖子, 細島康宏, 矢田雄介, 青木弘行, 佐藤博慶, 成田一衛, 黒澤寛之, 平山吉朗, 関根盛, 斎藤亮彦

    第55回日本腎臓学会学術総会  2012.6 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症における尿中メガリン排泄量の測定意義

    細島康宏, 小笠原真也, 蒲澤秀門, 黒澤寛之, 鈴木芳樹, 富野康日己, 山縣邦彦, 成田一衛, 平山吉朗, 関根盛, 斎藤亮彦

    第55回日本糖尿病学会年次学術集会  2012.5 

     More details

    Language:Japanese  

    researchmap

  • 顕性蛋白尿を認めるメタボリックシンドローム患者におけるイルベサルタンによる血中・尿中MCP-1減少効果

    細島康宏, 酒巻裕一, 成田一衛, 斎藤亮彦

    第1回臨床高血圧フォーラム  2012.5 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷マウスにおける腎近位尿細管上皮細胞(PTEC)障害とメガリンの関与

    蒲澤秀門, 細島康宏, 笹川泰司, 矢田雄介, 保川亮太, 青木弘行, 金子麗華, 佐藤博慶, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第55回日本糖尿病学会年次学術集会  2012.5 

     More details

    Language:Japanese  

    researchmap

  • 腎不全患者におけるCGM(continuous glucose monitoring)による血糖変動の評価

    細島康宏, 飯野則昭, 高田琢磨, 鈴木裕美, 八幡和明, 鈴木芳樹, 斎藤亮彦

    第54回新潟透析懇話会学術集会  2012.4 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の発症・進展におけるネフロン傷害機序

    斎藤 亮彦

    第2回インクレチンセミナー in 新潟  2012.4 

     More details

    Language:Japanese  

    researchmap

  • インスリン治療導入のノウハウ

    斎藤 亮彦

    インスリン治療導入のノウハウ  2012.4 

     More details

    Language:Japanese  

    researchmap

  • 当院初の膵腎同時移植例における血糖コントロールについて

    細島康宏, 飯野則昭, 山本智, 大矢洋, 佐藤好信, 齋藤和英, 高橋公太, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第41回新潟糖尿病談話会  2012.2 

     More details

    Language:Japanese  

    researchmap

  • 合併症を予防するための糖尿病治療

    斎藤 亮彦

    新潟市糖尿病対策推進会議 生活習慣改善教室  2012.1 

     More details

    Language:Japanese  

    researchmap

  • 良質な糖尿病治療と合併症の予防

    斎藤 亮彦

    糸魚川市医師会学術講演会  2012.1 

     More details

    Language:Japanese  

    researchmap

  • 有酸素運動とレジスタンストレーニングを含む生活習慣改善プログラムによる尿中アルブミン排泄量の減少効果

    矢田雄介, 蒲澤佳子, 細島康宏, 齋藤麻里子, 田中典子, 鈴木芳樹, 荒川正昭, 成田一衛, 斎藤亮彦

    日本腎臓リハビリテーション学会  2012.1 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症における尿中メガリン排泄量の測定意義

    細島康宏, 小笠原真也, 黒澤寛之, 鈴木芳樹, 富野康日己, 山縣邦弘, 成田一衛, 平山吉朗, 関根盛, 斎藤亮彦

    第23回日本糖尿病性腎症研究会  2011.12 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病治療と腎症の予防

    斎藤 亮彦

    糖尿病レクチャーミーティング  2011.11 

     More details

    Language:Japanese  

    researchmap

  • Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes mellitus International conference

    Ogasawara S, Hosojima M, Kaseda R, Narita I, Hirayama Y, Sekine S, Saito A

    44th Annual Meeting of American Society of Nephrology 2011  2011.11 

     More details

    Language:English  

    researchmap

  • Prolactin receptor was up-regulated in the proximal tubules of the kidney in the cardio-renal syndrome model mice International conference

    Tsuchida Y, Kaneko Y, Saito A, Yamamoto T, Narita I

    44th Annual Meeting of American Society of Nephrology 2011  2011.11 

     More details

    Language:English  

    researchmap

  • 合併症を予防するための糖尿病治療

    斎藤 亮彦

    第11回 阿賀北 糖尿病を知る集い  2011.10 

     More details

    Language:Japanese  

    researchmap

  • インスリン治療導入のノウハウ

    斎藤 亮彦

    津川地区糖尿病勉強会  2011.10 

     More details

    Language:Japanese  

    researchmap

  • 高脂肪食負荷モデルにおける腎障害機序 −メガリンを介するエンドサイトーシス/オートファジー系の異常系の異常

    青木弘行, 蒲澤秀門, 細島康宏, 笹川泰司, 矢田雄介, 金子麗華, 鈴木哲世, 樋口文恵, 佐藤博慶, 飯野則昭, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第18回新潟糖尿病性腎症研究会  2011.9 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の新しいバイオマーカーとしてのメガリン

    斎藤 亮彦

    Diabetes Face to Face 腎臓を守る糖尿病治療の会  2011.9 

     More details

    Language:Japanese  

    researchmap

  • Significance of urinary full-length and ectodomain forms of megalin in patients with type 2 diabetes International conference

    Ogasawara S, Hosojima M, Kabasawa H, Kaseda R, Yamamoto-Kabasawa K, Sato H, Takeda T, Suzuki Y, Narita I, Yamagata K, Tomino Y, Gejyo F, Hirayama Y, Sekine S, Saito A

    2011Forefronts Symposium -Fore Fronts in Nephroloby  2011.9 

     More details

    Language:English  

    researchmap

  • Regulation of megalin expression proximal tubule cells by angiotensin II-, inslin- and LPS- TNF-α-mediated signaling cross-talk International conference

    Hosojima M, Kabasawa H, Takeyama A, Sato H, Yamamoto-Kabasawa K, Kaseda R, Narita I, Saito A

    2011Forefronts Symposium -Fore Fronts in Nephroloby  2011.9 

     More details

    Language:English  

    researchmap

  • メタボリックシンドロームに関連した腎障害と高尿酸血症

    斎藤 亮彦

    富岡市甘楽郡医師会学術講演会  2011.7 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の発症機序と治療の新しい動向

    斎藤 亮彦

    「悠腎会」特別講演会  2011.7 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病における尿中全長型および細胞外領域型メガリンの測定の意義

    斎藤亮彦, 小笠原真也, 細島康宏, 忰田亮平, 蒲澤秀門, 山本-蒲澤佳子, 佐藤博慶, 黒澤寛之, 竹田徹朗, 鈴木芳樹, 成田一衛, 山縣邦弘, 富野康日己, 下条文武, 平山吉朗, 関根盛

    日本プロテオーム学会2011年会  2011.7 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の病態と治療−DPP-4阻害薬の話題をふまえて−

    斎藤 亮彦

    南魚沼市第3回Meet The Expert  2011.6 

     More details

    Language:Japanese  

    researchmap

  • 培養近位尿細管上皮細胞におけるLPS-TNFα-ERK1/2シグナル経路を介したメガリンの発現調節機構

    佐藤博慶, 竹山綾, 蒲澤秀門, 長江多恵子, 金子麗華, 樋口文恵, 鈴木哲世, 山本佳子, 細島康宏, 竹田徹朗, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第54回日本腎臓学会学術総会  2011.6 

     More details

    Language:Japanese  

    researchmap

  • 心腎症候群モデルマウスと関連遺伝子の検索

    土田陽平, 金子佳賢, 斎藤亮彦, 山本格, 成田一衛

    第54回日本腎臓学会学術総会  2011.6 

     More details

    Language:Japanese  

    researchmap

  • 低タンパク血症にもかかわらず軽度タンパク尿を呈したネフローゼ症候群患者のmegalin発現の検討

    小椋雅夫, 亀井宏一, 佐藤舞, 藤丸拓也, 石川智朗, 宇田川智宏, 松岡健太郎, 斎藤亮彦, 伊藤秀一

    第54回日本腎臓学会学術総会  2011.6 

     More details

    Language:Japanese  

    researchmap

  • 培養近位尿細管細胞におけるLPS-TNFα-ERK1/2シグナル経路を介したメガリンの発現調節機構

    斎藤亮彦, 竹山綾, 佐藤博慶, 蒲澤秀門, 長江多恵子, 金子麗華, 樋口文恵, 鈴木哲世, 山本佳子, 細島康宏, 忰田亮平, 飯野則昭, 竹田徹朗, 鈴木芳樹, 成田一衛

    第54回日本腎臓学会学術総会  2011.6 

     More details

    Language:Japanese  

    researchmap

  • 第54回日本腎臓学会学術総会

    山本佳子, 細島康宏, 蒲澤秀門, 飯野則昭, 竹田徹朗, 鈴木芳樹, 成田一衛, 荒川正昭, 斎藤亮彦

    第54回日本腎臓学会学術総会  2011.6 

     More details

    Language:Japanese  

    researchmap

  • CKDの病態把握と予後推定における尿中メガリン測定の意義

    小笠原真也, 忰田亮平, 蒲澤秀門, 竹田徹朗, 鈴木芳樹, 成田一衛, 平山吉朗, 関根盛, 斎藤亮彦

    第54回日本腎臓学会学術総会  2011.6 

     More details

    Language:Japanese  

    researchmap

  • Urinary full-length form of megalin is a novel biomarker for diabetic nephropathy International conference

    Saito A, Ogasawara S, Kabasawa H, Hosojima M, Kaseda R, Takeda T, Suzuki Y, Narita I, Hirayama Y, Sekine S

    7th International Congress on Uremia Research and Toxicity  2011.5 

     More details

    Language:English  

    researchmap

  • 全身性自己免疫疾患治療経過中に抗GAD抗体の陽性と推移が確認できた糖尿病の3例

    蒲澤秀門, 山本佳子, 細島康宏, 忰田亮平, 小林大介, 和田庸子, 小屋俊之, 村上修一, 竹田徹朗, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第54回日本糖尿病学会年次学術集会  2011.5 

     More details

    Language:Japanese  

    researchmap

  • 培養近位尿細管細胞におけるLPS-TNFα-ERK1/2シグナル経路を介したメガリンの発現調節機構

    斎藤亮彦, 竹山綾, 佐藤博慶, 蒲澤秀門, 長江多恵子, 金子麗華, 樋口文恵, 鈴木哲世, 山本佳子, 細島康宏, 忰田亮平, 飯野則昭, 竹田徹朗, 鈴木芳樹, 成田一衛

    第54回日本糖尿病学会年次学術集会  2011.5 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病の最近の治療−DPP-4阻害役の話題をふまえて−

    斎藤 亮彦

    Meet the Expert in 佐渡  2011.4 

     More details

    Language:Japanese  

    researchmap

  • CKDから腎・心血管傷害発症を抑制させるポイントとは?

    斎藤亮彦, 丸山弘樹, 羽入修

    World Kidney Day 2011シンポジウム パネルディスカッション(コメンテーター)  2011.3 

     More details

    Language:Japanese  

    researchmap

  • インスリン治療導入のノウハウ

    斎藤 亮彦

    上越頸北地区インスリンセミナー  2011.3 

     More details

    Language:Japanese  

    researchmap

  • International Symposium Dietary Protein for Human Health International conference

    Watanabe R, Kubota M, Saito A, Kumagai T, Kadowaki M

    Effect of rice protein on the progression of diabetic nephropathy  2011.3 

     More details

    Language:English  

    researchmap

  • Downregulation of megalin via LPS-TNFa-ERKl/2 International conference

    Takeyama A, Sato H, Soma-Nagae T, Kabasawa H, Suzuki A, Kaneko R, Higuchi F, Yamamoto K, Hosojima M, Kaseda R, lino N, Takeda T, Narita I, Saito A

    International Symposium Dietary Protein for Human Health  2011.3 

     More details

    Language:English  

    researchmap

  • 糖尿病性腎症の病態機序とメガリン研究

    斎藤 亮彦

    第4回群馬CKD研究会  2011.2 

     More details

    Language:Japanese  

    researchmap

  • Churg-Strauss症候群の加療中に抗GAD抗体が陽転化した1型糖尿病の1例

    蒲澤秀門, 小屋俊之, 古川俊貴, 忰田亮平, 飯野則昭, 竹田徹朗, 鈴木芳樹, 斎藤亮彦, 成田一衛

    第48回日本糖尿病学会関東甲信越地方会  2011.1 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の新しい治療の動向

    斎藤 亮彦

    第5回Niigata Young Assembly for Nephrologyo(NYAN)−新潟腎臓病学のための若手の集い−  2011.1 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドローム腎症におけるエンドサイトーシス受容体メガリンの病的役割とオートファジーとの関連

    斎藤 亮彦

    平成22年度オートファジー研究会  2011.1 

     More details

    Language:Japanese  

    researchmap

  • 利尿剤併用が有用である立場から

    斎藤 亮彦

    ARB Forum in Niigata ~ミカムロ配合錠AP発売記念講演~  2010.12 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドローム関連腎症の発症・進展機序におけるメガリンの関与

    佐藤博慶, 笹川泰司, 蒲澤秀門, 飯野則昭, 鈴木哲世, 金子麗華, 青木弘行, 樋口文恵, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第22回日本糖尿病性腎症研究会  2010.12 

     More details

    Language:Japanese  

    researchmap

  • シンポジウム「糖尿病の診断と治療の急速な展開」 5.新しい腎症の診断法

    斎藤 亮彦

    第661回新潟医学会  2010.10 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドロームと腎障害

    斎藤 亮彦

    第1回新潟NASH研究会  2010.10 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管におけるメガリンを介するエンドサイトーシス機構のイメージング解析

    斎藤 亮彦

    第42回日本臨床分子形態学会総会・学術集会  2010.9 

     More details

    Language:Japanese  

    researchmap

  • 透析患者における糖尿病の薬物治療

    竹田徹朗, 斎藤亮彦, 鈴木芳樹, 成田一衛

    第37回東北腎不全研究会  2010.8 

     More details

    Language:Japanese  

    researchmap

  • 食塩感受性をふまえた高血圧治療

    斎藤 亮彦

    やませみの会  2010.6 

     More details

    Language:Japanese  

    researchmap

  • 尿中PCX測定系の構築と臨床的意義

    黒澤寛之, 小笠原真也, 淺沼克彦, 富野康日己, 山縣邦弘, 斎藤亮彦, 平山吉朗, 関根盛, 原正則

    第53回日本腎臓学会学術総会  2010.6 

     More details

    Language:Japanese  

    researchmap

  • 尿中メガリンELISA測定系の構築とCKD評価における有用性

    小笠原真也, 黒澤寛之, 竹田徹朗, 飯野則昭, 佐藤博慶, 鈴木芳樹, 淺沼克彦, 富野康日己, 山縣邦弘, 成田一衛, 下条文武, 平山吉郎, 関根盛, 斎藤亮彦

    第53回日本腎臓学会学術総会  2010.6 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドローム関連腎症の発症・進展機序におけるメガリンの関与

    笹川泰司, 蒲澤秀門, 佐藤博慶, 鈴木哲世, 塩田友也, 相馬多恵子, 生山健児, 竹山綾, 山本佳子, 細島康宏, 今井直史, 飯野則昭, 竹田徹朗, 山本格, 鈴木芳樹, 成田一衛, 斎藤亮彦

    第53回日本腎臓学会学術総会  2010.6 

     More details

    Language:Japanese  

    researchmap

  • Urinary shedding forms of megalin as novel biomarkers of proximal tubular injury International conference

    Saito A, Ogasawara S, Kurosawa H, Takeda T, Iino N, Sato H, Suzuki Y, Asanuma K, Tomino Y, Narita I, Gejyo F, Hirayama Y, Sekine S

    ISN Nexus-The Kidney and the Vascular System: Emerging Culprits in Pathogenesis and Advances in Therapy  2010.4 

     More details

    Language:English  

    researchmap

  • 2型糖尿病とインクレチン療法

    斎藤 亮彦

    加茂市医師会学術講演会  2010.3 

     More details

    Language:Japanese  

    researchmap

  • LH-RH誘導体使用後,HbAlcの急上昇を認めた2型糖尿病の一例

    竹山綾, 蒲澤秀門, 飯野則昭, 竹田徹朗, 坂爪実, 成田一衛, 斎藤亮彦, 鈴木芳樹

    第39回新潟糖尿病談話会  2010.2 

     More details

    Language:Japanese  

    researchmap

  • IgA腎症における尿中メガリン測定の意義

    小笠原真也, 黒澤寛之, 竹田徹朗, 飯野則昭, 佐藤博慶, 浅沼克彦, 富野康日己, 山縣邦弘, 成田一衛, 平山吉朗, 関根盛, 斎藤亮彦

    第33回IgA腎症研究会  2010.1 

     More details

    Language:Japanese  

    researchmap

  • Stevens-Johnson症候群の治療経過中に急激に血糖コントロールが悪化した2型糖尿病血液透析患者の1例

    斎藤 亮彦

    第40回新潟糖尿病談話会  2010 

     More details

    Language:Japanese  

    researchmap

  • 多剤併用にもかかわらず血圧コントロール不良の糖尿病性腎症 第4期の1例

    蒲澤秀門, 竹田徹朗, 斎藤亮彦, 鈴木芳樹, 成田一衛

    第4回高血圧と糖尿病研究会  2010 

     More details

    Language:Japanese  

    researchmap

  • 尿中メガリン測定系の構築とその評価—2つの異なるCKDバイオマーカーとしての尿中メガリン排泄様式

    小笠原真也, 黒澤寛之, 竹田徹朗, 飯野則昭, 佐藤博慶, 鈴木芳樹, 浅沼克彦, 富野康日己, 山縣邦弘, 成田一衛, 下条文武, 平山吉朗, 関根盛, 斎藤亮彦

    第10回腎不全病態治療研究会  2009.12 

     More details

    Language:Japanese  

    researchmap

  • 尿中メガリン測定系の構築とその評価—糖尿病性腎症の2つの異なるバイオマーカーとしての尿中メガリン排泄様式

    小笠原真也, 黒澤寛之, 竹田徹朗, 飯野則昭, 佐藤博慶, 鈴木芳樹, 浅沼克彦, 富野康日己, 山縣邦弘, 成田一衛, 下条文武, 平山吉朗, 関根盛, 斎藤亮彦

    第21回日本糖尿病性腎症研究会  2009.12 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の発症・進展機序とメガリン

    斎藤 亮彦

    1回Advans研究会  2009.12 

     More details

    Language:Japanese  

    researchmap

  • 新潟から見る 食・健康・文化

    斎藤 亮彦

    フードメッセ in 新潟  2009.11 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病治療のABCD

    斎藤 亮彦

    五泉市東蒲原郡医師会講演会  2009.10 

     More details

    Language:Japanese  

    researchmap

  • 肥満者に対する低カロリー食によるアルブミン尿の減少効果は尿酸排泄率(FEUA)の改善および血清レプチンの低下と関連する

    竹田徹朗, 山本佳子, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 成田一衛

    第47回新潟腎臓懇話会  2009.10 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の発症・進展機序:糸球体・血管系と尿細管・間質系の相互作用

    斎藤 亮彦

    茨城糖尿病性腎症研究会  2009.10 

     More details

    Language:Japanese  

    researchmap

  • Establishment of ELISA system to evaluate ectodomain and full-length forms of megalin shed in human urine International conference

    Ogasawara S, Kurosawa H, Takeda T, Iino N, Sato H, Suzuki Y, Asanuma K, Tomino Y, Yamagata K, Narita I, Gejyo F, Hirayama Y, Sekine S, Saito A

    42nd Annual Meeting of American Society of Nephrology 2009  2009.10 

     More details

    Language:English  

    researchmap

  • 腎臓における低分子量蛋白の代謝に関する最新のトピックス

    斎藤 亮彦

    第41回日本臨床検査自動化学会  2009.10 

     More details

    Language:Japanese  

    researchmap

  • Calorie diet reduces albuminuria in proportion to the improvement in serum leptin level and fractional excretion of uric acid in obese men International conference

    Takeda T, Yamamoto K, Iino N, Narita I, Saito A

    42nd Annual Meeting of American Society of Nephrology 2009  2009.10 

     More details

    Language:English  

    researchmap

  • 血液透析導入後,ウイルス性腸炎から肥満が改善し,透析を離脱している糖尿病性腎症の1例

    渡邊要, 三浦隆義, 金子佳賢, 後藤眞, 竹田徹朗, 斎藤亮彦, 鈴木芳樹, 成田一衛

    第16回新潟糖尿病性腎症研究会  2009.9 

     More details

    Language:Japanese  

    researchmap

  • 腎内アンジオテンシン系の活性化機序

    清水昭博, 松阪泰二, 新村文男, 市川家國, 斎藤亮彦, 西山成

    第15回分子腎臓研究会  2009.9 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の発症機序と予防のABCD

    斎藤亮彦

    第19回新潟糖尿尿スタッフセミナー  2009.8 

     More details

    Language:Japanese  

    researchmap

  • 培養近位尿細管上皮細胞におけるGlucose, Insulin, EGF, Ang IIによるMegalinの発現調整機構

    佐藤博慶, 山本佳子, 細島康宏, 相馬多恵子, 鈴木哲世, 蒲澤秀門, 竹山綾, 笹川泰司, 生山健児, 塩田友也, 飯野則昭, 竹田徹朗, 鈴木芳樹, 下条文武, 斎藤亮彦

    第52回日本腎臓学会学術総会  2009.6 

     More details

    Language:Japanese  

    researchmap

  • Megalin, Cubilin, Amnionless遺伝子安定発現MDCK細胞の樹立

    鈴木哲世, 竹田徹朗, 佐藤博慶, 笹川泰司, 蒲澤秀門, 竹山綾, 山本佳子, 細島康宏, 相馬多恵子, 飯野則昭, 鈴木芳樹, 下条文武, 斎藤亮彦

    第52回日本腎臓学会学術総会  2009.6 

     More details

    Language:Japanese  

    researchmap

  • LPSによる培養近位尿細管細胞におけるmegalinの発現調節

    竹山綾, 佐藤博慶, 相馬多恵子, 蒲澤秀門, 山本佳子, 笹川泰司, 飯野則昭, 竹田徹朗, 鈴木芳樹, 下条文武, 斎藤亮彦

    第52回日本腎臓学会学術総会  2009.6 

     More details

    Language:Japanese  

    researchmap

  • IgG4関連腎症の長期臨床経過

    佐伯敬子, 今井尚史, 伊藤朋之, 山崎肇, 本間則行, 鈴木健介, 斎藤亮彦

    第52回日本腎臓学会学術総会  2009.6 

     More details

    Language:Japanese  

    researchmap

  • マウス近位尿細管におけるMegalinを介したタンパク取り込みのin vivoイメージング

    生山健児, 蒲澤秀門, 佐藤博慶, 山本佳子, 竹山綾, 笹川泰司, 細島康宏, 飯野則昭, 竹田徹朗, 鈴木芳樹, 追手巍, 下条文武, 斎藤亮彦

    第52回日本腎臓学会学術総会  2009.6 

     More details

    Language:Japanese  

    researchmap

  • 膠原病と1型糖尿病を合併した2例についての検討

    山本佳子, 坂巻裕一, 石黒美穂子, 小林大介, 細島康宏, 和田庸子, 飯野則昭, 村上修一, 竹田徹朗, 鈴木芳樹, 中野正明, 斎藤亮彦, 下條文武

    第52回日本糖尿病学会年次学術集会  2009.5 

     More details

    Language:Japanese  

    researchmap

  • 培養近位尿細管上皮細胞におけるGlucose-Insulin-Ang IIシグナル相互作用によるMegalinの発現調節機構

    佐藤博慶, 細島康宏, 山本佳子, 相馬多恵子, 鈴木哲世, 蒲澤秀門, 竹山綾, 笹川泰司, 生山健児, 塩田友也, 飯野則昭, 竹田徹朗, 鈴木芳樹, 下條文武, 斎藤亮彦

    第52回日本糖尿病学会年次学術集会  2009.5 

     More details

    Language:Japanese  

    researchmap

  • Effects of lifestyle modification with combibnes aerobic and resistance exercise on urinary albmin excretion in the population with metabolic syndrome International conference

    Yamamoto K, Hosojima M, Saito M, Tanaka J, Hashiba M, Iino N, Takeda T, Suzuki Y, Gejyo F, Arakawa M, Saito A

    3rd International Congress on Prediabetes and the Metabolic Syndrome  2009.4 

     More details

    Language:English  

    researchmap

  • The efficacy of pioglitazone on the plasma asiponectin level and glucose control in patients with steroid-induced diabetes International conference

    Kaseda R, Hosojima M, Yamamoto K, Iino N, Takeda T, Suzuki Y, Saito A

    3rd International Congress on Prediabetes and the Metabolic Syndrome  2009.4 

     More details

    Language:English  

    researchmap

  • 糖尿病,高血圧の診療中に微小変化型ネフローゼ症候群を合併した高齢者の一例

    清野洋, 坂巻裕一, 金子佳賢, 後藤眞, 竹田徹朗, 西慎一, 斎藤亮彦, 鈴木芳樹

    第三回高血圧と糖尿病研究会  2009.3 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の発症・進展機序:近位尿細管機能異常を1つの起点として

    斎藤 亮彦

    第16回明日の腎臓病糖尿病を考える若手の会  2009.3 

     More details

    Language:Japanese  

    researchmap

  • 強皮症と皮膚筋炎のオーバーラップ症候群に1型糖尿病を合併した1例

    細島康宏, 竹田徹朗, 竹山綾, 蒲澤秀門, 山本佳子, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下條文武

    第38回新潟糖尿病談話会  2009.2 

     More details

    Language:Japanese  

    researchmap

  • 肥満者に対するフォーミュラ食を用いた減量プログラムによるアルブミン尿の減少効果

    竹田徹朗, 山本佳子, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武

    第106回日本内科学会講演会  2009.2 

     More details

    Language:Japanese  

    researchmap

  • 食後高血糖の病態とその治療

    斎藤 亮彦

    村上市岩船郡医師会学術講演会  2009.2 

     More details

    Language:Japanese  

    researchmap

  • 生活習慣病から身を守るABCD

    斎藤 亮彦

    新潟「食と健康」フォーラム  2009.2 

     More details

    Language:Japanese  

    researchmap

  • 強皮症と皮膚筋炎のオーバーラップ症候群に1型糖尿病を合併した一例

    石黒美穂子, 細島康宏, 竹山綾, 蒲澤秀門, 山本佳子, 飯野則昭, 竹田徹朗, 斎藤亮彦, 鈴木芳樹, 下条文武

    第46回日本糖尿病学会間等甲信越地方会  2009.1 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病・メタボリックシンドロームと血管障害

    斎藤 亮彦

    Stroke Conference −脳卒中予防のために!糖尿病治療の観点から−  2008.12 

     More details

    Language:Japanese  

    researchmap

  • 肥満者に対する減量プログラムは尿中アルブミンを減少させる

    竹田徹朗, 山本佳子, 細島康宏, 竹山綾, 蒲澤秀門, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武

    日本糖尿病性腎症研究会  2008.12 

     More details

    Language:Japanese  

    researchmap

  • 慢性腎臓病の新規発症に関わる危険因子の検討

    飯野則昭, 成田一衛, 下条文武, 斎藤亮彦

    日本糖尿病性腎症研究会  2008.12 

     More details

    Language:Japanese  

    researchmap

  • 本型米食の医学的意義

    斎藤 亮彦

    食と花の世界フォーラムにいがた2008 食と健康の国際会議 食と健康の新潟国際フォーラム  2008.11 

     More details

    Language:Japanese  

    researchmap

  • Predictive factors for the development of CKD in the general Japanese population International conference

    Iino N, Narita I, Saito A, Gejyo F

    41st Annual Meeting of American Society of Nephrology 2008  2008.11 

     More details

    Language:English  

    researchmap

  • 糖尿病腎症と高血圧治療

    斎藤 亮彦

    第136回小千谷市魚沼市川口町地区学術講演会  2008.9 

     More details

    Language:Japanese  

    researchmap

  • 肥満者に対するフォーミュラ食を用いた低エネルギー食による尿中アルブミン排泄量の減少効果

    竹田徹朗, 山本佳子, 細島康宏, 竹山綾, 蒲澤秀門, 下条文武, 飯野則昭, 斎藤亮彦, 鈴木芳樹

    第19回新潟糖尿病臨床研究会  2008.9 

     More details

    Language:Japanese  

    researchmap

  • 有酸素およびレジスタンス運動療法を含む生活習慣指導による尿中アルブミン排泄量の減少効果

    山本佳子, 細島康宏, 忰田亮平, 飯野則昭, 田中純太, 竹田徹朗, 斎藤亮彦, 鈴木芳樹, 下条文武, 荒川正昭

    第19回新潟糖尿病臨床研究会  2008.9 

     More details

    Language:Japanese  

    researchmap

  • 大規模疫学データを用いた慢性腎臓病の新規発症に関わる危険因子の検討

    飯野則昭, 山本桂子, 竹田徹朗, 成田一衛, 鈴木芳樹, 下条文武, 斎藤亮彦

    第15回新潟糖尿病性腎症研究会  2008.9 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病の経過中にMPO-ANCAによる腎機能悪化が疑われた1例

    飯野則昭, 山本佳子, 大森健太郎, 竹田徹朗, 成田一衛, 下条文武, 斎藤亮彦

    第19回新潟糖尿病臨床研究会  2008.9 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症と高血圧の発症機序:近位尿細管機能異常をひとつの起点として

    斎藤 亮彦

    Hypertension Forum  2008.8 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病治療と腎症の予防

    斎藤 亮彦

    中魚沼郡学術講演会  2008.6 

     More details

    Language:Japanese  

    researchmap

  • Angiotensin II and insulin-mediated signaling pathways that regulate the expression of megalin in cultured proximal tubule cells International conference

    Hosojima M, Iino N, Kobayashi A, Soma T, Sato H, Takeda T, Nishiyama A, Thekkumkara TJ, Suzuki Y, Gejyo F, Saito A

    ISN Nexus-Linking Research to Practice Diabetes and the Kidney  2008.6 

     More details

    Language:English  

    researchmap

  • 肥満者に対するフォーミュラ食を用いた減量によるアディポサイトカイン・尿中アルブミンの変動

    竹田徹朗, 山本佳子, 細島康宏, 竹山綾, 蒲澤秀門, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武

    第51回日本腎臓学会学術総会  2008.5 

     More details

    Language:Japanese  

    researchmap

  • Dent病責任遺伝子(CLCN5)G333Rミスセンス変異による糖鎖修飾異常

    佐藤博慶, 田沼厚人, 竹田徹朗, 細島康宏, 鈴木哲世, 山本佳子, 飯野則昭, 下条文武, 斎藤亮彦

    第51回日本腎臓学会学術総会  2008.5 

     More details

    Language:Japanese  

    researchmap

  • 慢性腎臓病を発症する危険因子を大規模検診データから明らかにする横断研究

    飯野則昭, 成田一衛, 下条文武, 斎藤亮彦

    第51回日本腎臓学会学術総会  2008.5 

     More details

    Language:Japanese  

    researchmap

  • メタボリック症候群による尿細管障害機序

    斎藤 亮彦

    第51回日本腎臓学会学術総会  2008.5 

     More details

    Language:Japanese  

    researchmap

  • Anemia is a predictive factor for the development of CKD only in man, but not in women, of general Japanese population International conference

    Iino N, Narita I, Saito A, Gejyo F

    11th Asian Pacific Congress of Nephrology  2008.5 

     More details

    Language:English  

    researchmap

  • 肥満者に対するフォーミュラ食を用いた低エネルギー食による尿中アルブミン排泄量の減少効果

    竹田徹朗, 山本佳子, 細島康宏, 竹山綾, 蒲澤秀門, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武

    第51回日本糖尿病学会年次学術会議  2008.5 

     More details

    Language:Japanese  

    researchmap

  • Angiotensin IIおよびInsulinによる近位尿細管上皮細胞機能分子群の細胞内輸送機序の解析

    山本佳子, 細島康宏, 佐藤博慶, 蒲澤秀門, 竹山綾, 飯野則昭, 竹田徹朗, 鈴木芳樹, 下条文武, 斎藤亮彦

    第51回日本腎臓学会学術総会  2008.5 

     More details

    Language:Japanese  

    researchmap

  • 『慢性腎臓病新規発症に関わる高血圧,糖尿病などの各種危険因子の役割 −新潟県の人間ドック受診者からの解析−』

    飯野則昭, 竹田徹朗, 成田一衛, 鈴木芳樹, 斎藤亮彦, 下条文武

    新潟県医師会生涯学習講座 第二回高血圧と糖尿病研究会  2008.3 

     More details

    Language:Japanese  

    researchmap

  • 生体腎移植後,妊娠・出産された1型糖尿病の一例

    竹田徹朗, 細島康宏, 山本卓, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武

    第37回新潟糖尿病談話会  2008.3 

     More details

    Language:Japanese  

    researchmap

  • 無治療糖尿病患者に合併した気腫性腎盂炎の一例

    小林大介, 大滝恭弘, 藤村健夫, 中枝武司, 村上修一, 竹田徹朗, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武

    第37回新潟糖尿病談話会  2008.3 

     More details

    Language:Japanese  

    researchmap

  • 腎臓の蛋白代謝機構とメガリン

    斎藤 亮彦

    第43回信州腎セミナー  2008.3 

     More details

    Language:Japanese  

    researchmap

  • Angiotensin II および Insulinによる近位尿細管上皮細胞機能分子群の複合的調節機構の解析

    山本佳子, 細島康宏, 忰田亮平, 佐藤博慶, 蒲澤秀門, 竹山綾, 相馬多恵子, 飯野則昭, 竹田徹朗, 鈴木芳樹, 下条文武, 斎藤亮彦

    第51回日本糖尿病学会年次学術会議  2008 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管上皮細胞による代謝と循環 動態調節機構:CKDの病態との関連

    斎藤 亮彦

    KAGAWA Expert Meeting  2007.12 

     More details

    Language:Japanese  

    researchmap

  • アンジオテンシンⅡおよびインスリンシグナルを介した近位尿細管エンドサイトーシス受容体メガリンとその関連分子の機能調節

    斎藤亮彦, 細島康宏, 山本佳子, 佐藤博慶, 小林麻子, 相馬多恵子, 飯野則昭, 竹田徹朗, 西山成, 鈴木芳樹, 下条文武

    第19回日本糖尿病性腎症研究会  2007.12 

     More details

    Language:Japanese  

    researchmap

  • 基調講演 食と健康−糖尿病・メタボリックシンドロームの予防と合併症の対策について

    斎藤 亮彦

    第2回NBRP抗加齢食品開発セミナー 新潟バイオリサーチパークフォーラム  2007.11 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 慢性腎臓病(CKD)の病態

    斎藤 亮彦

    形態部門 一般検査領域研修会  2007.11 

     More details

    Language:Japanese  

    researchmap

  • 心不全に対する積極的介入によりエリスロポイエチン抵抗性貧血が改善した腹膜透析の一例

    飯野則昭, 後藤眞, 山本卓, 丸山弘樹, 下条文武, 斎藤亮彦

    第23回新潟CAPDセミナー  2007.11 

     More details

    Language:Japanese  

    researchmap

  • 2型糖尿病にIgA腎症を合併した一例

    亀田茂美, 井口昭, 近藤大介, 忰田亮平, 大森健太郎, 飯野則昭, 竹田徹朗, 斎藤亮彦, 鈴木芳樹, 下条文武

    第43回新潟腎臓懇話会  2007.11 

     More details

    Language:Japanese  

    researchmap

  • メガリンの機能と腎傷害

    斎藤 亮彦

    第1回川島腎糸球体カンファレンス  2007.11 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 生活習慣病に関連する慢性腎臓病

    斎藤 亮彦

    第635回新潟医学会  2007.10 

     More details

    Language:Japanese  

    researchmap

  • Megalin mediates tubule injury induced by proteinuria International conference

    Motoyoshi Y, Matsusaka T, Saito A, Willnow TE, Ichiawa I

    40th Annual Meeting of American Society of Nephrology 2007  2007.10 

     More details

    Language:English  

    researchmap

  • Angiotensin II and insulin-mediated signaling cross-talks for the expression of megalin in cultured proximal tubule cells International conference

    Hosojima M, Iino N, Kobayashi A, Kaseda R, Nishiyama A, Thekkumkara TJ, Takeda T, Gejyo F, Saito A

    40th Annual Meeting of American Society of Nephrology 2007  2007.10 

     More details

    Language:English  

    researchmap

  • Effects of combined aerobic and resistance exercise on albuminuria: Analysis of parameters associated with its reduction International conference

    Yamamoto K, Hosojima M, Saito M, Tanaka J, Hashiba M, Iino N, Takeda T, Suzuki Y, Gejyo F, Saito A, Arakawa M

    40th Annual Meeting of American Society of Nephrology 2007  2007.10 

     More details

    Language:English  

    researchmap

  • 食にまつわる健康の問題:糖尿病・メタボリックシンドロームの予防と合併症の対策

    斎藤 亮彦

    食と花の世界フォーラム にいがた2007  2007.10 

     More details

    Language:Japanese  

    researchmap

  • アンジオテンシンⅡおよびインスリンシグナルの拮抗的クロストークを介したメガリンの発現調節機構

    細島康宏, 飯野則昭, 小林麻子, 忰田亮平, 山本佳子, 鈴木哲世, 笠井綾香, 竹田徹朗, 西山成, 鈴木芳樹, 下条文武, 斎藤亮彦

    第14回新潟糖尿病性腎症研究会  2007.9 

     More details

    Language:Japanese  

    researchmap

  • 若年性2型糖尿病にIgA腎症を合併した一例

    井口昭, 近藤大介, 忰田亮平, 大森健太郎, 飯野則昭, 竹田徹朗, 今井直史, 西慎一, 斎藤亮彦, 鈴木芳樹, 下条文武

    第18回新潟糖尿病臨床研究会  2007.9 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドロームの概念について

    斎藤 亮彦

    (財)社会保険健康事業財団 保健指導者研修会  2007.8 

     More details

    Language:Japanese  

    researchmap

  • 生活習慣病とCKD

    斎藤 亮彦

    旧三市中蒲東蒲地区講演会  2007.7 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 血管保護を考えた糖尿病の薬物療法

    斎藤 亮彦

    脳・糖尿病エキスパートミーティング  2007.7 

     More details

    Language:Japanese  

    researchmap

  • 新潟県下越地方における透析患者の糖尿病治療の実態

    竹田徹朗, 山本佳子, 細島康宏, 忰田亮平, 保坂聖子, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武

    第52回日本透析医学会学術集会・総会  2007.6 

     More details

    Language:Japanese  

    researchmap

  • amnionlessの細胞膜発現に対するmegalinの役割

    鈴木哲世, 竹田徹朗, 笠井綾香, 山本佳子, 細島康宏, 小林麻子, 飯野則昭, 鈴木芳樹, 下条文武, 斎藤亮彦

    第50回日本腎臓学会学術総会  2007.5 

     More details

    Language:Japanese  

    researchmap

  • 運動療法による尿中アルブミン排泄量の減少効果

    山本佳子, 細島康宏, 忰田亮平, 飯野則昭, 竹田徹朗, 斎藤亮彦, 鈴木芳樹, 下条文武, 荒川正昭

    第50回日本糖尿病学会年次学術集会  2007.5 

     More details

    Language:Japanese  

    researchmap

  • 腎不全患者におけるミチグリニドの薬物動態と有用性

    竹田徹朗, 山本佳子, 細島康宏, 忰田亮平, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武

    第50回日本糖尿病学会年次学術集会  2007.5 

     More details

    Language:Japanese  

    researchmap

  • アンジオテンシンII-AT1a受容体を介するメガリンの発現抑制機構とインスリンによる拮抗作用

    細島康宏, 飯野則昭, 小林麻子, 忰田亮平, 山本佳子, 西山成, 竹田徹朗, 鈴木芳樹, 下条文武, 斎藤亮彦

    第50回日本腎臓学会学術総会  2007.5 

     More details

    Language:Japanese  

    researchmap

  • 自己免疫性膵炎,ミクリッツ病などIgG4関連全身疾患における腎病変の検討

    佐伯敬子, 西慎一, 伊藤朋之, 山崎 肇, 宮村祥二, 今井直史, 上野光博, 斎藤亮彦, 下条文武

    第50回日本腎臓学会学術総会  2007.5 

     More details

    Language:Japanese  

    researchmap

  • シンポジウム メタボリックシンドロームと腎疾患の係わり

    斎藤 亮彦

    第630回新潟医学会  2007.4 

     More details

    Language:Japanese  

    researchmap

  • 生活習慣病と慢性腎臓病(CKD)

    斎藤 亮彦

    第13回新発田地区生活習慣病懇話会  2007.4 

     More details

    Language:Japanese  

    researchmap

  • 著しい高血圧を呈した腎障害をもつ糖尿病患者の一例

    忰田亮平, 近藤大介, 新谷茂樹, 大森健太郎, 竹田徹朗, 成田一衛, 斎藤亮彦, 鈴木芳樹, 下条文武

    第1回高血圧と糖尿病研究会  2007.3 

     More details

    Language:Japanese  

    researchmap

  • ワークショップ 近位尿細管エンドサイトーシス受容体メガリンとCa・P代謝

    斎藤 亮彦

    第18回日本腎性骨症研究会  2007.2 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 糖尿病・メタボリックシンドロームとCKD

    斎藤 亮彦

    新潟市医師会病診連携講演会  2007.2 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 CKD治療におけるARBの用量依存効果に関する研究(DOSEUP Study)

    斎藤 亮彦

    悠腎会  2007.1 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 CKD治療におけるARBの用量依存効果に関する研究(DOSEUP Study)

    斎藤 亮彦

    第6回遊腎会  2007.1 

     More details

    Language:Japanese  

    researchmap

  • 教育講演 腎不全の機序と病態

    斎藤 亮彦

    第39回日本臨床化学会関東甲信越支部新潟分科会研修会  2007.1 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンの機能調節:微量アルブミン尿の出現機序との関連

    斎藤亮彦, 細島康宏, 保坂聖子, 小林麻子, 忰田亮平, 鈴木哲世, 笠井綾香, 山本佳子, 飯野則昭, 竹田徹朗, 鈴木芳樹, 下条文武

    第18回日本糖尿病性腎症研究会  2006.12 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 糖尿病・メタボリックシンドロームと腎障害:近位尿細管上皮細胞の代謝機能調節異常

    斎藤 亮彦

    第628回新潟医学会  2006.12 

     More details

    Language:Japanese  

    researchmap

  • 運動療法が尿中アルブミン排泄に与える効果

    細島康宏, 田中純太, 山本佳子, 羽柴正夫, 斎藤麻里子, 斎藤亮彦, 鈴木芳樹, 下条文武, 荒川正昭

    第17回日本臨床スポーツ医学会学術集会  2006.11 

     More details

    Language:Japanese  

    researchmap

  • 運動後急性腎不全を発症した腎性低尿酸血症の一例

    細島康宏, 竹田徹朗, 田中純太, 山本佳子, 羽柴正夫, 斎藤亮彦, 鈴木芳樹, 下条文武, 荒川正昭

    第17回日本臨床スポーツ医学会学術集会  2006.11 

     More details

    Language:Japanese  

    researchmap

  • Long-term renal prognosis of Japanese patients with obesity/metabolic syndrome-related nephropathy International conference

    Saito A, Ueno M, Hosojima M, Kaseda R, Hosaka K, Iino N, Takeda T, Nishi S, Suzuki Y, Gejyo F

    39th Annual Meeting of American Society of Nephrology  2006.11 

     More details

    Language:English  

    researchmap

  • Megalin-mediated endocytosis of cystatin C, a protein marker of the glomerular filtration rate. International conference

    Kaseda R, Takeda T, Iino N, Hosojima M, Kobayashi A, Hosaka K, Suzuki Y, Gejyo F, Saito A

    39th Annual Meeting of American Society of Nephrology  2006.11 

     More details

    Language:English  

    researchmap

  • 生活習慣病・アンチエイジング(抗加齢医学)等に関する円滑な医療および情報提供サービスシステムの開発レニンーアンジオテンシンーアルドステロン系の新展開

    斎藤 亮彦

    第2回新潟医療関連産学連携交流会  2006.10 

     More details

    Language:Japanese  

    researchmap

  • Overview 腎局所のRAAS-近位尿細管上皮細胞の役割

    斎藤 亮彦

    レニンーアンジオテンシンーアルドステロン系の新展開  2006.9 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管におけるメガリン,キュビリン,Na+/H+交換輸送体の分子間相互作用の解析:糖尿病性腎症の初期病変形成機序との関連

    斎藤亮彦, 細島康宏, 小林麻子, 忰田亮平, 保坂聖子, 鈴木哲世, 笠井綾香, 山本佳子, 飯野則昭, 竹田徹朗, 鈴木芳樹, 下条文武

    第13回新潟糖尿病性腎症研究会  2006.9 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管細胞におけるmegalinのendocytosis機構の解明

    竹田徹朗, 保坂聖子, 小林麻子, 細島康宏, 忰田亮平, 飯野則昭, 下条文武, 斎藤亮彦

    第12回分子腎臓研究会  2006.9 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病・メタボリックシンドロームと腎臓研究

    斎藤 亮彦

    臨床研修医のための新潟腎セミナー2006  2006.8 

     More details

    Language:Japanese  

    researchmap

  • シンポジウム 尿毒素蛋白代謝に関わる機能分子の応用

    斎藤亮彦, 下条文武

    第51回日本透析医学会学術集会・総会  2006.6 

     More details

    Language:Japanese  

    researchmap

  • メガリンのエンドサイトーシス機構におけるnon-muscle myosin heavy chain IIA(NMHC-IIA)の役割

    竹田徹朗, 保坂聖子, 小林麻子, 細島康宏, 忰田亮平, 飯野則昭, 下条文武, 斎藤亮彦

    第49回日本腎臓学会学術総会  2006.6 

     More details

    Language:Japanese  

    researchmap

  • Dent病責遺伝子(CLCN5)G333Rミスセンス変異の細胞内発現異常

    細島康宏, 竹田徹朗, 田沼厚人, 忰田亮平, 保坂聖子, 濱ひとみ, 飯野則昭, 下条文武, 斎藤亮彦

    第49回日本腎臓学会学術総会  2006.6 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドローム関連腎症患者の長期予後

    斎藤亮彦, 上野光博, 忰田亮平, 細島康宏, 保坂聖子, 飯野則昭, 竹田徹朗, 西慎一, 鈴木芳樹, 下条文武

    第49回日本腎臓学会学術総会  2006.6 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管上皮細胞におけるメガリンとNMHC-IIAの分子間相互作用

    保坂聖子, 竹田徹朗, 小林麻子, 飯野則昭, 細島康宏, 忰田亮平, 下条文武, 斎藤亮彦

    第49回日本腎臓学会学術総会  2006.6 

     More details

    Language:Japanese  

    researchmap

  • 新規GFRマーカー,シスタチンCの腎代謝におけるメガリンの役割

    忰田亮平, 竹田徹朗, 飯野則昭, 細島康宏, 小林麻子, 保坂聖子, 鈴木芳樹, 下条文武, 斎藤亮彦

    第49回日本腎臓学会学術総会  2006.6 

     More details

    Language:Japanese  

    researchmap

  • 心腎症候群による末期腎不全に腹膜透析を導入した3例

    飯野則昭, 丸山弘樹, 中村元, 霜鳥正明, 下条文武, 斎藤亮彦

    第51回日本透析医学会学術集会・総会  2006.6 

     More details

    Language:Japanese  

    researchmap

  • 腎臓の病気とその研究

    斎藤 亮彦

    財)佐々木環境技術振興財団 科学技術知識普及事業 工医連携研究促進セミナー  2006.5 

     More details

    Language:Japanese  

    researchmap

  • 肥満・メタボリックシンドローム関連腎症患者の予後(糖尿病合併例を含めて)

    斎藤亮彦, 上野光博, 忰田亮平, 細島康宏, 保坂聖子, 飯野則昭, 竹田徹朗, 西慎一, 鈴木芳樹, 下条文武

    第49回日本糖尿病学会年次学術集会  2006.5 

     More details

    Language:Japanese  

    researchmap

  • モリブデン補酵素硫化酵素(MOCOS)遺伝子異常による著しい低尿酸血症を示した2型糖尿病家系

    竹田徹朗, 田沼厚人, 斎藤亮彦, 成田一衛, 下条文武

    第49回日本糖尿病学会年次学術集会  2006.5 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病を有する透析患者における糖尿病治療の実態

    竹田徹朗, 細島康宏, 忰田亮平, 保坂聖子, 飯野則昭, 斎藤亮彦, 鈴木芳樹, 下条文武, 大森伯, 矢田省吾, 鈴木靖, 五十嵐仁, 惠以盛, 濱ひとみ, 菊地 博, 柄澤良, 長賢治, 岡田雅美

    第48回新潟透析懇話会学術集会  2006.4 

     More details

    Language:Japanese  

    researchmap

  • 原発性腎疾患患者の蛋白尿に対するシルニジピンの効果

    竹田徹朗, 成田一衛, 上野光博, 西慎一, 坂爪実, 斎藤亮彦, 下条文武, 矢田省吾, 濱斉

    2006.4 

     More details

    Language:Japanese  

    researchmap

  • ワークショップ:血清IgG4高値症例の臨床的検討 International conference

    佐伯敬子, 山崎肇, 宮村祥二, 斎藤亮彦, 下条文武

    第50回(中)日本リウマチ学会総会・学術集会/第15回国際リウマチシンポジウム  2006.4 

     More details

    Language:Japanese  

    researchmap

  • Workshop: Clinical features of patients with elevation of serum IgG4 International conference

    Saeki T, Yamazaki H, Miyamura S, Saito A, Gejyo F

    2006.4 

     More details

    Language:English  

    researchmap

  • 著しい高血圧を呈した腎障害をもつ糖尿病患者の一例

    忰田亮平, 近藤大介, 新谷茂樹, 大森健太郎, 竹田徹朗, 成田一衛, 斎藤亮彦, 鈴木芳樹, 下条文武

    第1回高血圧と糖尿病研究会  2006.3 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドロームと腎障害

    斎藤 亮彦

    第9回中越腎カンファレンス学術講演会  2006.3 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドロームと腎障害

    斎藤 亮彦

    第15回糖尿病性腎症セミナー  2006.2 

     More details

    Language:Japanese  

    researchmap

  • 尿毒素蛋白代謝を目的とした細胞移植療法の基礎検討

    斎藤 亮彦

    新潟細胞・再生療法シンポジウム  2006.1 

     More details

    Language:Japanese  

    researchmap

  • 高齢者におけるインスリンリスプロ混合製剤25(ヒューマログミックス25)の使用経験

    細島康宏, 斎藤亮彦, 竹田徹朗, 鈴木涼子, 川村邦雄, 吉嶺文俊, 鈴木芳樹, 下条文武

    第43回日本糖尿病学会関東甲信越地方会  2006.1 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 近位尿細管のエンドサイトーシス機構と関連疾患

    斎藤 亮彦

    第72回関東小児腎臓病研究会  2005.12 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 尿毒素蛋白代謝を目的とした腎機能再生

    斎藤 亮彦

    ハニカムフィルムのメディカル応用に関するフォーラム  2005.12 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドローム関連腎症の病態:蛋白代謝過剰負荷仮説

    斎藤亮彦, 竹田徹朗, 小林麻子, 小山裕子, 濱ひとみ, 田沼厚人, 保坂聖子, 忰田亮平, 細島康宏, 飯野則昭, 上野光博, 西 慎一, 鈴木芳樹, 下条文武

    第17回日本糖尿病性腎症研究会  2005.12 

     More details

    Language:Japanese  

    researchmap

  • ARI-Diabetes Complications Trial (ADCT) 結果報告

    斎藤 亮彦

    新潟糖尿病合併症フォーラム  2005.11 

     More details

    Language:Japanese  

    researchmap

  • Non-muscle myosin heavy chain IIA is involved in endocytosis of megalin through the interaction with Dab2 in proximal tubular cells International conference

    Takeda T, Hosaka K, Kobayashi A, Kaseda R, Gejyo F, Saito A

    38th Annual Meeting of the American Society of Nephrology  2005.11 

     More details

    Language:English  

    researchmap

  • 運動療法介入が尿中ポリオール代謝産物に与える影響について

    細島康宏, 田中純太, 羽柴正夫, 長崎浩爾, 齋藤麻里子, 竹田徹朗, 斎藤亮彦, 下条文武, 荒川正昭

    第16回日本臨床スポーツ医学会学術集会  2005.11 

     More details

    Language:Japanese  

    researchmap

  • エンドサイトーシス受容体メガリンと関連分子の相互作用:腎臓の蛋白代謝機構とその病態

    斎藤亮彦, 竹田徹朗, 永井雅昭, 下条文武

    文部科学省科学研究費補助金特定領域研究「メンブレントラフィック−分子機構から分子機構から高次機能への展開−」第3回全体班会議  2005.11 

     More details

    Language:Japanese  

    researchmap

  • ミニレクチャー 尿酸代謝と腎 −メタボリックシンドロームの観点から−

    斎藤 亮彦

    第3回新潟尿酸代謝フォーラム  2005.10 

     More details

    Language:Japanese  

    researchmap

  • 腎障害合併高血圧症患者の蛋白尿に対するシルニジピンの効果

    竹田徹朗, 成田一衛, 上野光博, 西 慎一, 近藤大介, 坂爪実, 風間順一郎, 丸山弘樹, 斎藤亮彦, 下条文武, 濱齊

    第28回日本高血圧学会総会  2005.9 

     More details

    Language:Japanese  

    researchmap

  • メタボリックシンドロームに関連する腎症と高血圧の発症機序:蛋白代謝過剰負荷仮説

    斎藤亮彦, 竹田徹朗, 小山裕子, 濱ひとみ, 田沼厚人, 保坂聖子, 忰田亮平, 細島康宏, 飯野則昭, 鈴木芳樹, 下条文武

    第12回新潟糖尿病性腎症研究会  2005.9 

     More details

    Language:Japanese  

    researchmap

  • エンドサイトーシス受容体メガリンを利用した腹膜透析合併症の予防法の開発

    斎藤 亮彦

    2004年度腹膜機能リサーチ研究報告会  2005.7 

     More details

    Language:Japanese  

    researchmap

  • 種々の近位尿細管上皮細胞(PTC)におけるグリセルアルデヒド由来AGEのエンドサイトーシス機構の解析

    佐藤聖子, 竹田徹朗, 濱ひとみ, 田沼厚人, 悴田亮平, 鈴木芳樹, 竹内正義, 下条文武, 斎藤亮彦

    第48回日本腎臓学会学術総会  2005.6 

     More details

    Language:Japanese  

    researchmap

  • IgG4関連間質性腎炎

    佐伯敬子, 斎藤亮彦, 山崎肇, 上野光博, 宮村祥二, 下条文武

    第48回日本腎臓学会学術総会  2005.6 

     More details

    Language:Japanese  

    researchmap

  • シンポジウム 近位尿細管における蛋白再吸収・代謝機構とメガリンの役割

    斎藤亮彦, 竹田徹朗, 小山裕子, 濱ひとみ, 田沼厚人, 下条文武

    第48回日本腎臓学会学術総会  2005.6 

     More details

    Language:Japanese  

    researchmap

  • 非免疫性糸球体肥大を呈する症例の臨床病態解析:メタボリック症候群関連腎症

    斎藤亮彦, 竹田徹朗, 小山裕子, 濱ひとみ, 田沼厚人, 下条文武

    第48回日本腎臓学会学術総会  2005.6 

     More details

    Language:Japanese  

    researchmap

  • Podocyte cytoskeleton is connected to the integral membrane protein, podocalyxin

    Takeda T, Farquhar MG

    2005.6 

     More details

    Language:English  

    researchmap

  • 肝から血中に放出された肝型脂肪酸結合蛋白(L-FABP)の腎への集積機序

    竹田徹朗, 小山裕子, 濱ひとみ, 田沼厚人, 悴田亮平, 佐藤聖子, 下条文武, 斎藤亮彦

    第48回日本腎臓学会学術総会  2005.6 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管上皮細胞におけるグリセルアルデヒド由来AGEのエンドサイトーシス機構とメガリンの役割

    竹田徹朗, 佐藤聖子, 濱ひとみ, 忰田亮平, 田沼厚人, 鈴木芳樹, 竹内正義, 下条文武, 斎藤亮彦

    第48回日本糖尿病学会年次学術集会  2005.5 

     More details

    Language:Japanese  

    researchmap

  • メガリンを介するレプチン,L-FARBの近位尿細管での取り込み代謝:糖尿病・メタボリック症候群における腎代謝負荷機構

    斎藤亮彦, 竹田徹朗, 濱ひとみ, 小山裕子, 田沼厚人, 佐藤聖子, 忰田亮平, 鈴木芳樹, 下条文武

    第48回日本糖尿病学会年次学術集会  2005.5 

     More details

    Language:Japanese  

    researchmap

  • 腎臓におけるレプチンの代謝と作用機序

    濱ひとみ, 斎藤亮彦, 竹田徹朗, 田沼厚人, 保坂聖子, 忰田亮平, 鈴木芳樹, 下条文武

    第9回新潟県糖尿病勉強会  2005.4 

     More details

    Language:Japanese  

    researchmap

  • IgG4-related lymphoplasmacytic disease International conference

    Saeki T, Saito A, Yamazaki H, Ueno M, Miyamura S, Gejyo F

    The 49th Annual Scientific Meeting and The 14th International Rheumatology Symposium  2005.4 

     More details

    Language:English  

    researchmap

  • IgG4関連リンパ球,形質細胞増殖性疾患

    佐伯敬子, 斎藤亮彦, 山崎肇, 上野光博, 宮村祥二, 下条文武

    第49回日本リウマチ学会総会・学術集会/第14回国際リウマチシンポジウム  2005.4 

     More details

    Language:Japanese  

    researchmap

  • Role of megalin, a proximal tubular endocytotic receptor, in the pathogenesis of diabetic and metabolic syndrome-related nephropathies. International conference

    Saito A, Takeda T, Hama H, Oyama Y, Sato K, Tanuma A, Kaseda R, Ueno M, Nishi S, Suzuki Y, Gejyo F

    3rd Korea Japan Nephrology Forum  2005.3 

     More details

    Language:English  

    researchmap

  • メタボリック症候群に関する腎症:蛋白代謝過剰負荷の分子機構

    斎藤亮彦, 竹田徹朗, 小山裕子, 濱ひとみ, 田沼厚人, 佐藤聖子, 忰田亮平, 上野光博, 西 慎一, 鈴木芳樹, 下条文武

    第11回動脈硬化症成因治療研究会  2005.3 

     More details

    Language:Japanese  

    researchmap

  • 12年間放置した結果著名な浮腫を来たし透析導入に至った若年発症の2型糖尿病の一例

    井口清太郎, 竹田徹朗, 斎藤亮彦, 下条文武

    第34回新潟糖尿病談話会  2005.3 

     More details

    Language:Japanese  

    researchmap

  • 腎障害合併高血圧患者に対するシルニジピンの効果

    竹田徹朗, 成田一衛, 上野光博, 西 慎一, 近藤大介, 坂爪 実, 丸山弘樹, 風間順一郎, 斎藤亮彦, 下条文武, 太田隆志, 津田晶子, 矢田省吾, 濱齊, 大原一彦, 荻野宗次郎

    新潟N型カルシウムチャネル研究会  2005.3 

     More details

    Language:Japanese  

    researchmap

  • 尿毒素蛋白代謝を目的とした細胞移植療法の基礎検討

    斎藤 亮彦

    新潟細胞・再生療法シンポジウム  2005.1 

     More details

    Language:Japanese  

    researchmap

  • 基調講演 実験膜性腎症抗原メガリン:エンサイドーシス受容体としての特性と病的役割

    斎藤 亮彦

    The Frontiers of Nephrology 2005 in Niigata  2005.1 

     More details

    Language:Japanese  

    researchmap

  • 透析アミロイドーシスに関する研究

    山本卓, 長谷川一浩, 山口格, 斎藤亮彦, 内木宏延, 下条文武

    平成16年度厚生労働省難治性疾患克服研究事業 アミロイド沈着による病的要素の検索に関する研究/アミロイドーシスに関する調査研究合同研究報告会  2005.1 

     More details

    Language:Japanese  

    researchmap

  • 培養近位尿細管上皮細胞を用いたアルデヒド由来AGEの取り込み経路の検討

    斎藤亮彦, 竹田徹朗, 佐藤聖子, 濱ひとみ, 田沼厚人, 忰田亮平, 下条文武, 竹内正義, 鈴木芳樹

    第16回日本糖尿病性腎症研究会  2004.12 

     More details

    Language:Japanese  

    researchmap

  • 高血圧合併糖尿病患者におけるニルバジピンの抗酸化作用

    斎藤亮彦, 竹田徹朗, 田沼厚人, 濱ひとみ, 佐藤聖子, 永井雅昭, 鈴木芳樹, 下条文武

    第34回日本腎臓学会東部学術大会  2004.11 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 糖尿病の薬物療法

    斎藤 亮彦

    三市中蒲東蒲医師会学術講演会  2004.10 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリン介するAGE代謝経路:治療のターゲットとなるか?

    斎藤 亮彦

    第19回日本糖尿病合併症学会  2004.10 

     More details

    Language:Japanese  

    researchmap

  • 特別講演 糖尿病性腎症の発症機序と対策

    斎藤 亮彦

    三共製薬 外部講師研修会  2004.9 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管上皮細胞におけるアルデヒド由来AGEの取り込み・代謝機構とメガリンの役割

    佐藤聖子, 竹田徹朗, 田沼厚人, 濱ひとみ, 忰田亮平, 今井直史, 鈴木芳樹, 下条文武, 斎藤亮彦

    第11回新潟糖尿病性腎症研究会  2004.9 

     More details

    Language:Japanese  

    researchmap

  • Cellular uptake of glyceraldehyde-and glycolaldehyde-modified AGE via megalin, a proximal tublar endocytosis receptor International conference

    Saito A, Sato K, Takeda T, Tanuma A, Hama H, Nagai M, Takeuchi M, Horiuchi S, Gejyo F

    The 8th International Symposium on the Maillard Reaction  2004.8 

     More details

    Language:English  

    researchmap

  • 特別講演 エンドサイトーシス受容体メガリン:糖尿病性腎症および尿毒症病態における役割と臨床的応用性

    斎藤 亮彦

    第604回新潟医学会  2004.7 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症の発症機序と対策

    斎藤 亮彦

    2004年上越地区糖尿病合併症研究会  2004.7 

     More details

    Language:Japanese  

    researchmap

  • ラミニンA鎖コア蛋白は,advanced glycation end product(AGE)結合性を有する

    田沼厚人, 斎藤亮彦, 濱ひとみ, 佐藤聖子, 永井雅昭, 竹田徹朗, 吉田豊, 戸田年総, 堀内正公, 下条文武

    第47回日本腎臓学会学術総会  2004.5 

     More details

    Language:Japanese  

    researchmap

  • 水晶発振子マイクロバランス法(Affinix Q)を用いたメガリンの尿毒素リガンドとの結合解析

    斎藤亮彦, 濱ひとみ, 佐藤聖子, 田沼厚人, 永井雅昭, 竹田徹朗, 下条文武

    第47回日本腎臓学会学術総会  2004.5 

     More details

    Language:Japanese  

    researchmap

  • メガリンーキュビリン共役系の解析:トランスフェリン取り込みに関与するキュビリンの機能的領域の同定

    濱ひとみ, 竹田徹朗, 田沼厚人, 佐藤聖子, 永井雅昭, 下条文武, 斎藤亮彦

    第47回日本腎臓学会学術総会  2004.5 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンによる各種AGEの結合および細胞内取り込み機構

    佐藤聖子, 斎藤亮彦, 竹田徹朗, 濱ひとみ, 田沼厚人, 永井雅昭, 鈴木芳樹, 下条文武

    第47回日本腎臓学会学術総会  2004.5 

     More details

    Language:Japanese  

    researchmap

  • メガリンのエンドサイトーシスにおけるアダプター蛋白ARHの役割

    永井雅昭, 竹田徹朗, 斎藤亮彦, 下条文武, M. G. Farquhar

    第47回日本腎臓学会学術総会  2004.5 

     More details

    Language:Japanese  

    researchmap

  • 各種AGEの結合・細胞取り込みに関わる近位尿細管エンドサイトーシス受容体メガリンの役割

    斎藤亮彦, 竹田徹朗, 濱ひとみ, 田沼厚人, 佐藤聖子, 永井雅昭, 鈴木芳樹, 竹内正義, 山岸昌一, 堀内正公, 下条文武

    第47回日本糖尿病学会年次学術集会  2004.5 

     More details

    Language:Japanese  

    researchmap

  • 糸球体上皮の形態保持におけるアダプター蛋白NHERF2の役割

    竹田徹朗, 永井雅昭, 斎藤亮彦, 下条文武

    第47回日本腎臓学会学術総会  2004.5 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病による血管内皮障害における接着阻害分子podocalyxin/CD34の役割

    竹田徹朗, 斎藤亮彦, 下条文武

    第47回日本糖尿病学会年次学術集会  2004.5 

     More details

    Language:Japanese  

    researchmap

  • 細胞移植による腎機能の再生

    斎藤 亮彦

    92回日本泌尿器科学会総会  2004.4 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病による血管内皮障害における接着阻害分子podocalxin/CD34の役割

    竹田徹朗, 斎藤亮彦, 下条文武

    第10回動脈硬化症成因治療研究会  2004.3 

     More details

    Language:Japanese  

    researchmap

  • 当院糖尿病外来における睡眠時無呼吸症候群合併症についての検討

    中山秀章, 松山菜穂, 窪田由希子, 竹田徹朗, 斎藤亮彦, 吉澤弘久, 鈴木芳樹, 下条文武

    第33回新潟糖尿病談話会  2004.3 

     More details

    Language:Japanese  

    researchmap

  • 分子間相互作用解析装置AffinixQを用いたエンドサイトーシス受容体メガリンの新規リガンドの探索

    斎藤亮彦, 竹田徹朗, 濱ひとみ, 佐藤聖子, 田沼厚人, 永井雅昭, 下条 文武

    第19回新潟細胞生物学研究会  2004.2 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンと腎疾患の病態・治療

    斎藤 亮彦

    第5回神田川腎セミナー  2004.1 

     More details

    Language:Japanese  

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンを介するAGEの取り込み経路

    斎藤亮彦, 竹田徹朗, 濱ひとみ, 田沼厚人, 佐藤聖子, 下条文武, 鈴木芳樹, 堀内正公

    第15回日本糖尿病性腎症研究会  2003.12 

     More details

    Language:Japanese  

    researchmap

  • 特に腎症の治療について

    斎藤 亮彦

    糖尿病市民セミナー・新潟  2003.11 

     More details

    Language:Japanese  

    researchmap

  • Identification of novel G333R CLCN5 mutation in Dent's disease and decreased megalin expression in the kidney biopsy specimen International conference

    Tanuma A, Saito A, Obayashi H, Takeda T, Hama H, Ueno M, Nishi S, Yamamoto T, Gejyo F

    36th Annual Meeting of American Society of Nephrology 2003  2003.11 

     More details

    Language:English  

    researchmap

  • メガリンを介する尿毒素蛋白の取り組み・代謝機構と治療的応用性

    斎藤亮彦, 濱ひとみ, 田沼厚人, 佐藤聖子, 竹田徹朗, 永井雅昭, 鈴木芳樹, 堀内正公, 下条文武

    第4回腎不全病態治療研究会  2003.11 

     More details

    Language:Japanese  

    researchmap

  • Leptin is a novel endocytic ligand for megalin International conference

    Hama H, Saito A, Takeda T, Tanuma A, Xie Y, Kazama JJ, Gejyo F

    36th Annual Meeting of American Society of Nephrology 2003  2003.11 

     More details

    Language:English  

    researchmap

  • A renal metabolic pathway for liver-type fatty acid-binding protein, a carrier of multiple hydrophobic molecules International conference

    Oyama Y, Takeda T, Hama H, Tanuma A, Iino N, Kazama, JJ Ma M, Yamamoto T, Gejyo F, Saito A

    36th Annual Meeting of American Society of Nephrology 2003  2003.11 

     More details

    Language:English  

    researchmap

  • First PDZ domain is required for NHERF2 dimerization: role of scaffold protein in podocyte International conference

    Takeda T, Nagai M, Saito A, Farquhar MG, Gejyo F

    36th Annual Meeting of American Society of Nephrology 2003  2003.11 

     More details

    Language:English  

    researchmap

  • 抗ヒト免疫不全ウイルス療法中に発症した糖尿病の1例

    竹田徹朗, 斎藤亮彦, 田中由紀子, 西堀武明, 塚田弘樹, 下条文武, 黒川和泉

    第113回日本内科学会信越地方会  2003.10 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病による内皮障害における接着阻害分子podocalyxinの役割

    竹田徹朗, 斎藤亮彦, 下条文武

    第10回新潟糖尿病性腎症研究会  2003.9 

     More details

    Language:Japanese  

    researchmap

  • 著しい骨軟化症を呈した成人発症型Fanconi症候群の一例

    細島康宏, 高田琢磨, 竹田徹朗, 斎藤亮彦, 下条文武

    第33回日本腎臓学会東部学術大会  2003.9 

     More details

    Language:Japanese  

    researchmap

  • 腎に発現する機能分子の応用

    斎藤 亮彦

    第18回新潟腎シンポジウム  2003.8 

     More details

    Language:Japanese  

    researchmap

  • 糖尿病性腎症に対する生体腎移植後,血糖コントロール悪化例に対して超速効型インスリンを用い,その改善をみた一例

    竹田徹朗, 斎藤亮彦, 西慎一, 下条文武, 斎藤和英, 高橋公太

    7回新潟移植再生研究会  2003.5 

     More details

    Language:Japanese  

    researchmap

  • スカベンジャー受容体メガリンの頂側ソーティング機構

    竹田徹朗, 濱ひとみ, 田沼厚人, 斎藤亮彦, 下条文武, M. G. Farquhar

    第46回日本腎臓学会学術総会  2003.5 

     More details

    Language:Japanese  

    researchmap

  • メガリンを介するレプチンの細胞取り込みと代謝

    濱ひとみ, 斎藤亮彦, 田沼厚人, 竹田徹朗, 高田琢磨, 謝院生, 下条文武

    第46回日本腎臓学会学術総会  2003.5 

     More details

    Language:Japanese  

    researchmap

  • メガリンを介する肝型脂肪酸結合蛋白(L-FABP)の細胞取り込みと代謝

    小山裕子, 斎藤亮彦, 竹田徹朗, 田沼厚人, 濱ひとみ, 高田琢磨, 下条文武

    第46回日本腎臓学会学術総会  2003.5 

     More details

    Language:Japanese  

    researchmap

  • メガリンを介したglycolaldehyde-modified AGEの細胞取り組み

    斎藤亮彦, 田沼厚人, 濱ひとみ, 高田琢磨, 竹田徹朗, 鈴木芳樹, 堀内正公, 下条文武

    第46回日本糖尿病学会年次学術集会  2003.5 

     More details

    Language:Japanese  

    researchmap

  • 成人発症型ファンコニー症候群の一例

    細島康宏, 高田琢麿, 竹田徹朗, 斎藤亮彦, 下条文武, 遠藤栄之助, 徳永邦彦, 遠藤直人

    第34回新潟腎臓懇話会  2003.4 

     More details

    Language:Japanese  

    researchmap

  • 細胞移植による腎機能の再生

    斎藤 亮彦

    第92回泌尿器科学会総会  2003.4 

     More details

    Language:Japanese  

    researchmap

  • ステロイド誘発糖尿病に対するナテグリニドの使用経験

    高田琢磨, 伊藤聡, 田中由紀子, 竹田徹朗, 斎藤亮彦, 下条文武, 鈴木芳樹

    新潟ファスティック講演会  2003.3 

     More details

    Language:Japanese  

    researchmap

  • メガリン発現細胞を用いた透析アミロイドーシスの予防療法を開発するための基礎的検討

    斎藤亮彦, 下條文武

    労働省特定疾患対策研究事業 アミロイド沈着による病的要素の検索に関する研究 アミロイドーシスに関する研究調査 平成14年度合同研究報告会  2003.1 

     More details

    Language:Japanese  

    researchmap

▶ display all

Industrial property rights

  • 腎障害の抑制におけるシラスタチンの利用

    斎藤亮彦, 後藤佐和子, 平山吉朗, 関根盛

     More details

    Application no:特願2018-087294  Date applied:2018.11

    Patent/Registration no:特許6548803  Date issued:2019.7

    researchmap

  • 試料中のアンジオテンシンペプチドの量を測定するための方法及びアンジオテンシンペプチドの定量キット

    斎藤亮彦, 吉田豊, 後藤佐和子

     More details

    Application no:特願2017-128700  Date applied:2017.6

    researchmap

  • 幼少期投与用の肥満及び/又は肥満関連腎症予防組成物、幼少期投与用の肥満及び/又は肥満関連腎症予防薬、食品、並びに肥満及び/又は肥満関連腎症を予防する方法

    斎藤亮彦, 細島康宏, 樋口裕樹

     More details

    Application no:特願2017-061684  Date applied:2017.3

    researchmap

  • 米タンパク質を有効成分とする血清尿酸低下剤

    斎藤 亮彦, 細島 康宏, 門脇 基二, 久保田 真敏, 藤井 幹夫, 近藤 葉月

     More details

    Applicant:亀田製菓株式会社

    Application no:特願2015-554716  Date applied:2014.12

    Patent/Registration no:特許第6088071号  Date issued:2017.2

    J-GLOBAL

    researchmap

  • メガリン拮抗剤

    斎藤亮彦, 青木信将, 堀好寿, 桑原頌治, 細島康宏, 岩田博司, 松田砂織

     More details

    Application no:特願2015-559110  Date applied:2014.1

    Patent/Registration no:特許6508655  Date issued:2019.4

    researchmap

  • 米糠タンパク質を含む糖尿病性腎症進展抑制用栄養組成物

    門脇 基二, 久保田 真敏, 斎藤 亮彦, 細島 康宏, 渡邊 令子, 橋本 博之

     More details

    Applicant:国立大学法人 新潟大学, 公立大学法人新潟県立大学, 築野食品工業株式会社

    Application no:特願2013-118021  Date applied:2013.6

    Announcement no:特開2014-233266  Date announced:2014.12

    J-GLOBAL

    researchmap

  • タンパク質栄養組成物

    門脇 基二, 斎藤 亮彦, 細島 康宏, 久保田真敏, 渡邊 令子, 藤井 幹夫

     More details

    Applicant:国立大学法人 新潟大学, 公立大学法人新潟県立大学, 亀田製菓株式会社

    Application no:特願2013-017197  Date applied:2013.1

    Announcement no:特開2014-147315  Date announced:2014.8

    Patent/Registration no:特許第6139150号  Date issued:2017.5

    J-GLOBAL

    researchmap

  • 急性腎障害の検査方法

    斎藤 亮彦, 黒澤 寛之, 平山 吉朗

     More details

    Applicant:国立大学法人 新潟大学, デンカ生研株式会社

    Application no:特願2012-045844  Date applied:2012.3

    Announcement no:特開2013-181830  Date announced:2013.9

    Patent/Registration no:特許第6083937号  Date issued:2017.2

    J-GLOBAL

    researchmap

  • 糖尿病性腎症の検査方法

    原 正則, 斎藤 亮彦, 富野 康日己, 淺沼 克彦, 黒澤 寛之, 小笠原 真也, 平山 吉朗

     More details

    Applicant:原 正則, 国立大学法人 新潟大学, 学校法人順天堂, デンカ生研株式会社

    Application no:特願2011-518307  Date applied:2010.6

    Patent/Registration no:特許第5759372号  Date issued:2015.6

    J-GLOBAL

    researchmap

  • 腎疾患の検査方法

    原 正則, 斎藤 亮彦, 富野 康日己, 淺沼 克彦, 黒澤 寛之, 小笠原 真也, 平山 吉朗

     More details

    Applicant:原 正則, 国立大学法人 新潟大学, 学校法人順天堂, デンカ生研株式会社

    Application no:特願2011-518306  Date applied:2010.6

    Patent/Registration no:特許第5677294号  Date issued:2015.1

    J-GLOBAL

    researchmap

  • 腎障害の検出用マーカーとしての尿中メガリンの使用

    斎藤 亮彦, 富野 康日己, 淺沼 克彦, 小笠原 真也, 黒澤 寛之, 平山 吉朗

     More details

    Applicant:国立大学法人 新潟大学, 学校法人順天堂, デンカ生研株式会社

    Application no:特願2011-511418  Date applied:2010.4

    Patent/Registration no:特許第5694145号  Date issued:2015.2

    J-GLOBAL

    researchmap

  • 尿中ヒトメガリンを測定することを含む腎疾患検出方法

    斎藤 亮彦, 富野 康日己, 淺沼 克彦, 小笠原 真也, 黒澤 寛之, 平山 吉朗

     More details

    Applicant:国立大学法人 新潟大学, 学校法人順天堂, デンカ生研株式会社

    Application no:特願2009-108498  Date applied:2009.4

    Announcement no:特開2010-256250  Date announced:2010.11

    Patent/Registration no:特許第5424702号  Date issued:2013.12

    J-GLOBAL

    researchmap

  • 尿中タンパク質定量用の尿前処理剤、尿前処理方法、及び尿中タンパク質定量方法。

    斎藤 亮彦, 原 正則, 小笠原 真也, 平山 吉朗, 黒澤 寛之

     More details

    Applicant:国立大学法人 新潟大学, 原 正則, デンカ生研株式会社

    Application no:特願2009-534406  Date applied:2008.9

    Patent/Registration no:特許第5515740号  Date issued:2014.4

    J-GLOBAL

    researchmap

  • ヒトメガリンの測定方法(米国)

    斎藤亮彦, 竹田徹朗, 小笠原真也, 三浦州平

     More details

    Application no:特願PCT/JP2007/056660  Date applied:2007.3

    Date published:2011.6

    Patent/Registration no:特許US 7955809 B2  Date issued:2014.4

    researchmap

  • ヒトメガリンの測定方法

    斎藤亮彦, 竹田徹朗, 小笠原真也, 三浦州平

     More details

    Application no:特願2006-089306  Date applied:2006.3

    Patent/Registration no:特許4865377 

    researchmap

▶ display all

Works

  • Pathological role of megalin in tubular damage

    2001

     More details

  • メガリンの尿細管障害での役割

    2001

     More details

Awards

  • 第16回医学奨励賞 学術奨励賞

    2017   旭川医科大学医学部医学科同窓会   メガリンを標的とした腎臓病の新しい診断・治療法の開発

    斎藤 亮彦

     More details

  • 第9回加藤記念研究助成

    1998  

     More details

    Country:Japan

    researchmap

  • 第2回分子腎臓研究会優秀研究奨励賞

    1996  

     More details

    Country:Japan

    researchmap

  • 塚田医学奨励会研究助成金

    1991  

     More details

    Country:Japan

    researchmap

Research Projects

  • メガリンの構造と機能の精密解析に基づく腎臓病の病態解明と診断・治療の新たな創薬

    Grant number:21H02934

    2021.4 - 2025.3

    System name:科学研究費助成事業

    Research category:基盤研究(B)

    Awarding organization:日本学術振興会

    斎藤 亮彦, 後藤 佐和子, 細島 康宏

      More details

    Grant amount:\17160000 ( Direct Cost: \13200000 、 Indirect Cost:\3960000 )

    researchmap

  • 糖尿病性腎臓病の新規尿中マーカー、細胞外ドメイン切断型メガリンの尿中逸脱機序

    Grant number:20K08629

    2020.4 - 2023.3

    System name:科学研究費助成事業

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    細島 康宏, 斎藤 亮彦

      More details

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    糖尿病性腎臓病の早期診断と予後予測においては尿中アルブミンの測定が重要であるが、様々な問題点も指摘されており、新しいバイオマーカーの開発が求められている。これまでに我々は、腎臓の近位尿細管エンドサイトーシス受容体であるメガリンに着目し、その発現調節機構、他分子との相互作用に関する基礎研究を行うとともに、ヒト尿中メガリン(全長型および細胞外ドメイン切断型)ELISA測定系を開発した。その結果、それらのメガリンの尿中排泄量測定が、糖尿病性腎臓病の重症度や病態の評価に有用であり、既存のバイオマーカーとは異なる新しいマーカーになり得る可能性を示してきた。さらに、細胞外ドメイン型尿中メガリンが新規の糖尿病関連薬などにより鋭敏に増減することも明らかにしてきたが、その尿中への逸脱機序の詳細は未だ十分に解明されていない。そこで本研究は、細胞外ドメイン型メガリンの尿中逸脱機序の詳細を明らかにすることを目的としている。
    研究は主に、「細胞内輸送実験系を用いたメガリンの細胞内リサイクリングと細胞外逸脱の関係」、「DKDの進展時における細胞外ドメイン型尿中メガリンの逸脱機序の解析」、「SGLT2阻害薬使用時の細胞外ドメイン型尿中メガリンの逸脱機序」、「バルドキソロンメチル使用時の細胞外ドメイン型尿中メガリンの逸脱機序」の4つの内容を明らかにしていく計画であった。今年度は、培養細胞においてメガリンの細胞内リサイクリングと細胞外逸脱の関係を検討し得る実験系を確立しただけでなく、糖尿病性腎臓病モデルマウスを用いた検討、さらにはSGLT2阻害薬およびバルドキソロンメチルを使用した動物実験を行い、その予備的なデータを得ることができた。来年度以降も継続的に検討を行っていく予定である。

    researchmap

  • 23Na-MRIを用いたネフローゼ症候群の病態生理の解析

    Grant number:20K08586

    2020.4 - 2023.3

    System name:科学研究費助成事業

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    忰田 亮平, 成田 一衛, 細島 康宏, 斎藤 亮彦, 寺田 康彦

      More details

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    腎臓内でのNa+ハンドリングの可視化は、腎臓領域の研究での悲願であり、特に、ネフローゼ症候群では、Na+の貯留と浮腫の成因として、underfillingとoverfillingの機序が提唱されているが、腎臓内のNa+の全体像を明らかにできる方法は今までなかった。申請者らは、マウスのごく小さな腎臓に対して、23Na-MRI(磁気共鳴映像法)を用いて23Naをもとにした画像化に成功し、水の効率的な再吸収が可能となる対向流増幅系のNa+の濃度勾配・Na+の貯留の状態を可視化した。この23Na-MRI画像をもとに、今まで理解できなかったネフローゼ症候群における「腎臓全体のNa+のハンドリング・Na+の貯留」と「Na+の再吸収に関わるチャネル・トランスポーター」の関係を明らかにすることで、病態生理の解明を試みる。腎臓全体でのネフローゼ症候群のNa+の再吸収に関わる機構の異常を解明することを目的とする。①ネフローゼモデルマウス(NEP25マウス)を用いて、ネフローゼ症候群といった病的状態では、腎臓内のNa+再吸収に関わる作用点 (チャネル・トランスポーター)がどのように変化するか明らかにする。②さらに、Na+の再吸収に影響する薬剤、具体的には、副腎皮質ステロイド、SGLT2阻害薬、RAS阻害薬、トルバプタン、ミネラルコルチコイド受容体(MR)拮抗薬、ヒト心房性ナトリウム利尿ペプチド(hANP)、バソプレッシン等について検討する。③腎臓内Agt、AngII量や挙動と画像所見を元にしたNa+の再吸収機構の関連について検討する。

    researchmap

  • メガリンを基盤とするα-klotho、FGF23による新規リン代謝調節機構の解明

    Grant number:19K08674

    2019.4 - 2023.3

    System name:科学研究費助成事業

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    桑原 頌治, 斎藤 亮彦

      More details

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    本研究課題の目的は、腎臓のリン代謝におけるメガリンを基盤とする新規調整メカニズムの解明である。これまでの研究から、腎臓近位尿細管の管腔測に発現するメガリンは様々な分子の輸送や代謝に関与する重要な機能分子であることが示されており、同じく管腔測に発現する他の膜タンパク質の働きにも関与することが示唆されている。本研究により、腎臓のメガリンをほぼ完全に欠損するノックアウトマウスの尿中ではα-klothoタンパク質の排泄が明確に増加していることを発見し、またそのα-klothoタンパク質が全長型ではなく、何らかの形で切断された形態である可能性を見出すことができた。α-klthoタンパク質は老化関連因子として同定され、さらにリン代謝への関与も証明されているが、リン代謝における作用メカニズムは不明な点が多い。本研究では人工的に合成したα-klothoタンパク質を用いた実験動物への投与や培養近位尿細管細胞への添加によるメカニズム解明の実験系を構築した。本研究の仮説である、メガリンを介した腎近位尿細管における直接的なリン輸送への関与を検討する目的で、メガリン発現を阻害することによるリン輸送への影響を引き続き検討している。

    researchmap

  • メガリンを標的とした薬剤性腎障害治療戦略の開発

    Grant number:19K08673

    2019.4 - 2023.3

    System name:科学研究費助成事業

    Research category:基盤研究(C)

    Awarding organization:日本学術振興会

    青木 信将, 渡部 聡, 斎藤 亮彦

      More details

    Grant amount:\4290000 ( Direct Cost: \3300000 、 Indirect Cost:\990000 )

    薬剤性腎障害は、腎臓分野に限らず、感染症治療、抗腫瘍療法など幅広い分野での問題となっている。申請者らはメガリンを介する腎障害発症機序を解明し、メガリン拮抗薬シラスタチン(CS)を同定、バンコマイシン(VCM)、コリスチン(COL)、シスプラチン(CDDP)による腎障害の軽減を報告した。本研究では、CSの効果・作用機序に対する研究、腎毒性薬物との相互作用、薬物動態解析を含む非臨床・臨床試験を行う。さらにコンパニオン診断薬として尿中メガリンの薬剤性腎障害での有用性評価を行う。
    当該年度においては、CS併用下でのCDDP抗腫瘍効果の評価について、マウスモデルを用いて解析を行った。CDDPの腎障害を腎組織、尿生化学検査により評価し、CS併用時の抗腫瘍効果と腎障害の変化について検討している。CDDPとCSを同時投与により腎組織中のKIM-1発現は減少しBUNも減少することが確認された。CDDP高用量投与群においては、強い抗腫瘍効果が認められ、CSと併用することで腎障害をきたさず抗腫瘍効果を高められることが示された。
    実臨床においてはCS併用療法の効果と有害事象について、VCM使用患者を後方視的に解析し、IPM/CS併用者とそれ以外のカルバペネム系薬併用者で腎障害抑制効果を確認している。現在多変量解析など詳細を検討中である。
    CSはドラッグリポジショニングの適用例と考えられ、早期の臨床応用が期待される。
    本研究で得られる薬剤特性に関する知見により、臨床応用を見据えた臨床試験への展開を検討中である。尿中メガリンによる新規検査法とあわせ、新たな腎機能温存戦略につなげる。

    researchmap

  • メガリンをターゲットとした慢性腎臓病および急性腎障害の診断・予防・治療法の開発

    2018.4 - 2021.3

    System name:科学研究費助成事業(科学研究費補助金)基盤研究(B)

    Awarding organization:文部科学省

    斎藤 亮彦

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 肥満・メタボリックシンドローム関連腎障害の病態にリンクした尿中メガリン排泄の意義

    2017.4 - 2020.3

    System name:科学研究費助成事業(科学研究費補助金)基盤研究(C)

    Awarding organization:文部科学省

    細島 康宏

      More details

    Grant type:Competitive

    researchmap

  • メガリンを標的とした腎機能温存・再生療法の開発

    2016.4 - 2019.3

    System name:腎疾患実用化研究事業

    Awarding organization:国立研究開発法人日本医療研究開発機構

    斎藤 亮彦

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 糖尿病性腎症の進展予防にむけた病期分類−病理−バイオマーカーを統合した診断法の開発

    2015.4 - 2018.3

    System name:腎疾患実用化研究事業

    Awarding organization:国立研究開発法人日本医療研究開発機構

    和田 隆志

      More details

    Grant type:Competitive

    researchmap

  • 慢性腎臓病の病態機序におけるメガリンの役割と尿中メガリン測定の臨床的意義

    2014.4 - 2017.3

    System name:科学研究費助成事業(科学研究費補助金) 基盤研究(C)

    Awarding organization:文部科学省

    斎藤 亮彦

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Investigation of the mechanism underlying urinary excretion of megalin, a novel biomarker of diabetic kidney disease

    Grant number:26860630

    2014.4 - 2017.3

    System name:Grants-in-Aid for Scientific Research

    Research category:Grant-in-Aid for Young Scientists (B)

    Awarding organization:Japan Society for the Promotion of Science

    Hosojima Michihiro, DE Shankhajit, KUWAHARA Shoji, KABASAWA Hideyuki, SAITO Akihiko

      More details

    Grant amount:\3770000 ( Direct Cost: \2900000 、 Indirect Cost:\870000 )

    I studied the mechanism underlying urinary excretion of megalin, a multiligand endocytic receptor in the proximal tubules, in diabetic kidney disease (DKD). Urinary extracellular vesicle (UEV) excretion and full-length megalin (C-megalin) content in UEVs or in their exosomal fraction increased along with the progression of the albuminuric stages in patients with type 2 diabetes mellitus (T2DM). C-megalin excretion from cultured immortalized rat proximal tubule cells via extracellular vesicles was increased via lysosomal dysfunction in association with megalin-mediated cellular uptake of advanced glycation endproducts, which is significantly blocked by an exosome-specific inhibitor, GW4869. In a high-fat diet-induced, megalin-mediated DKD model in mice, urinary C-megalin excretion also increased via UEVs. Collectively, exocytosis-mediated urinary C-megalin excretion is linked with the megalin-mediated mechanism underlying the development and progression of DKD in T2DM.

    researchmap

  • 慢性腎臓病の進行を促進する薬剤等による腎障害の早期診断法と治療法の開発

    2013.4 - 2016.3

    System name:厚生労働科学研究費 難治性疾患等克服研究事業(腎疾患対策研究事業)

    Awarding organization:厚生労働省

    成田 一衛

      More details

    Grant type:Competitive

    researchmap

  • 尿中メガリンは腎組織血流障害における急性腎臓病(AKD)のマーカーとなり得るか

    2012.4 - 2014.3

    System name:科学研究費助成事業(科学研究費補助金) 挑戦的萌芽研究

    Awarding organization:文部科学省

    髙橋 昌

      More details

    Grant type:Competitive

    researchmap

  • ヒト腎機能に及ぼす米・米糖タンパク質の影響に関する研究

    2011.4 - 2014.3

    System name:農林水産物・食品の機能性等を解析・評価するための基盤技術の開発(米タンパク質の新規生体調節機能性の先導的開発と機構解析)

    Awarding organization:農林水産省

    門脇 基ニ

      More details

    Grant type:Competitive

    researchmap

  • 米・米糖タンパク質の新規機能性の解明と食品開発

    2008.4 - 2011.3

    System name:国立研究開発法人科学技術振興機構(JST)重点地域研究開発推進プログラム(育成研究)

    Awarding organization:文部科学省

    門脇 基ニ

      More details

    Grant type:Competitive

    researchmap

  • 近位尿細管エンドサイトーシス受容体メガリンと関連分子の発現調節および相互作用の機序

    2007.4 - 2009.3

    System name:科学研究費助成事業(科学研究費補助金) 基盤研究(C)

    Awarding organization:文部科学省

    斎藤 亮彦

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • 透析アミロイドーシスを予防するための細胞移植療法の開発:メガリン発現細胞の樹立

    2007.4 - 2009.3

    System name:科学研究費助成事業(科学研究費補助金) 萌芽研究

    Awarding organization:文部科学省

    下條 文武

      More details

    Grant type:Competitive

    researchmap

  • 糸球体障害時における接着阻害分子ポドカリキシンの糖鎖調節とアダプター蛋白の役割

    2006.4 - 2008.3

    System name:科学研究費助成事業(科学研究費補助金) 基盤研究(C)

    Awarding organization:文部科学省

    竹田 徹朗

      More details

    Grant type:Competitive

    researchmap

  • 糸球体上皮細胞障害時における接着阻害分子ポドカリキシンとアダプター蛋白の役割

    2004.4 - 2006.3

    System name:科学研究費助成事業(科学研究費補助金) 基盤研究(C)

    Awarding organization:文部科学省

    竹田 徹朗

      More details

    Grant type:Competitive

    researchmap

  • エンドサイトーシス受容体メガリンによる尿毒素蛋白代謝分子機序と細胞治療への応用

    2004.4 - 2006.3

    System name:科学研究費助成事業(科学研究費補助金) 基盤研究(C)

    Awarding organization:文部科学省

    斎藤 亮彦

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • β2−mアミロイド繊維形成の阻害物質の探索

    2003.4 - 2006.3

    System name:科学研究費助成事業(科学研究費補助金) 萌芽研究

    Awarding organization:文部科学省

    下條 文武

      More details

    Grant type:Competitive

    researchmap

  • エンドサイトーシス受容体メガリンの機能の解析と腎臓内科学的および再生医学的応用

    2002.4 - 2004.3

    System name:科学研究費助成事業(科学研究費補助金) 基盤研究(C)

    Awarding organization:文部科学省

    斎藤 亮彦

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • メガリンの近尿位細管での生理的・病的機能の解析とその分子特性の腎臓内科学的応用

    1998.4 - 2001.3

    System name:科学研究費助成事業(科学研究費補助金)基盤研究(C)

    Awarding organization:文部科学省

    斎藤 亮彦

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Analysis of the pathogenesis of diabetic nephropathy

      More details

    Grant type:Competitive

    researchmap

  • 新規素材ハニカム膜を用いた糸球体上皮細胞培養と同細胞における糖鎖付加酵素の役割

    System name:科学研究費助成事業(科学研究費補助金) 基盤研究(C)

    Awarding organization:文部科学省

    竹田 徹朗

      More details

    Grant type:Competitive

    researchmap

  • 近位尿細管エンドサイトーシスの分子機構と慢性腎臓病の発症機序における病的役割

    System name:科学研究費助成事業(科学研究費補助金) 基盤研究(C)

    Awarding organization:文部科学省

    斎藤 亮彦

      More details

    Authorship:Principal investigator  Grant type:Competitive

    researchmap

  • Analysis of physiological and pathophysiological functions of megalin and its related proteins

      More details

    Grant type:Competitive

    researchmap

  • Bioengineering for renal disease

      More details

    Grant type:Competitive

    researchmap

▶ display all